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The immune system protects the body against a wide spectrum of pathogens like bacteria, 
viruses as well as tumor cells. The rapid but non-specific innate immune response serves as 
the first line of defense against invaders [1]. Dendritic cells play a key role in the induction of 
the adaptive immune response, in which lymphocytes are able to specifically recognize and 
eliminate pathogens [2]. Upon recognition of pathogen-derived danger signals, DCs internalize 
these pathogens and subsequently present pathogen-derived antigenic peptides on MHC I or 
MHC II molecules to naïve CD8+ or CD4+ T cells respectively. Each T cell displays an unique 
T cell receptor (TCR) and specific recognition of MHC-peptide complexes, combined with 
co-stimulation by the dendritic cells, will lead to clonal expansion of antigen specific T cells. 
Activated CD8+ cytotoxic T cells can kill tumor and virus-infected cells. CD4+ helper T cells 
facilitate the activation and differentiation of other immune cells like B cells. Activated B cells 
produce antibodies (soluble immunoglobulins) to neutralize pathogens. A striking feature of 
the humoral immune response is the increase in antibody affinity over time. Understanding 
the regulation of B cell activation and differentiation into plasma cells that secrete high affinity 
antibodies, will improve vaccine strategies and help boost immunity or fight autoimmune 
pathologies. 
B cells that are activated via the B cell receptor (BCR) signaling complex internalize and 
process the antigen for presentation on MHC II molecules [3]. When CD4+ helper T cells of the 
same antigen specificity recognize antigenic peptides presented by MHC II on the surface of B 
cells, they deliver signals that promote B cell proliferation. At this stage B cells can differentiate 
into short-lived plasmablasts and start early antibody production or start a germinal center 
(GC) reaction [4]. GCs are dynamic and temporary structures within lymphoid organs, in which 
B cells undergo iterative rounds of random somatic hypermutation (SHM) of the BCR, and 
extensive selection of progressively higher-affinity mutants. B cells with a higher affinity BCR are 
able to acquire more antigen from follicular dendritic cells (FDCs) and present higher densities 
of antigenic peptide via MHC II [5]. They are outcompeting B cells with low affinity BCR by 
acquiring survival signals from a limiting number of follicular helper CD4+ T cells [6,7]. B cells 
with the highest affinity BCR are allowed to differentiate into long-lived plasma cells which 
produce high affinity antibodies. Alternatively, GC B cells differentiate into memory B cells that 
provide long-lived protection against secondary infection [8].
Regulation of the B cell response is complex and the outcome is influenced by the type of 
antigen, whether the antigen is cell associated or soluble, and by co-stimulatory signals that are 
provided to the B cells [9,10]. Tetraspanin four-transmembrane proteins play a crucial role in B 
cell responses as shown by impaired antibody production by CD37- and CD81-deficient B cells 
[11–16]. CD81-/- B cells are impaired in B cell activation due to loss of CD19 plasma membrane 
expression [17]. CD37 regulates the organization of α4β1 integrin on B cells and is therefore 
involved in B cell survival [16]. In mammals, 33 different tetraspanins have been identified, 
and their specificity is in large part determined by the structure of the large extracellular loop. 
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Although this region is highly variable in size and sequence composition, it does contain four, six 
or eight conserved cysteine residues forming disulfide bridges. This feature enables classification 
of tetraspanins into groups, with CD9, CD53 and CD81 having four, and CD37, CD63, CD82 
and CD151 having six conserved cysteine residues [18,19]. In addition, tetraspanin proteins 
are to variable extents glycosylated and palmitoylated. Tetraspanins have a role in membrane 
organization by generating a hierarchical network of protein-protein interactions. They are 
believed to self-associate into “tetraspanin-enriched microdomains” containing multiple 
members of the tetraspanin family. Specific tetraspanins recruit their specific partner proteins 
into these microdomains, forming functional complexes within the membrane [20,21]. This 
model of tetraspanin based membrane organization is mostly based on co-immunoprecipitation 
studies using detergents, in which incomplete or differential solubilization or differential 
recognition of certain tetraspanin protein complexes could have led to unreliable results. 
Moreover, these bulk assays do not provide information on the stoichiometry or heterogeneity 
of these tetraspanin-enriched microdomains. Novel advanced microscopy technologies now 
enable visualization of the endogenous tetraspanin web. We believe that it is crucial to resolve 
the organization of the tetraspanin web to be able to understand how tetraspanin proteins 
modify the function of their interacting partner molecules. 
Tetraspanin CD53 is, like CD37, exclusively expressed by cells of the immune system and 
is therefore suspected to play an important role in the immune response. This hypothesis is 
strengthened by the observation that individuals deficient for CD53, suffer from recurrent 
heterogeneous infectious diseases [22]. Up till now, investigations did not lead to mechanistic 
insight in the modulation of the immune response by CD53. Ligation of CD53 on B and T 
cells with antibodies leads to resistance to apoptosis which may involve phosphorylation of 
Akt [23]. In addition, ligation of CD53 induces calcium mobilization in multiple cell types 
[24] and activation of the signaling molecule protein kinase C (PKC) [25]. However, CD53 is 
not believed to be a receptor, and the physiological relevance of these antibody-crosslinking 
studies are therefore questionable. In addition, contradictory responses have been observed in 
studies analyzing cell proliferation upon CD53 crosslinking [26,27]. These studies do suggest 
a possible role for CD53 in modulating signaling cascades in immune cells, whilst not being 
a receptor itself. CD53 has been shown to interact with PKC [28], integrins [29], BCR [30] 
and MHC molecules [31,32]. The interactions between CD53 and other membrane associated 
partner proteins were investigated using mild detergents and are therefore most likely indirect 
interactions. Whether these associations of CD53 with MHC molecules, PKC and/or the BCR 
have functional consequences remains elusive, and it is unclear how CD53 can couple to 
signaling pathways. Based on former studies on other members of the tetraspanin superfamily 
we postulate that CD53 regulates the localization and function of membrane associated partner 
proteins. In this thesis we determined the role of CD53 in B cell and dendritic cell functions of 
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which membrane organization is crucial. We particularly focused on the composition of the 
BCR signaling complex and the organization of MHC molecules during antigen presentation. 
The aims of this thesis are:
•	 Provide an unbiased view of the tetraspanin web on immune cells using super-resolution 
imaging.
•	 Investigate the role of tetraspanin CD53 in BCR signaling and antigen presentation.
Chapter 1 discusses the different means of membrane organization, and the relevance of 
membrane compartmentalization for antigen-presenting cell function. In Chapters 2, 3 and 
4 the expression and subcellular localization of tetraspanin proteins are studied at multiple 
levels, from expression patterns within tissues to precise protein localization within the plasma 
membrane. In Chapter 2 we study the expression of tetraspanins CD53 and CD37 within human 
secondary lymphoid tissues using multispectral imaging. We show differential expression of 
CD53 and CD37 on B and T cells, which depends on the localization of the cells within tissues. 
The expression profile of all members of the tetraspanin family on human and murine dendritic 
cell subsets is presented in Chapter 3. In Chapter 4 we visualize tetraspanin proteins within the 
plasma membrane using super-resolution microscopy and challenge the current view of the 
tetraspanin web, in which multiple tetraspanin species are organized into a single domain. We 
show that tetraspanins are present in protein clusters of around 120 nm in diameter, that are 
adjacent to protein clusters containing other members of the tetraspanin family. 
In Chapters 5 and 6 we address the function of CD53 on antigen-presenting cells. In Chapter 
5 we show that CD53 interacts with PKC upon BCR signaling, and that B cells deficient in CD53 
are impaired in PKC activation. Chapter 6 discusses the role of CD53 in antigen presentation 
by dendritic cells. We show an interaction between CD53 and MHC molecules, and impaired 
cross-presentation via MHC I in CD53-deficient dendritic cells. In Chapter 7 the results of this 
thesis are discussed and I present a new view of the tetraspanin web.
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Abstract
The plasma membrane of immune cells is a highly organized cell structure that is 
key to the initiation and regulation of innate and adaptive immune responses. It is 
well-established that immunoreceptors embedded in the plasma membrane have 
a non-random spatial distribution which is important for coupling to components 
of intracellular signaling cascades. In the last two decades, specialized membrane 
microdomains, including lipid rafts and tetraspanin-enriched microdomains have 
been identified. These domains are preformed structures (‘physical entities’) that 
compartmentalize proteins, lipids and signaling molecules into multi-molecular 
assemblies. In antigen-presenting cells, different microdomains containing 
immunoreceptors (major histocompatibility complex proteins, pattern-recognition 
receptors, integrins, among others) have been reported that are imperative for 
efficient pathogen recognition, the formation of the immunological synapse and 
subsequent T cell activation. In addition, recent work has demonstrated that both 
tetraspanin microdomains and lipid rafts are involved in B cell receptor signaling 
and B cell activation. Research into the molecular mechanisms underlying 
membrane domain formation is fundamental to a comprehensive understanding 
of membrane-proximal signaling and antigen-presenting cell function. This review 
will also discuss the advances in the microscopy field for the visualization of the 
plasma membrane as well as the recent progress in targeting microdomains as 
novel therapeutic approach for infectious and malignant diseases.   
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Membrane microdomains
The plasma membrane is essential for cell function due to its unique role in the communication 
between the inside and outside of the cell. Immune cells rely on the activation and collaboration 
of multiple different receptors in the plasma membrane that are central to leukocyte function 
including antigen recognition and presentation, cell adhesion, and cytokine production. A 
contemporary goal of researchers has been to uncover how immune cells physically organize 
and compartmentalize receptors and signaling molecules into efficient, regulated membrane-
proximal signaling complexes. Whereas many studies have been performed on investigating the 
plasma membrane of T lymphocytes, this review focuses on new insights into the immunological 
relevance of microdomains in the membrane of antigen-presenting cells (APCs). 
In 1972, Singer and Nicolson presented their classical view of membrane structures in which 
monomeric and amphiphilic membrane proteins diffuse in a two-dimensional fluid lipid bilayer 
[1]. The identification of specialized membrane domains including lipid rafts, tetraspanin-
enriched microdomains, and caveolae has been a major breakthrough in cell biology and has 
changed the classical fluid mosaic model. Although different in size and composition we define 
them as membrane microdomains throughout this review. Lipid rafts are microdomains with 
an estimated size of 10-200nm present in the plasma membrane of all eukaryotic cells [2]. 
The outer leaflet of lipid rafts consists of cholesterol which binds to glycosphingolipids and 
promotes formation of a liquid ordered phase within the disordered glycerophospholipid bilayer 
of the plasma membrane (Fig. 1). The inner leaflet of lipid rafts is composed of saturated 
phospholipids [3, 4]. Inside the cell, the concentration of cholesterol is increased from the 
endoplasmatic reticulum to the Golgi, which may underlie the important role of cholesterol in 
the trafficking of transmembrane proteins to the plasma membrane [5]. Typical raft constituents 
within the outer leaflet are glycosylphosphatidylinositol (GPI)-anchored proteins [6], which 
partition to the lipid rafts in virtue of their glycolipid anchor. Different models have been 
proposed that underlie plasma membrane compartmentalization. Simons refers to lipid rafts 
as a membrane-organizing principle in which rafts allow lateral segregation of proteins in the 
plasma membrane and recruitment of signaling molecules in order to compartmentalize cellular 
events, including signal transduction, membrane traffic and endocytosis. Upon cross-linking 
of raft-associated receptors, two or more rafts may coalesce into larger domains where more 
sustained signaling can occur and anchoring to the actin cytoskeleton can take place (reviewed 
in [7]).
Chapter 1
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Kusumi proposes a major role for the actin cytoskeleton in his ‘picket-fence’ model that is 
described by a hierarchical three-tiered mesoscale-domain architecture present in the plasma 
membrane (reviewed in [8]). Mesoscale refers to a size greater than a nanometer and smaller 
than a micron. The first hierarchy are membrane compartments of 40-300nm formed 
by a fence of actin-based membrane cytoskeleton and pickets of transmembrane proteins 
anchored to this fence. The second-tier are raft domains of 2-20nm consisting of cholesterol, 
glycosphingolipids and GPI-anchored proteins. The third-tier are dynamic protein complexes 
of 3-10nm containing membrane-associated and integral membrane proteins. In this ‘picket-
fence’ model, transmembrane proteins and phospholipids can undergo hop diffusion between 
membrane compartments, whereas they can move freely within a compartment emphasizing 
the important role of the actin cytoskeleton [8] versus the more classical model of lipid raft 
compartmentalization described by Simons and others [5]. The nanoscale size of rafts is also 
Lipid raft Non raft membrane 
GPI-anchored 
protein
Cholesterol
Non-raft 
TM protein
Raft associated
TM protein
Sphingolipid
Tetraspanin
Tetraspanin
partners
A
B
Figure 1: Schematic representation of a lipid raft and a tetraspanin-enriched microdomain. 
(A) Lipid raft. Lipid rafts are enriched in sphingolipids, cholesterol, and GPI-anchored proteins. Certain transmembrane 
(TM) proteins are specifically associating with lipid rafts, whereas other proteins are excluded. (B) Tetraspanin-enriched 
microdomain. Tetraspanin proteins specifically recruit one or more partner molecules (including (immuno-)receptors and 
signaling molecules) whereby they induce the formation of multi-molecular complexes in the membrane. These protein-
protein interactions can be direct or indirect (via other members of the tetraspanin family) forming so-called tetraspanin-
enriched microdomains, or the ‘tetraspanin-web’ (see text for details). Molecules depicted in this schematic representation 
of membrane microdomains are not drawn to scale.
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consistent with the ‘lipid shell’ model which proposes that each protein is surrounded by a ring 
of laterally organized lipids [9].
Sixty years ago, small (60-80nm) microdomains, called caveolae, present on specific cell 
types were first identified using electron microscopy [10, 11]. Caveolae are cholesterol-enriched 
membrane invaginations consisting of caveolin proteins and cavin proteins. These proteins 
interact with each other in order to regulate signal transduction, endocytosis, and transport of 
free cholesterol (reviewed in [12, 13]). Like lipid rafts, caveolae can cluster together and form 
extensive networks [14]. In the immune system, they are found in certain myeloid [15] and 
lymphoid [13] cell lineages depending on the activation and maturation state of the cell. Studies 
on murine macrophages revealed that caveolae structural proteins are important regulators 
of macrophage number and phenotype in the lung [16], and caveolin proteins may promote 
differentiation of monocytes into macrophages [17]. The role of caveolae in other APCs is not 
well established and will therefore not be the focus in the remainder of this review. 
During the nineties, a novel type of membrane microdomain was identified: the tetraspanin-
enriched microdomain (TEM) [18]. Tetraspanins are a family of four transmembrane proteins 
present on the plasma membrane and on intracellular vesicles of virtually all mammalian cell types. 
Their structure is characterized by four transmembrane domains, a small and a large extracellular 
loop and 2 short cytoplasmic tails [19]. The size of a TEM varies between cell types and diameter 
sizes between 100-300nm have been reported (Table 1). The assembly of TEMs is dependent on 
tetraspanin-tetraspanin interactions and tetraspanin interactions with transmembrane receptors, 
enzymes, adhesion molecules (integrins and others) and signaling molecules (reviewed in [20, 
21]). These interactions can be divided into three levels [22, 23]. Level 1 refers to very robust 
and direct interactions that are stable in strong detergents (i.e. Triton X-100). Level 2 interactions 
are less robust and are disrupted by strong detergents, but are stable in hydrophobic detergents 
(i.e. Brij 96 or Brij 97). Level 3 consists of weaker indirect interactions only detected in mild, 
less hydrophobic, detergents (i.e. Brij 99 or CHAPS). These different interaction levels reveal the 
concept of a tetraspanin web, in which tetraspanins are organizers of multi-molecular complexes 
on the plasma membrane. Each tetraspanin molecule recruits specifically one or more partner 
molecules, following interaction with another tetraspanin molecule to form larger complexes [23] 
(Fig. 1). The composition of TEMs is highly dependent on the specific cell type studied, and it has 
been shown that different TEMs exist within one particular cell type [24]. In the Golgi complex 
tetraspanin proteins can be palmitoylated, which allows dynamic homo- or heterodimerization 
with another tetraspanin molecule or with associated proteins in the plasma membrane. 
Palmitoylation is the covalent attachment of fatty acids, such as palmitic acid, to cysteine residues 
of membrane proteins, which promotes protein-protein interactions in the lipid environment. 
This post-translational modification was shown to be important for the assembly of TEMs, as 
previously described for tetraspanins CD9 [25] and CD151 [26]. These protein-protein interactions 
in the plasma membrane have an important role in intercellular (adhesion, migration, synapse 
Chapter 1
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formation) and intracellular (organizers of membrane-signaling complexes) interactions as well as 
intracellular protein transport and endo- and exocytosis. TEMs are not static entities, instead there 
is now prevailing evidence from studies in living cells that both their localization and composition 
are dynamic [25, 27]. There is constant diffusion of individual tetraspanins and partner proteins 
between specific microdomains, which may induce clustering of two or more TEMs in order 
to enhance the strength of a response. Furthermore, the diffusion dynamics of the different 
molecules present in the microdomain can be influenced by ligation of a receptor within the TEM.
Despite the different biochemical principles regulating rafts and TEMs, these microdomains 
are dynamic in time and space, and their molecular constituents may exchange between 
different types of microdomains [22, 25, 28]. In the remainder of this review, we will focus on 
the characterization and function of lipid rafts and tetraspanin-enriched microdomains in APCs.
Approaches to characterize microdomains
The formation of membrane microdomains depends on lipid-lipid, lipid-protein and protein-
protein interactions, indicating the existence of a variety of biochemical principles that allow 
these interactions to occur at the molecular level. Strong interactions between cholesterol and 
sphingolipids promote their co-segregation in raft domains, which in turn can sequester specific 
signaling proteins allowing the formation of large signaling complexes. In the past, the nanoscale 
size and dynamic nature of lipid rafts have posed technical challenges for their identification 
Table I. Characteristics of tetraspanin-enriched microdomains and lipid rafts
TEM Lipid raft
Estimated diameter size 100-300nm [24] 10-200nm [2]
Content/ characterization Enriched in tetraspanins, tetraspanin-
partner proteins, cholesterol.
Enriched in cholesterol, sphingomyelin, 
lipids with saturated acyl chains, raft-
a-like proteins (GPI-anchored, caveolin, 
other).
Biochemical features Partition into low-density fractions of 
sucrose gradients. Resistant to mild 
detergents (Brij 97) at 37°C a. Partially 
dependent on cholesterol b.
Partition into low-density fractions of 
sucrose gradients. Resistant to non-ionic 
detergents (Tx-100) at 4°C. Dependent 
on cholesterol b.
Signaling molecules PKC, PI4K, phosphatases, Rac, other.
 
Src kinases, H-Ras, PI3K/Akt , 
B and T cell receptor associated signaling 
effectors.
Although TEMs and conventional lipid rafts display some similarities (both enriched in cholesterol and partition into low-
density fractions of sucrose gradients), there are a number of critical differences that distinguish these two microdomains. 
a Tetraspanin–protein interactions have been classified into three categories based on their stringency in different 
detergents (see text for more details). This concept is also relevant for lipid rafts since the protein content of DRMs differs 
depending on the detergent utilized. b Although direct interactions between tetraspanins and their partners are resistant 
to cholesterol depletion [22], signal transduction downstream of TEMs is affected by MCD treatment [36]. 
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and the study of their composition. A solution to this problem came with the discovery that 
segregation of certain proteins into lipid rafts was determined by their capacity to reside in a 
specific fraction of membrane-derived material that appeared to resist detergent treatments 
[29, 30]. These so-called detergent resistant membranes (DRMs) were initially isolated after 
cell lysis in the presence of the detergent Triton X-100 and subsequent ultracentrifugation 
on sucrose gradient where the floating fraction was found to contain DRMs (for a detailed 
description of the most widely used protocols see [31]). Another frequently used technique 
to study lipid rafts is methyl-β-cyclodextrin (MCD) treatment, which depletes cholesterol, an 
essential constituent of lipid rafts, from the plasma membrane.
It should be noted that DRM extraction has been primarily used to determine the association 
of membrane proteins with lipid rafts. In fact, although localization of TEMs in DRMs has been 
documented [32, 33], seminal work from the Hemler laboratory has demonstrated that TEMs are 
discrete units that are distinct from lipid rafts but can occasionally interact with them [22, 34] 
(Table 1). In addition, proteomics approaches have demonstrated that the composition of TEMs 
is specifically distinct from that of lipid rafts as different sets of proteins were detected in lipid 
rafts and TEMs (reviewed in [35]). Part of the controversy was caused by the sensitivity of both 
DRMs and TEMs to cholesterol depletion by MCD, although for the integrity of TEMs the effects 
of cholesterol depletion were reported to be milder [36]. MCD has been widely, and sometimes 
without including basic controls of cell viability or residual cholesterol levels, used to determine 
the association of membrane proteins with lipid rafts. Lack of receptor functionality upon MCD 
treatment has often been attributed to impaired colocalization with lipid rafts. However, one 
should consider that MCD has been shown to exert pleiotropic effects among which destruction 
of clathrin-coated pits [37, 38] and rearrangement of the cytoskeleton [28, 39].  
Despite the slightly artifactual nature of both DRMs and MCD treatment, one should 
acknowledge that these approaches have been instrumental to the original identification 
of the potential raftophilic/raftophobic nature of a large variety of proteins. However, it is 
increasingly recognized that protein-protein and protein-lipid interactions that mediate the 
formation of specific membrane compartments or scaffolds are often transient and highly 
dynamic. Therefore, although DRMs give a broad view of domain composition, they represent 
a bulk snapshot of a specific situation and cannot provide information on the spatiotemporal 
variations of the membrane domains. Moreover, while the use of the detergent Triton has been 
shown to induce formation of DRMs [40], different detergents have different ability to selectively 
solubilize membrane proteins or enrich glycosphingolipids and cholesterol [41], emphasizing 
the notion that DRMs might not be fully representative of lipid rafts. Fast developments in 
fluorescence microscopy techniques have now made it possible to measure protein aggregation 
state, dynamics, and interactions in living cells, facilitating in situ measurements of biochemical 
parameters and revealing novel aspects of membrane microdomain organization and function.
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Although a detailed overview of all the state of the art microscopy techniques that can 
image membrane domains falls outside the scope of this review, it is worth to highlight the 
increasing application of novel imaging techniques that are perfectly suited to visualize the 
nanoscale organization of the plasma membrane, including lipid rafts and TEMs. Images of 
membrane domains were initially obtained by using immunogold labeling and transmission 
electron microcopy on either membrane sheets or intact cells [42-45]. With the advent of 
super-resolution microscopy techniques in the past decade, techniques such as Near-fi eld 
Scanning Optical Microscopy (NSOM), Stimulated Emission Depletion (STED) and localization 
microscopy were shown to be capable of directly mapping out the nanoscale landscape of 
the cell surface [46-48] (Fig. 2). Nanoscale proximity of raft components and transmembrane 
adhesion receptors has been revealed by NSOM imaging of the cell surface of human monocytes 
[49, 50], while pioneering measurements of STED combined with Fluorescence Correlation 
Spectroscopy (STED-FCS) have been able to determine fast diffusion of phospholipids and 
sphingolipids in living cells [51, 52]. More recently, photoactivated localization microscopy 
(PALM) in combination with pair-correlation analysis has been shown to be a promising tool 
to analyze complex organization patterns of membrane proteins enabling quantifi cation of 
protein cluster size, density and abundance in the cell membrane [53].
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Figure 2. Model illustrating microdomains in the plasma membrane which can facilitate immunoreceptor clustering, cross-
talk, and immune cell signaling. 
(1) Clustering. Immunoreceptors can be clustered within membrane microdomains leading to an increase of receptor 
avidity. (2) Cross-talk. Membrane microdomains provide a local environment which facilitates cross-talk between 
different immunoreceptors and their co-receptors resulting in enhancement (or dampening) of their function. In addition, 
regulators of signaling can be excluded. (3) Signaling. Signaling molecules are specifi cally recruited toward membrane 
domains, where stable signaling complexes are being created. It should be noted that the plasma membrane is much 
more crowded with proteins than depicted in this model adding an extra level of complexity. An example of visualization 
of membrane microdomains is given in the upper right corner: confocal and super-resolution microscopy (STED) of 
tetraspanin microdomains in the plasma membrane of human B cells, demonstrating the need for advanced imaging 
techniques to investigate single membrane microdomains and their constituents. The diameter size of a TEM in B cells is 
estimated to be around 100nm. Scale bars indicate 2 mm.
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Single molecule imaging, such as Förster Resonance Energy Transfer and Fluorescence 
Lifetime Microscopy (FRET-FLIM) and multi-color single particle tracking (SPT), can provide 
a view of protein dynamic behavior at the molecular level [54]. Elegant FRET-FLIM studies 
from the Sanchez-Madrid group have demonstrated the existence of specialized preformed 
tetraspanin-enriched adhesive platforms at the plasma membrane of endothelial cells containing 
VCAM-1 or ICAM-1, ligands for the leukocyte integrins VLA-4 (α4β1) and LFA-1, as well as 
the tetraspanins CD151 and CD9, respectively [27]. This study shows that also the spatial 
organization of membrane receptors in non-immune cells affects immune cell function during 
cell-cell interactions, such as adhesion and transmigration. Despite the numerous interactions 
discovered between tetraspanins and immune receptors, only few similar studies have been 
performed on immune cells [55].
Whereas FRET-FLIM generally provides averaged values of ensemble measurements, SPT 
offers the opportunity to distinguish fractions of proteins exhibiting different dynamic behavior. 
An excellent example was provided by Jaqaman and colleagues who used SPT to investigate 
the dynamics and signaling of the scavenger receptor CD36 at the plasma membrane of 
macrophages which was controlled by the cortical cytoskeleton [56]. Recent work from our 
laboratory also demonstrated the power of SPT to study immune receptor nanoscale organization 
and function. On monocyte-derived dendritic cells (DCs), we followed single molecules of the 
pathogen-recognition receptor DC-SIGN and demonstrated a direct relationship between spatial 
nanopatterning and lateral diffusion to provide DC-SIGN with the exquisite ability to bind many 
different viruses [57]. On the cell surface of human monocytes, where the integrin LFA-1 is 
organized in nanometer-sized domains [45, 49], we unraveled the intricate coupling between 
conformation and lateral diffusion of LFA-1 microdomains. Domain mobility was crucial for 
the formation of stable and large clusters that initiate LFA-1 mediated leukocyte adhesion 
[58]. In addition, these novel imaging techniques have now provided compelling evidence that 
tetraspanins regulate the mobility of integrin molecules in the plasma membrane. The physical 
association of the laminin-binding α6 integrin with tetraspanin CD151 was demonstrated to 
promote random-confined diffusion of the integrin in mammary cells, which may regulate its 
interaction with the cytoskeletal protein talin [59]. In B lymphocytes, we have shown that the 
tetraspanin CD37 is required for the mobility and clustering of α4β1 integrin molecules in 
the plasma membrane, which is important for plasma cell survival and antibody production 
[60]. These studies provide novel mechanistic insights into the contribution of TEMs to integrin 
lateral motility and adhesive properties. Still, studies addressing the mechanisms underlying 
TEM dynamics and interactions in the plasma membrane are scarce, in particular in immune 
cells. The elegant study on the mobility of single molecules of tetraspanin CD9 in prostate 
carcinoma cells revealed that CD9 mostly exhibits Brownian diffusion at the plasma membrane, 
but is transiently confined to platforms that are enriched in CD9 and its interaction partners 
[25] again highlighting the importance to investigate TEMs in living cells. Although no single 
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technique is able to unravel the concept of membrane receptor compartmentalization and 
function, we believe that the best approach toward understanding the principles of membrane 
microdomains is to compare and contrast results obtained with the existent methods as well as 
exploring new techniques as they are developed and improved. The advantages and limitations 
of the discussed microscopy techniques, that are able to image all types of microdomains, are 
nicely reviewed elsewhere [61]. A major current challenge in the field is to increase insight 
into the molecular mechanisms underlying the regulation of membrane-proximal signaling by 
membrane microdomains in immune cells.
Signal transduction regulated by plasma membrane microdomains 
It is well-established that signaling transduction efficiency is dependent on the selective 
concentration of signaling proteins into discrete clusters in the plasma membrane (reviewed 
in [62, 63]), including their recruitment into specialized microdomains such as rafts and TEMs 
[64, 65]. Whereas some proteins constitutively reside in rafts, like most Src family kinases, other 
proteins become only transiently associated with rafts, for example upon activation. Similarly, 
protein kinase C (PKC) recruitment to TEMs and subsequent activation is an inducible process 
that depends on integrin activation [66]. Thus, microdomains can serve as ‘scaffolds’ to localize 
and transiently concentrate specific signaling molecules [67]. The time a protein resides within 
a microdomain can be altered upon oligomerization of the protein after for example multivalent 
ligand binding. In addition, activated receptors can induce coalescence of rafts with a different 
composition resulting in large and stable structures on the plasma membrane [64, 68] again 
underscoring the dynamic nature of the signaling capacity of membrane microdomains. 
Within the microdomain environment, receptors can be modified by local kinases, leading to 
further downstream signaling. Indeed proteomics data demonstrate an enrichment of specific 
signaling molecules in rafts fractions compared to total membrane fractions [69] (Table 1). 
Although the exact mechanisms underlying this enrichment need to be identified, it is apparent 
that special domains or motifs in the molecular structure of signaling proteins determines their 
localization to the plasma membrane [62]. This concept is nicely illustrated by members of 
the ubiquitously expressed proteins of the Ras family of GTPases. The importance of Ras for 
APC biology is illustrated by R-Ras-deficient murine DCs that show impaired maturation and 
T lymphocyte priming, which is linked to defective LPS signaling [70]. H-Ras and K-Ras are 
highly homologous proteins, still they generate very distinct signaling outputs, due to their 
different lipid anchors interacting with different regions of the plasma membrane. H-Ras, 
which is palmitoylated, has transient interactions with lipid rafts, whereas K-Ras clusters in 
non-raft areas of the plasma membrane [42]. Palmitoylation by itself is not a prerequisite for raft 
localization since this modification has also been shown essential for tetraspanin-tetraspanin 
interactions, the stability of TEMs, and its signaling capacity [71, 72]. Several tetraspanins have 
been reported to interact with G protein subunits, phosphatidylinositol 4-kinase, and activated 
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PKC isoforms in many different cell types including APCs (reviewed in [21, 65, 73]). Whether 
these signaling proteins interact directly to tetraspanins is unclear, but the intracellular or the 
transmembrane regions of tetraspanins have been implicated in their interaction with PKC [66, 
74, 75]. Interestingly, some tetraspanins contain a PDZ motif in their C-terminal tail, which 
facilitates the anchoring of transmembrane proteins to the cytoskeleton and hold together 
signaling complexes, thus providing a direct way to sequester components of a signaling 
cascade to TEMs [21, 76]. Furthermore, several studies have demonstrated that TEMs are 
implicated in regulation of the JNK and Akt signaling pathways [60, 77-79]. In B cells, we have 
recently shown the requirement of tetraspanin CD37 for proper α4β1 integrin mobility and 
clustering, which is essential for Akt signaling and survival of IgG1-producing plasma cells [60]. 
Many studies support the concept that tetraspanins act as linker molecules to recruit kinases 
in the proximity of integrins [66, 72, 80]. Strikingly, it was shown that tetraspanin CD37 is able 
to signal by itself, as it contains predicted ITAM-like and ITIM-like motifs in its two intracellular 
tails [81]. Antibody cross-linking of CD37 on B cells resulted in recruitment of Lyn and SHP1 
via its ITIM-like domain, leading to cell death, whereas its ITAM-like domain recruited PI3K 
and Akt leading to cell survival. Thus, upon antibody ligation of CD37, two opposing stimuli 
act simultaneously on the Akt signaling pathway, although the involvement of Fc receptors 
cannot be completely excluded in this study. Different groups have demonstrated that TEMs 
can also inhibit signal transduction pathways by the recruitment of phosphatases [82, 83], or 
alternatively by the sequestering of kinases away from their site of action [84, 85]. Recently, the 
C-terminal cytoplasmic domain of tetraspanin CD81 was shown to directly interact with the 
GTPase Rac and to inhibit Rac activation [86]. 
Taken together, microdomains are implicated in enhancing or dampening signaling from 
immune receptors by serving as platforms for the dynamic assembly of signaling complexes. 
Considering the complexity of TEMs and lipid rafts, it not surprising that they regulate many 
different signaling pathways by their capacity to not only include but also exclude proteins from 
microdomains. For instance, phosphatase CD45, a negative regulator of receptor signaling, 
is well-known to be excluded from lipid rafts [87]. Another example is the interaction of 
tetraspanins (CD81, CD82) with CD4 and CD8 co-receptors, that can sequester these proteins 
away from the T cell receptor signaling complex in the plasma membrane [84]. Next to 
regulating the recruitment of signaling molecules and activation of immune receptors on the 
plasma membrane, microdomains can also promote cross-talk between different receptors (Fig. 
2). These fascinating processes will be discussed below, taking pattern-recognition receptors 
(PRRs), major histocompatibility complex (MHC) class II and the B cell antigen receptor (BCR) 
as classical examples of immune receptors regulated by membrane microdomains during the 
course of an immune response. 
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Pattern-recognition receptors
APCs are equipped with a broad panel of specific PRRs that are essential for the recognition and 
uptake of pathogens. APCs bind pathogens by means of complex multi-molecular interactions 
between different PRRs and a wide variety of microbial structures called pathogen-associated 
molecular patterns (PAMPs). Efficient pathogen recognition and uptake is dependent on a 
high level of organization of PRRs in the plasma membrane of APCs. There is now increasing 
evidence that specialized microdomains can serve as organizing platforms that facilitate 
PRR multimerization and clustering; cross-talk between different PRRs; and integration of 
downstream signal transduction pathways. The two main PRR subclasses that are expressed 
on the plasma membrane of APCs include C-type lectin receptors (CLRs) and Toll-like receptors 
(TLRs). 
Receptor multimerization is a well-defined mechanism that increases receptor avidity and 
ligand engagement. A classical example is the CLR DC-SIGN which exists as tetramers in the 
plasma membrane, and is clustered into microdomains during DC differentiation [44, 88]. A 
direct structural relationship between tetramer stability and nanoclustering formation sustained 
by the neck region of DC-SIGN has recently been reported [57]. This provides DC-SIGN with 
the ability to bind nanoscale pathogens (viruses) of different sizes highlighting a physiological 
role for nanoclustering. Another CLR, Dectin-1, has been found to cluster in a ‘phagocytic 
synapse’ (a structure reminiscent of the immunological synapse formed between APCs and T 
cells) in myeloid cells which is crucial for triggering phagocytosis and full anti-fungal activity 
[89]. Different studies have shown that Dectin-1 interacts with tetraspanin proteins (CD63 and 
CD37) on the cell surface of APCs which may facilitate Dectin-1 clustering [90, 91]. CD37-
deficiency leads to impaired stabilization of Dectin-1 molecules in the membrane of APCs due 
to increased internalization. The Dectin-1-CD37 interaction has also functional consequences 
since Dectin-1-mediated interleukin-6 production by APCs is inhibited by CD37.
TLRs have also been reported to dimerize into homodimers and/or heterodimers which 
facilitates recruitment of intracellular signaling adapters and kinases. Dimer formation of TLRs 
occurs at both the extracellular Leucin-rich repeat domain and the cytosolic TIR domain. TLR 
localization into microdomains may further induce receptor clustering. TLR2 and TLR4-CD14 
recruitment to lipid rafts has been described [92-94], although other studies documented 
TLR4 association with tetraspanin microdomains in macrophages [95]. It is not unlikely that 
different pools of TLRs exist in the membrane that are localized to different microdomains. 
Regulation of these receptor pools may be linked to ligand-specific cellular responses and/or 
depend on the activation status of the cell. This hypothesis may be resolved by investigating TLR 
clustering and localization in living APCs using high resolution microscopy (such as multi-color 
SPT). Recently, the scavenger receptor CD36 has been found in multi-molecular complexes 
composed of tetraspanin CD9, CD81, integrins, and Syk kinase [96]. Although not a classical 
PRR, CD36 can recognize Plasmodium falciparum and bacterial diacylglycerides. Similarly, the 
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scavenger receptor CD5 that recognizes β-glucan in fungal cell wall was reported to interact 
with the tetraspanin CD9 although functional implications of this interaction have not been 
reported [97]. Thus, assembly of PRRs in membrane microdomains may underlie the mechanism 
of receptor multimerization (reviewed in [98-100]). It is important to note that besides the 
presence of PRRs in preassembled clusters, pathogen binding itself will further induce PRR 
clustering, possibly altering PRR-induced signaling intensity and duration.
Receptor cross-talk refers to the collaborative induction of a response by different receptors 
that is distinct from the response elicited by individual receptors. Microdomains are believed 
to provide a platform for efficient receptor cross-talk in the plasma membrane. For example, 
mutual signaling from TLR2 and Dectin-1 is documented to be required for pro-inflammatory 
cytokine production by APCs upon β-glucan binding [101]. Besides synergistic responses, the 
outcome of PRR cross-talk may also dampen unwarranted immune responses when receptors 
act antagonistically. For example, there is now evidence of existing inhibitory interactions 
between different TLRs in the membrane of human PBMCs [102]. A consequence of such 
receptor cross-talk is the integration of different signal transduction pathways which eventually 
determines the outcome of the immune response aimed to eradicate the pathogen (reviewed 
in [100]). However, less well-known is the existence of cross-talk between different signaling 
molecules already at the level of the plasma membrane [62]. In this context signaling molecules 
that contain specific protein or lipid binding specificity can dock at the plasma membrane which 
often directly coincides with their activation. For example, the kinase Syk gets recruited to the 
phosphorylated ITAM-like motif in the intracellular tail of Dectin-1 upon yeast binding [103]. 
Although the precise role of lipid rafts and TEMs in PRR cross-talk needs to be established, 
evidence is accumulating that membrane microdomains are important for the formation of 
multi-molecular signaling complexes by providing a local environment that allows for efficient 
physical interactions between signaling molecules and PRRs [98]. 
MHC class II
APCs utilize MHC class II molecules to present non-self peptides to CD4+ T cells. As the 
abundance of relevant MHC class II-peptide complexes is rather low, it is necessary to organize 
and cluster MHC on the APC surface for efficient antigen-specific T cell activation. Early 
crystallography studies of MHC class II molecules revealed a structure described as a dimer of 
heterodimers [104] that supported a model in which superdimers of MHC II molecules may 
facilitate the activation of T cells by cross-linking T cell receptors [105]. However, this could 
not explain how sufficient numbers of agonistic MHC-peptide complexes from all over the 
cell surface could be concentrated in the centre of a synapse to activate T cells. It is now 
widely accepted that MHC molecules cluster in the plasma membrane of APC [106]. MHC 
class II-peptide complexes in mature DC are collectively transported to the plasma membrane 
where they remain pre-clustered at the cell surface [107, 108]. This has led to the concept 
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that MHC-peptide complexes cluster into specialized microdomains in APC prior to the 
formation of the immunological synapse [109]. This concept has been supported by different 
studies that provide evidence for a functional association of MHC class II molecules with lipid 
rafts. Disrupting raft integrity on B cells indeed results in inhibition of MHC class II antigen 
presentation at low antigen concentration. Since the surface expression of MHC class II and the 
peptide binding to MHC class II were unaltered after raft disruption, a model was postulated 
in which lipid rafts locally concentrate MHC class II-peptide complexes, crucial for efficient 
antigen presentation at low doses of antigen [110]. However, there is also compelling evidence 
that MHC class II molecules interact with tetraspanins (CD9, CD63, CD37, CD53, CD81, CD82) 
demonstrated by immunoprecipitation studies [18, 111], FRET microscopy [55], and electron 
microscopy [112, 113]. These studies revealed that tetraspanins are enriched on the internal 
membranes of MHC II enriched compartments (MIICs) in B cells where they can interact with 
MHC class II, HLA-DM and HLA-DO [112, 113]. In immature DCs however, CD63 was found 
exclusively in MIICs, whereas CD9, CD53 and CD81 mainly interact with MHC class II at the 
plasma membrane [114], indicating that individual tetraspanins can selectively interact with 
MHC class II in different compartments. Selective enrichment of tetraspanin molecules in the 
central supramolecular activation complex formed between APCs and T cells has also been 
demonstrated [115]. 
In addition, co-clustering of murine MHC class II molecules I-A and I-E has been reported 
to depend on TEMs. In CD9-deficient DCs, MHC I-E failed to co-cap with I-A molecules and 
exogenous expression of CD9 in CD9-negative B cells enhanced I-A/I-E interaction [116]. This 
model was challenged in a study in which cholesterol depletion, but not absence of CD9, did 
affect I-A/I-E interaction [117]. This controversy may be explained by sensitivity of both DRMs 
and TEMs to cholesterol depletion by MCD, favoring a model where both microdomains are 
involved in MHC clustering. The mobility of MHC class II molecules in the plasma membrane is 
also dependent on cholesterol [118]. Furthermore, single molecule tracking revealed that MHC 
class II molecules undergo hop diffusion between membrane compartments [119], providing a 
possible explanation for the molecular exchange between microdomains.  
Interestingly, some studies reported that tetraspanins associate predominately with 
peptide-loaded MHC class II complexes [114, 120]. Tetraspanins were found in complexes with 
multimerized MHC class II molecules as shown by immunoprecipitations with the antibody 
CDw78 [121]. These domains were enriched with the CD86 co-stimulatory molecule and the 
peptide editor HLA-DM, and carried a restricted peptide repertoire. In contrast, the HLA-DR 
molecules found in rafts displayed a highly diverse peptide repertoire [120]. However, these 
studies must be interpreted with caution since the specificity of the CDw78 antibody has been 
questioned [122]. Silencing of tetraspanins CD9, CD63 and CD81 (but not CD82) resulted in 
increased MHC class II expression, but did not affect MHC class II peptide loading [123]. Still, 
the importance of tetraspanins in antigen presentation and T cell activation has been validated 
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by studies with APCs from tetraspanin-deficient mice. DCs lacking CD37 or CD151 are hyper-
stimulatory to T cells by different mechanisms. Whereas CD151 regulates co-stimulation, CD37 
is implicated in inhibiting antigen presentation via MHC class I and class II molecules [124]. 
Thus, individual tetraspanins on APCs have specific functions that can even be opposing, for 
example tetraspanins CD9 and CD82 may promote MHC clustering, whereas others, such as 
CD37 may dysregulate MHC clustering at the plasma membrane. In addition, cooperation 
between tetraspanins has also been demonstrated; CD37xTssc6 double knockout DCs were 
significantly more hyper-stimulatory than DCs isolated from either single knockout mouse 
[125]. Taken together, TEMs have been implicated in the assembly (clustering), stabilization 
and/or trafficking of MHC class II-peptide complexes. The complexity of the composition of 
the tetraspanin web and their localization within the cell warrants further studies to clarify the 
precise function of TEMs in the MHC class II lifecycle.
B cell antigen receptor
The BCR complex is composed of a membrane-bound immunoglobulin which mediates binding 
to antigen, and the Igα/Igβ (CD79) heterodimer which couples the receptor to downstream 
signaling pathways. Igα and Igβ contain an ITAM motif, which becomes phosphorylated by Src-
family tyrosine kinases after receptor engagement. This allows for recruitment and activation 
of the cytosolic Syk/Zap70 family of protein tyrosine kinases, leading to downstream signaling 
[126]. In resting B cells, BCRs are located into non-raft areas of the plasma cell membrane. Upon 
antigen binding, BCR molecules oligomerize, and rapidly translocate into lipid rafts where BCR 
signaling is facilitated. This was not only determined using biochemical methods [127], but was 
also visualized in living cells by fluorescent microscopy [128, 129]. Partitioning into lipid rafts 
is intrinsic to the BCR itself and independent of BCR signaling or the actin cytoskeleton [130] .
CD19 forms together with complement receptor CD21, tetraspanin CD81 and Leu-13 an 
essential co-receptor complex for the BCR. This co-receptor complex lowers the threshold for 
B cell activation, as activated CD19 recruits signaling molecules to the BCR [131]. Interestingly, 
BCR that is co-ligated to the CD19/CD21 complex has a longer retention time in lipid rafts, 
resulting in the formation of a stable signaling-active complex at the plasma membrane [132]. 
Subsequently, BCR internalization and targeting of the BCR to MHC class II peptide-loading 
compartments is required for antigen presentation. This process was found to depend on 
the association of phosphorylated clathrin with lipid rafts [133]. The BCR is able to continue 
signaling after being endocytosed, providing a means to activate different kinases at different 
subcellular locations [134]. The role of tetraspanin CD81 in the BCR co-receptor complex is 
critical, since CD81 is required for stabilizing mature CD19 on the plasma membrane of both 
human and murine B cells [135-139]. Moreover, CD19, CD21 and the BCR fail to translocate 
into DRMs in CD81-deficient cells after co-ligation of CD21 and the BCR [32]. Palmitoylation of 
the cytoplasmic tail of CD81 is increased upon co-ligation of the BCR and CD19/CD21/CD81 
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complex, which is needed for the stabilization of protein complexes in both lipid rafts [140] and 
TEMs. Thus CD81 is critically involved in BCR localization to microdomains and thereby promotes 
BCR signaling. The finding that CD81 can localize to both TEMs and lipid rafts exemplifies again 
the dynamics and molecular exchange that occurs between different types of microdomains. 
An additional means through which the BCR can be compartmentalized is via the cortical 
actin cytoskeleton. The actin cytoskeleton acts as a barrier to BCR diffusion, compartmentalizing 
the BCR from activating co-receptors including CD19, thereby preventing spontaneous BCR 
signaling in resting B cells. Disruption of the actin network is sufficient to induce robust 
signaling in B cells in the absence of BCR stimulation [141]. After B cell activation, however, the 
cortical actin cytoskeleton needs to be remodeled, in order for BCR clusters and rafts to coalesce 
and to form stable signaling platforms [142, 143]. Ezrin-Radixin-Moesin proteins, which link 
the actin cytoskeleton with plasma membrane proteins are transiently dephosphorylated upon 
BCR stimulation. This results in dissociation of the plasma membrane from the underlying 
actin cytoskeleton, and a transient increase in BCR diffusion [142, 144]. Recently, Mattila and 
colleagues elegantly showed that signaling through the BCR is regulated by combined action 
of the actin cytoskeleton and the CD81 tetraspanin web in primary B cells [145]. Using super-
resolution microscopy techniques and CD19- and CD81-deficient B cells, they deciphered the 
role of the tetraspanin network in BCR signaling induced by cytoskeleton disruption. In contrast 
to the release of the BCR, CD19 diffusion is not altered upon disruption of the cytoskeleton. 
Instead, CD19 is restrained by the tetraspanin network, shown by the significantly faster 
diffusion of CD19 in CD81-deficient cells. CD81 thus holds co-receptor CD19 in place to interact 
with mobile BCR nanoclusters released after cytoskeleton disruption. Whether BCR signaling is 
initiated in lipid rafts, or whether initial signaling needs to occur before reorganization of the 
actin cytoskeleton allows the BCR microdomains to move into stable raft signaling platforms still 
needs to be addressed. Taken together, these studies demonstrate that the interplay between 
different microdomains including lipid rafts and TEMs is essential for efficient signaling via the 
BCR. In the following section, the relevance of membrane microdomains in different diseases 
will be discussed together with the possibilities to target these structures as novel therapeutics.
Implications of microdomains in immune-related diseases
Prevailing evidence suggest that certain pathogens utilize rafts and tetraspanin microdomains 
to gain entry and to survive inside the cell. Pathogens can use different strategies to take 
advantage of microdomains in the membrane. For example, bacteria such as Salmonella 
typhimurium and Legionella pneumophila exploit lipid rafts to create phagosomes that allow 
them to survive inside antigen-presenting cells (reviewed in [146]). Several bacteria enter 
phagocytic cells through raft-associated proteins (such as CD55 and CD48) that prevents 
trafficking to lysosomes, thus avoiding degradation and antigen presentation. Although there 
is no evidence for the presence of PRRs in caveolar structures, a role for caveolae in pathogen 
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uptake has been reported. For example, enrichment of GPI-anchored proteins (such as CD48) 
into caveolae has been documented that can bind bacterial antigens and thereby facilitate 
pathogen entry into host cells [147]. In addition, caveolin proteins have been reported to inhibit 
downstream signaling pathways of TLRs [148].
Also, certain viruses including Hepatitis C virus (HCV) and human immunodeficiency virus 
(HIV-1) use rafts and tetraspanin microdomains for virus assembly and budding [24] (reviewed in 
[149, 150]). HCV binds directly to the extracellular loop of tetraspanin CD81 to invade not only 
APCs, but also lymphocytes and hepatocytes. The clinical relevance of HCV-CD81 interaction 
was shown by the capacity of CD81-specific antibodies to mediate protection to HCV infection 
in vivo [151]. Similarly, blocking CD55 could prevent host-pathogen interactions [146]. In 
addition, cholesterol-sequestering agents that interfere with cholesterol biosynthesis (statins) 
may have therapeutic value for patients with infectious disease and sepsis [152]. Another novel 
approach is the use of recombinant soluble tetraspanin EC2 proteins that may interfere with 
tetraspanin microdomain assembly [153] exemplified by their potency to inhibit CCR5-tropic 
HIV-1 infection of macrophages [154]. Taken together, collaboration between different PRRs 
increases the specificity of recognition, extends their signaling competence, and enables the 
host to respond to almost any type of infection. At the same time, certain pathogens have 
evolved mechanisms to take advantage of membrane microdomains for their own benefit. The 
challenge is to translate this knowledge into new therapeutic strategies for emerging infectious 
diseases. 
The broad influence and the complex role of the tetraspanin web on cell function is reflected 
in the diversity of phenotypes observed in human tetraspanin deficiencies. Tetraspanin TM4SF2 
is mutated in families with X-linked mental retardation [155], and mutations in TSPAN12 cause 
familial exudative vitreoretinopathy [156-158]. A mutation in CD151 leading to loss of the 
integrin-binding domain, causes defects in assembly of basement membranes in kidney and 
skin. These patients suffer from renal failure, pretibial epidermolysis bullosa, sensorineural 
deafness and β-thalassemia minor [159]. In the immune system, tetraspanin proteins play a 
crucial role, as demonstrated by human tetraspanin deficiencies in CD53 and CD81. Lack of 
CD53 expression on neutrophils was found to be the cause of an immune deficiency syndrome 
in a family which suffered from opportunistic infections and reactivation of chronic silent 
mutations. Although the mechanism underlying this defect in immune cell function was not 
studied, a role for CD53 in the negative regulation of the immune response was postulated 
[160]. Furthermore, a patient with a gene defect in CD81 was reported with severe nephropathy 
and hypogammaglobulinemia. Absence of CD81 expression due to a homozygous splice site 
mutation resulted in a complete lack of CD19 expression on B cells. Rescue experiments by 
transduction of wildtype CD81 into the patient B cells showed that the CD81-deficient B cells 
are able to produce CD19, but the maturation and subsequent membrane expression of CD19 
are defected in CD81-negative B cells. As a consequence, BCR-mediated stimulation is affected, 
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resulting in impaired antibody responses and memory B cell formation [139]. Taken together, 
defects in individual tetraspanins can result in a wide variety of complex phenotypes, and 
one could speculate that unidentified mutations in tetraspanin proteins could be the cause of 
unexplained human diseases.
Targeted therapy of microdomains
In the last decade, evidence has accumulated that microdomains can be targets for novel 
treatment opportunities. For example, targeting components of lipid rafts as therapeutic 
intervention for cancer has been explored by inhibitors of the epidermal growth factor receptor 
(EGFR) that is overexpressed in breast cancer [161]. In malignancies of the immune system, 
the B cell marker CD20 has been targeted by rituximab, which was shown to be effective 
against non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL) (reviewed in [162]). 
In lymphoma B cell lines, it has been shown that upon binding of rituximab on the cell surface, 
CD20 molecules are redistributed to lipid rafts resulting in raft stability and organization, and 
subsequently induction of apoptosis via Src kinase-dependent pathway [163, 164]. Rituximab 
also inhibits BCR signaling by preventing re-localization into lipid rafts [165]. .Although the 
underlying mechanisms have not thoroughly been investigated, lipid raft constituents are 
being used to predict rituximab treatment affectivity. For example, the expression of the raft-
associated ganglioside GM1 differs between various primary B cell lymphomas, and low GM1 
expression has been shown to lead to unresponsiveness of lymphoma patients to rituximab 
treatment [166]. 
Polyunsaturated fatty acids from fish oil can have a potential therapeutic effect for patients 
suffering from inflammatory or autoimmune diseases, like colitis or asthma [167]. Although the 
exact underlying mechanisms remain to be defined, polyunsaturated fatty acids can enhance B 
cell function in vivo by increasing MHC class II expression and diminishing GM1 microdomain 
clustering [168, 169]. Lipids in microdomains can also serve as a therapeutic target exemplified 
by mouse anti-cholesterol antibodies that are specific for clustered cholesterol on the cell 
surface. Binding of this antibody to B cell lymphoma cells in vitro has been reported to recruit 
MHC class II and CD80 molecules into microdomains resulting in effective antigen presentation 
to T cells [170].
TEMs are already targeted by specific antibodies or soluble tetraspanin EC2 proteins to 
interfere with viral and bacterial infections as described above. Moreover, tetraspanins are 
currently under detailed investigation as new targets for therapy of hematopoietic malignancies. 
CD37 is highly expressed on B cells and is therefore a candidate therapeutic target for B cell 
malignancies, like CLL. Excitingly, CD37-specific small modular immunopharmaceutical (anti-
CD37 SMIP), has been shown to induce apoptosis and antibody dependent cellular cytotoxicity 
in lymphoma/leukemia cells in vitro [171], and humanized anti-CD37 SMIP is currently in a 
phase I/II clinical trials for relapsed CLL and non-Hodgkin’s lymphoma. Anti-CD37 SMIP induces 
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association of CD37 with phosphorylated signaling proteins (pSHP1, pLyn and pSrc) within 
DRMs of CLL patient cells, and thereby directly regulates CLL cell death [81]. Recently, dual-
ligand immunoliposomes have been tested as a new concept for targeted drug delivery and 
apoptosis in B-CLL cells [172]. These liposomal nanoconstructs express two types of antibody 
ligands with high affinity for B-CLL cells, such as CD19, CD20, and CD37. The antigen expression 
levels on the cell surface varies between patients and this study showed that a combination of 
anti-CD37 with either anti-CD20 or anti-CD19 led to higher binding and delivery efficiency of 
immunoliposomes than the single-antibody immunoliposomes. Taken together, these studies 
show the potential of targeting microdomains and provide a solid basis for further research and 
development of new therapies.
Concluding remarks
It is well established that the spatial organization of proteins and lipids in the plasma membrane 
into multi-molecular complexes is fundamental for inter- and intracellular communication. 
In APCs, specialized membrane microdomains are emerging as critical players that regulate 
fundamental immunological processes including pathogen recognition, antigen presentation, T 
cell activation and antibody production. Although we are only at the beginning of understanding 
the biology of membrane microdomains in APCs, we anticipate that advanced microscopy 
techniques will provide comprehensive new insights into the formation, dynamics, and signaling 
capacity of these highly specialized membrane structures. In particular, pioneering studies at 
the single molecule level in living cells has revealed that the dynamic behavior of components 
of lipid rafts and TEMs is heterogeneous, ranging from rapid diffusion to confinement. This 
may provide cells with the capacity to delicately regulate the formation of immunoreceptor 
signaling complexes in the plasma membrane that are essential for APC function. Indeed, 
recent studies have shown that tetraspanin proteins regulate the mobility of their interacting 
immunoreceptors in the plasma membrane [59, 60]. Since evidence is now accumulating that 
the development of different human diseases is dependent on early stage nanoscale changes 
of plasma membrane molecules, we envisage the exploitation of membrane microdomains as 
novel therapeutic targets for treatment of infectious and malignant diseases.  
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Abstract
Multispectral imaging is a novel microscopy technique that combines imaging 
with spectroscopy to obtain both quantitative expression data and tissue 
distribution of different cellular markers. Tetraspanins CD37 and CD53 are four-
transmembrane proteins involved in cellular and humoral immune responses. 
However, comprehensive immunohistochemical analyses of CD37 and CD53 
in human lymphoid organs have not been performed so far. We investigated 
CD37 and CD53 protein expression on primary human immune cell subsets in 
blood and in primary and secondary lymphoid organs. Both tetraspanins were 
prominently expressed on antigen-presenting cells, with highest expression of 
CD37 on B lymphocytes. Analysis of subcellular distribution showed presence 
of both tetraspanins on the plasma membrane and on endosomes. In addition, 
CD53 was also present on lysosomes. Quantitative analysis of expression and 
localization of CD37 and CD53 on lymphocytes within lymphoid tissues by 
multispectral imaging revealed high expression of both tetraspanins on CD20+ 
cells in B cell follicles in human spleen and appendix. CD3+ T cells within splenic 
T cell zones expressed lower levels of CD37 and CD53 compared to T cells in 
the red pulp of human spleen. B cells in human bone marrow highly expressed 
CD37, whereas the expression of CD53 was low. In conclusion, we demonstrate 
differential expression of CD37 and CD53 on primary human immune cells, their 
subcellular localization, and their quantitative distribution in human lymphoid 
organs. This study provides a solid basis for better insight into the function of 
tetraspanins in the human immune response.
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Introduction
The specific cellular architecture of primary and secondary lymphoid organs aids in the complex 
coordination of the initiation of the immune response against a wide variety of pathogens and 
tumor cells. The microarchitecture of lymphoid organs is highly dynamic and its structure changes 
constantly upon antigen encountering. Whereas primary lymphoid organs (bone marrow, 
thymus) are the major sites of lymphocyte development, secondary lymphoid organs (spleen, 
lymph nodes and mucosal-associated lymphoid tissues, like appendix) provide a sophisticated 
environment in which immune cells interact with each other, as well as with accessory cells and 
antigens. Secondary lymphoid organs have a remarkably similar microanatomy under homeostatic 
conditions in which essentially three different regions can be distinguished [1]. The outermost 
region is the antigen-sampling region where antigen-presenting cells, including macrophages 
and dendritic cells (DCs), sample and deliver antigens to the B and T cell areas. The outer cortex 
contains predominantly B cell follicles, where germinal centers (GCs) can develop and the inner 
cortex which comprises mainly T cells. A specialized conduit system, formed by interconnected 
fibroblastic reticular cells, supports migration of DCs and lymphocytes through different areas 
of the lymphoid organs to interact with other immune cells. In addition, this system provides 
a tubular network for distribution of small soluble antigens and immune modulators enabling 
communication between the antigen-sampling zone and the T cell zone [2].
Cell-cell communication and immune cell migration is controlled by a wide variety of 
different immunoreceptors embedded in the plasma membrane. These immunoreceptors are 
non-randomly distributed in the plasma membrane by means of specialized membrane domains 
[3]. This compartmentalization is essential for immune cell function, including pathogen 
recognition, antigen presentation and migration. Tetraspanin-enriched microdomains (TEM) 
are functional multi-molecular complexes in the plasma membrane [4–7] in which tetraspanins 
interact with each other and with partner molecules, like transmembrane immunoreceptors, 
enzymes and signaling proteins. Tetraspanin proteins belong to the superfamily of four-
transmembrane proteins that are expressed at the cell surface and in intracellular membranes. 
To date, 33 different tetraspanins have been characterized in humans of which tetraspanins 
CD37 and CD53 are specific for the immune system [5]. Tetraspanin CD37 has been studied 
extensively in CD37-deficient (Cd37-/-) mice in which both the cellular and humoral arms of 
the immune system are defective. CD37 inhibits T cell proliferation [8], interleukin-6 production 
by macrophages [9], and antigen presentation by DCs [10]. Moreover, CD37 tightly regulates 
antibody production by B cells [11]. Cd37-/- mice have a strikingly increased number of IgA+ 
plasma cells in their lymphoid organs, whereas the number of IgG+ plasma cells is low due to 
decreased survival signals in the GCs of the spleen [11,12]. The function of tetraspanin CD53 
has not been well studied although recurrent infections have been reported in a CD53-deficient 
family [13]. The underlying mechanism of tetraspanin function has been attributed to specific 
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interactions between tetraspanins and immunoreceptors (major histocompatibility complex 
(MHC) proteins, B cell receptor (BCR), integrins, and others) in the plasma membrane.
Despite the importance of tetraspanins in the immune system, little is known about their expression 
and micro-anatomical location. In this study, tetraspanins CD37 and CD53 were selected as these 
are amongst all tetraspanins exclusively present in the immune system. We report their expression 
on primary human blood immune cell subsets and detailed quantitative immunohistochemical 
analyses of their expression and localization in human primary and secondary lymphoid organs 
are revealed by multispectral imaging. This novel technique allows for direct unbiased overview of 
different tissues with the main advantage that, next to information on the single cell expression 
level, the differential tissue localization of individual cell subsets can be studied.
Materials and methods
Cells
Cells were obtained from buffy coats of healthy individuals with informed consent in accordance 
with institutional and international guidelines following the Declaration of Helsinki. Peripheral 
blood mononuclear cells (PBMCs) were obtained by Ficoll density centrifugation. PBMCs were 
cultured in RPMI-1640 supplemented with 2% human serum (HS) in Costar culture flasks (1x108 
cells / 75cm2 flask) to adhere monocytes for 1 hour at 37°C. After removal of PBLs, monocytes 
were harvested with cold PBS. 
Flow cytometry
Single cell suspensions were first stained with primary antibodies against human CD53 (mem53, 
Serotec), CD37 (WR17, home-made) or isotype controls in PBS with 1% BSA and 0.05% NaN3 
(PBA) supplemented with 2% HS for 30 min at 4°C, followed by incubation with goat-anti-mouse 
Alexa488 antibody (Molecular Probes). Next, cells were stained with the following anti-human 
antibodies: CD3-PE (HIT3a, Becton Dickinson), CD4-APC (RPA-T4, Biolegend), CD8-PerCP (SK1, 
Becton Dickinson), CD20-APC (2H7, eBioscience), CD14-PE (CLB-mon/1, Pelicluster, Sanquin), 
CD56-APC (NCAM16.2, Becton Dickinson), CD19-PerCP (4G7, Becton Dickinson), BDCA1-FITC 
(AD5-8E7, Miltenyi) and/or BDCA2-FITC (AC144, Miltenyi). Stained cells were analyzed using 
FACS Calibur (Becton Dickinson) and FlowJo software (version 9.7, TreeStar Inc.).
Confocal microscopy
Fibronectin-coated coverslips were made by incubation of 20μg/mL fibronectin (Roche) in PBS 
for 1 hour at 37°C. Monocytes were adhered on fibronectin-coated coverslips for 2 hours and 
subsequently fixed with 2% paraformaldehyde (PFA) and blocked with 3% BSA, 1% HS and 
10mM glycine in PBS for 30 min at room temperature (RT). Cells were permeabilized and stained 
with antibodies against CD53 (mem53, Serotec), CD37 (WR17, home-made), calreticulin (ER 
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marker, Sigma), syntaxin 12/13 (endosome marker, Synaptic Systems (cat. no. 110132)) and 
Lamp1 (lysosome marker, Sigma-Aldrich) in 0.5% saponin, 1% BSA, 10mM glycine, 1% HS in 
PBS, followed by goat-anti-mouse Alexa488 and goat-anti-rabbit Alexa647 (Molecular Probes). 
Samples were imaged with an Olympus FV1000 Confocal Laser Scanning Microscope. Images 
were analyzed using Fiji software [14].
Tissues
Human spleen samples were obtained from deceased human kidney donors and bone marrow and 
appendix samples were obtained from healthy donors, which was approved by the medical ethical 
committee for human research (Radboudumc, The Netherlands). All tissue samples were formalin-
fixed, paraffin-embedded, and cut in 4μm sections according to standard procedures [15].
Immunofluorescence
Tissues were deparaffinized, followed by antigen retrieval using 10mM citrate buffer and 
blocked with 10% normal goat serum (NGS) in PBA for 1 hour at RT. Tissues were first 
stained with antibodies against human CD37 (clone 2B8, Thermo Scientific) or CD53 (clone 
EPR4342(2), GenTex) diluted in 2% NGS in PBA for 1 hour at RT, followed by incubation with 
Alexa-conjugated secondary antibodies diluted in 1% NGS in PBA for 1 hour at RT. For nuclear 
staining, tissues were incubated for 5 min with DAPI (diluted 1:3000 in PBS). Tissue slides were 
fixed in 1% PFA in PBS for 15 min at RT and embedded in Mowiol mounting medium.
Immunohistochemistry
Tissues were deparaffinized, followed by antigen retrieval using 10mM citrate buffer, and blocked 
with 3% hydrogen peroxidase (H2O2) in methanol for 10 min at RT. Tissues were blocked with 2% 
HS in Tris-buffered saline (TBS) with 1% BSA for 45 min at RT, and stained with primary antibodies 
against human CD3 (clone CD3-12, AbD Serotec) or CD20 (clone L26, Thermo Scientific) 
diluted in TBS supplemented with 1% BSA overnight at 4°C. Next, tissues were incubated with 
biotinylated secondary antibodies diluted in TBS with 1% BSA, 1% HS and 1% NGS or normal 
horse serum (NHS) for 45 min at RT. After 1 hour incubation with avidin- and biotin-conjugated 
alkaline phosphatase (ABC-AP) solution, red color was developed by incubation with Warp Red 
Solution for 10 min. Secondly, tissues were stained with antibodies against human CD37 (clone 
2B8, Thermo Scientific) or CD53 (clone EPR4342(2), GenTex) diluted in PBS, 1% BSA, 2% HS 
for 45 min at RT, followed by incubation with biotinylated secondary antibodies in TBS with 1% 
BSA, 1% HS and 1% NHS or NGS for 45 min at RT. After 1h incubation with avidin- and biotin-
conjugated horseradish peroxidase (ABC-HRP) solution, blue color was developed by incubation 
with True Blue peroxidase substrate for 8 min. For technical reasons, CD20 and CD37 could not be 
stained on the same slide, as such single stainings for CD37 were performed. For nuclear staining, 
tissues were incubated for 1 min with Nuclear Red. Dried sections were embedded in Permount. 
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Multispectral imaging and quantitative digital analysis
Tissue slides were imaged using Vectra Intelligent Slide Analysis System (Version 2.0.8, PerkinElmer 
Inc.). This imaging technique combines imaging with spectroscopy where the entire spectrum 
is collected at every location of the image plane in an automatic manner. Images of single 
stained tissues for each fluorophore or chromogen, with its own unique spectral characteristics, 
were used to build spectral libraries with Nuance Multispectral Imaging System (Version 3.0.2, 
PerkinElmer Inc.). For correction of autofluorescence, an image was made from unstained 
human spleen tissue and the autofluorescence signal was subtracted from the spectrum for 
each fluorophore. These spectral libraries were used to unmix the original multispectral images 
obtained with the Vectra imaging system. Two red chromogens (Warp Red and Nuclear Red) 
with highly similar spectra were used of which correct unmixing has been described before 
[16]. A selection of 10 representative original multispectral images was used to train the inForm 
Advanced Image Analysis Software (Version 2.0.2, PerkinElmer Inc.) for quantitative image 
analysis (tissue and cell segmentation, quantification of the expression levels of proteins of 
interest) as described before [17,18]. The threshold for dim or bright tetraspanin expression 
was determined by objective examination of the staining intensity of non-immune cells in true 
blue negative regions. All the settings applied to the training images were saved within an 
algorithm allowing batch analysis of multiple original multispectral images of different samples 
of the same origin equally stained. The number of images used for quantification and statistical 
analysis of CD37 and CD53 distribution is dependent on the acquisition of the tissue slides 
during imaging; i.e. the position of the tissue on the coverslip can vary, leading to acquisition of 
less or more images. If a 20x image contains less than 10% of tissue, this image was discarded 
from the analysis. Finally, not all 20x images contained B cell follicles or T cell regions, resulting 
in a higher number of images analyzed for red pulp or lamina propria regions (Table S1).
Statistics
Statistical differences of tetraspanin expression between different tissue regions in human 
lymphoid organs were determined using the unpaired Student’s t-test or, in case of a non-
Gaussian distribution, the Mann-Whitney test (GraphPad Prism 5, GraphPad Software, San 
Diego, CA). All differences with P≤0.05 were considered to be statistically significant.
Results
Expression of CD37 and CD53 on immune cell subsets in blood
To investigate cell surface expression of tetraspanins CD37 and CD53 on the plasma membrane 
of different immune cell subsets in blood, PBLs were stained for CD4 (T cells), CD8/CD3/
CD56- (T cells), CD20 (B cells), CD14 (monocytes), CD56/CD3-/CD8- (NK cells) and BDCA1/
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CD19- (myeloid DC (mDC)) and BDCA2 (plasmacytoid DC (pDC)) (Fig. S1). We observed the 
highest CD37 expression on B cells and low to medium expression on T cells, monocytes and 
NK cells (Fig. 1A and B). CD53 was expressed on all subsets, with highest expression on B cells 
and monocytes (Fig. 1A and C). CD37 and CD53 were expressed on both mDCs and pDCs, 
with no apparent differences in expression level between the two DC subsets (Fig. 1D-F). It has 
been reported that tetraspanins can be expressed at intracellular membranes [19,20], which 
stimulated us to investigate the subcellular localization of CD37 and CD53. Monocytes were 
double stained with CD37 or CD53 antibodies in combination with antibodies specific for the 
endoplasmatic reticulum (ER), endosomes or lysosomes. Next to the expression on the plasma 
membrane, both CD37 and CD53 were abundantly expressed in the endosomes, in contrast to 
the ER (Fig. 2A and B). In the lysosomes, we observed only CD53 to be present.
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Figure 1: Expression of CD37 and CD53 on immune cell subsets in blood. 
(A) Flow cytometry analysis of expression of CD37 or CD53 (black line) on CD4 and CD8 T cells, B cells, monocytes and 
NK cells versus isotype control (grey line). Gating strategy is presented in Fig. S1. (B-C) Expression levels of CD37 (b) and 
CD53 (c) were normalized for isotype staining by background subtraction. Experiments were performed with PBLs from 
three healthy donors. Data present mean±SD. (D) Flow cytometry analysis of expression of CD37 or CD53 (black line) on 
mDCs (BDCA1+CD19-) or pDCs (BDCA2+) versus isotype control (grey line). (E-F) Expression levels of CD37 (e) and CD53 
(f) were normalized for isotype staining by background subtraction. Experiments were performed with PBLs from two 
healthy donors. Data present mean±SD.
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Multispectral analyses of human lymphoid organs
We investigated the tissue distribution of CD37 and CD53 in human lymphoid organs by 
multispectral imaging. In contrast to classical immunohistochemistry, multispectral imaging 
directly provides quantitative information into the differential tissue distribution of individual 
cell subsets. First, we investigated localization of CD37 and CD53 in human spleen. We 
observed that CD37 was more locally expressed in follicle-like structures when compared to 
CD53 which showed a more dispersed expression profile (Fig. 3A-E). To explore this in more 
detail, we performed double stainings of either the T cell marker CD3 or the B cell marker 
CD20 combined with CD37 or CD53 on primary (bone marrow) and secondary (spleen and 
appendix) lymphoid tissues. Figure 4 illustrates the technology of multispectral imaging and 
analysis of lymphoid tissue stained for the B cell marker CD20 (Warp Red), tetraspanin CD53 
(True Blue) and cell nuclei (Nuclear Red). Single stained tissues for each chromogen (Warp Red, 
True Blue and Nuclear Red) were used to create a spectral library containing the specific spectra 
of each used chromogen (Fig. 4A) allowing to unmix the original multispectral images (Fig. 4B). 
This resulted in separate images for each marker (Fig. 4D-F) that were used to generate the 
composite RGB image (Fig. 4C). We made use of two red chromogens (Warp Red and Nuclear 
Red) with highly similar spectra of which correct unmixing has been described before [16]. Next, 
analysis software was trained using 10 representative original multispectral images to segment 
the different tissue regions (B cell follicle and stromal tissue (red pulp in spleen or lamina propria 
in appendix)) based on a combination of parameters including cell morphology and specific 
staining (Fig. 4G) and individual cells based on nuclear characteristics (Fig. 4H). For each cell, 
CD20 positivity and CD53 expression were determined in relation to tissue localization (Fig. 
4I-L). These settings were saved within an algorithm allowing batch analysis of multiple original 
multispectral images of the same tissue and stainings. In Figure 5, we performed similar analysis 
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Figure 2: Subcellular localization of CD37 and CD53.
(A-B) Localization of CD37 (a) or CD53 (b) (green) in monocytes was studied by dual staining with calreticulin (ER), 
syntaxin13 (endosomes) or lamp1 (lysosomes) (red). Merge: co-localization in yellow (white arrows). Scale bar = 5μm.
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for lymphoid tissue stained for the T cell marker CD3 (Warp Red), tetraspanin CD37 (True Blue) 
and cell nuclei (Nuclear Red). Original multispectral images could be unmixed using the spectral 
library showed in Figure 4A (Fig. 5A-E). Next, tissue segmentation was performed for T cell 
zones, B cell follicle and red pulp (Fig. 5F), followed by cell segmentation (Fig. 5G) and analysis 
of CD3 and CD37 expression within the different tissue regions (Fig. 5H-L). As expected, B cell 
follicles mainly consisted of CD20 positive cells, and T cell zones contained mainly CD3 positive 
cells. The stromal tissue consisted of CD20 or CD3 negative and positive cells. Altogether, we 
established multispectral imaging analysis to combine quantitative tetraspanin expression data 
with specific tissue localization in human lymphoid tissues. 
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Figure 3: Expression of CD37 and CD53 on human spleen. 
(A) Original multispectral image of human spleen stained for CD37 (Alexa488), CD53 (Alexa568) and cell nuclei (DAPI). 
Scale bar = 100μm. (B-E) Composite RGB image (b) of unmixed CD37 (c, in green), CD53 (d, in red) and DAPI (e, in blue) 
signal after correction for autofluorescence. One representative image is shown.
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Figure 4: Spectral imaging analysis. 
Human spleen stained for CD20 (Warp Red), CD53 (True Blue) and cell nuclei (Nuclear Red). (A) The spectral library of 3 
chromogens (Warp Red (red line), True Blue (blue line) and Nuclear Red (green line)) was built in Nuance software using 
single stained human spleen tissues. (B) Representative original multispectral image. Scale bar = 100μm. (C-F) Composite 
RGB image (c) of unmixed CD20 (d, in red), CD53 (e, in blue) and nuclei (f, in green) signal. (G) Tissue segmentation; B cell 
follicle (B, yellow), red pulp (RP, green) and other tissue (blood vessels, collagen; blue). (H) Segmentation of individual cells 
(green) based on Nuclear Red staining. (I) Thresholds for Warp Red and True Blue staining were set to score CD20-CD53dim 
(blue), CD20+CD53dim (red), CD20+CD53bright (yellow) or CD20-CD53bright (green) cells. (J-L) Scatter plots showing optical 
densities for CD20 (Y-axis) and CD53 (X-axis) of individual cells in B cell follicles (j, l blue) and red pulp (k, l red) and 
thresholds used for scoring (dotted lines). A representative of 2000 cells per tissue region is plotted. 
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Figure 5: Spectral imaging analysis. 
Human spleen stained for CD3 (Warp Red), CD37 (True Blue) and cell nuclei (Nuclear Red). (A) Representative original 
multispectral image. Scale bar = 100μm. (B-E) Composite RGB image (b) of unmixed CD3 (c, in red), CD37 (d, in blue) 
and Nuclear Red (e, in green) signal using the spectral library (Fig. 4A). (F) Tissue segmentation; B cell follicle (B, yellow), T 
cell zone (T, red), red pulp (RP, green) and other tissue (blood vessels, collagen; blue). (G) Segmentation of individual cells 
(green) based on Nuclear Red staining. (H) Thresholds for Warp Red and True Blue staining were set to score CD3-CD37dim 
(blue), CD3+CD37dim (red), CD3+CD37bright (yellow) or CD3-CD37bright (green) cells. (I-L), scatter plots showing optical 
densities for CD3 (Y-axis) and CD37 (X-axis) of individual cells in T cell zone (i, l green), B cell follicles (j, l blue) and red 
pulp (k, l red) and thresholds used for scoring (dotted lines). A representative of 2000 cells per tissue region is plotted.
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Localization and quantitative expression of CD37 and CD53 in lymphoid 
organs
We studied the localization and expression of tetraspanin CD37 in primary and secondary 
lymphoid organs. Since bone marrow does not contain different T and B cell areas, tissue 
segmentation was not applicable and only cell segmentation was performed (Fig. 6A-C and Fig. 
7A-C). The intensity (optical density (OD)) of CD37 in bone marrow ranged from 0.05 – 0.85, 
with a mean of 0.29 (ODmean; Fig. 6D). We observed around 80% of all bone marrow cells 
to be CD37bright (Fig. 6E), and 90% of all T cells to be highly positive for CD37 (Fig. 6F). The 
scatter plots with the set thresholds to annotate cells with dim and bright expression of CD37 
and CD53 are shown in Figure 4J-L, Figure 5I-L and Supplementary Figures 2 and 3. In human 
spleen, B cell follicles, T cell zones and red pulp areas were efficiently distinguished (Fig. 6G-I 
and Fig. 7G-I). CD37 showed highest expression in the B cell follicles (ODmean = 0.22) compared 
to the T cell zones and red pulp areas (ODmean = 0.15; Fig. 6J). In splenic B cell follicles, twice as 
many cells were CD37bright, compared to the red pulp where only 45% of the cells was CD37bright 
(Fig. 6K). When focusing on CD37 expression on splenic T cells we observed that significantly 
more T cells were CD37bright in the red pulp as compared to T cells in T cell zones (Fig. 6L). In 
the appendix, B cell follicles and lamina propria regions were located immediately below the 
crypts (Fig. 6M-O and Fig. 7M-O). CD37 showed highest expression in B cell follicles (ODmean 
= 0.12) compared to the lamina propria (ODmean = 0.09) in appendix (Fig. 6P) which is in line 
with CD37 expression in spleen. In the B cell follicles in human appendix almost all cells were 
CD37bright, which was significantly more than in the lamina propria where around 80% of total 
cells expressed high levels of CD37 (Fig. 6Q). Similar to the red pulp in spleen, significantly more 
T cells in the lamina propria were CD37bright compared to the T cells within B cell follicles of the 
appendix (Fig. 6R). However, we need to be careful with interpreting these data, because the 
frequency of T cells in the appendix is very low.
Figure 6: Localization and expression of CD37. →
Bone marrow (A-F), spleen (G-L) and appendix (M-R). A, G, M Representative original multispectral image of lymphoid 
organ stained for CD3 (Warp Red), CD37 (True Blue) and cell nuclei (Nuclear Red). Scale bars represent 100 μm. (B, H, 
N) Composite RGB image after spectral unmixing of original image (red = CD3, blue = CD37, green = nuclei). (C, I, O) 
Scoring of CD3-CD37dim (blue), CD3+CD37dim (red), CD3+CD37bright (yellow) or CD3-CD37bright (green) cells. (D, J, P) Optical 
density of CD37 on individual cells in human bone marrow (d), in B cell follicles (blue line), T cell zones and red pulp (red 
line) of human spleen (j) and in B cell follicles (blue line) and lamina propria (red line) of human appendix (p). Optical 
densities were binned per 0.05 and normalized to % of max. (E-F) Percentage of CD37dim and CD37bright cells in total 
bone marrow (e) and in the CD3+ cell population of human bone marrow (f). (K-L) Percentage of total CD37bright cells in 
B cell follicle and red pulp (k), and in the CD3+ cell population within T cell zones and red pulp (l) of human spleen. (Q-R) 
Percentage of CD37bright cells in appendix (q) and in the CD3+ cell population within B cell follicle and lamina propria of 
human appendix (r). Each dot represents data of one 20x image from the lymphoid tissue. The red line represents the 
mean. *P<0.05, ****P<0.0001.
57
Multispectral imaging of CD37 and CD53
2
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0
20
40
60
80
100
Optical density total CD37
%
 o
f m
ax
Optical density total CD37
%
 o
f m
ax
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0
20
40
60
80
100 B cell follicle
T cell zone & red pulp
dim
CD37
bright
CD37
0
20
40
60
80
100
%
 o
f c
el
ls
dim
CD37
bright
CD37
0
20
40
60
80
100
%
 o
f C
D
3+
 c
el
ls
B cell
follicle
Red pulp
0
20
40
60
80
100
%
 C
D
37
 b
ri
gh
t o
f t
ot
al
 c
el
ls
T cell zone Red pulp
0
20
40
60
80
100
%
 C
D
37
 b
ri
gh
t o
f C
D
3+
 c
el
ls
Original Composite Scoring
Optical density total CD37
%
 o
f m
ax
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0
20
40
60
80
100 B cell follicle
Lamina propria
B cell
follicle
Lamina
propria
0
20
40
60
80
100
%
 C
D
37
 b
ri
gh
t o
f t
ot
al
 c
el
ls
0
20
40
60
80
100
B cell
follicle
Lamina
propria
%
 C
D
37
 b
ri
gh
t o
f C
D
3+
 c
el
ls
**** ****
**** ****
**** *
A
Original Composite Scoring
Original Composite Scoring
B C
D E F
G H I
J K L
M N O
P Q R
Figure 6: Localization and expression of CD37.
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Next, we performed multispectral imaging analyses for tetraspanin CD53 in human bone 
marrow, spleen and appendix. In bone marrow, the OD of CD53 ranged between 0.05 – 0.60, 
with an ODmean of 0.13 (Fig. 7D). The CD20+ B cells in bone marrow were mostly CD53dim (Fig. 
7E), contrary to the majority of CD3+ T cells that were CD53bright (Fig. 7F). In human spleen, we 
observed CD53 to be expressed at higher levels in B cell follicles (ODmean = 0.15) than in the 
red pulp and T cell zones (ODmean = 0.09; Fig. 7J). In contrast to human bone marrow, almost 
100% of CD20+ B cells in the spleen were CD53bright, significantly more than in the splenic red 
pulp where 85% of B cells expressed high levels of CD53 (Fig. 7K). Similar to CD37 expression, 
significantly more T cells in the red pulp compared to the T cell zone were CD53bright (Fig. 7L). 
In human appendix, CD53 was slightly higher expressed in B cell follicles (ODmean = 0.10) than 
in the lamina propria regions (ODmean = 0.07; Fig. 7P). B cells within B cell follicles and lamina 
propria, expressed similar levels of CD53 (Fig. 7Q), whereas significantly more T cells in the 
B cell follicle expressed high levels of CD53 compared to T cells in the lamina propria (Fig. 
7R). Together, these data demonstrate that CD37 and CD53 are differentially localized and 
expressed in human bone marrow and in B cell, T cell and red pulp or lamina propria regions 
in human spleen and appendix. Furthermore, B and T cells have different expression levels of 
tetraspanin proteins depending on their localization within the tissue.
Figure 7: Localization and expression of CD53. →
Bone marrow (A-F), spleen (G-L) and appendix (M-R). A, G, M Representative original multispectral image of lymphoid 
organ stained for CD20 (Warp Red), CD53 (True Blue) and cell nuclei (Nuclear Red). Scale bars represent 100 μm. (B, H, 
N) Composite RGB image after spectral unmixing of original image (red = CD20, blue = CD53, green = nuclei). (C, I, O) 
Scoring of CD20-CD53dim (blue), CD20+CD53dim (red), CD20+CD53bright (yellow) or CD20-CD53bright (green) cells. (D, J, P) 
Optical density of CD53 on individual cells in human bone marrow (d), in B cell follicles (blue line), T cell zones and red 
pulp (red line) of human spleen (j) and in B cell follicle (blue line) and lamina propria (red line) of human appendix (p). 
Optical densities were binned per 0.05 and normalized to % of max. (E-F) Percentage of CD53dim and CD53bright cells in 
the CD20+ cell population (e) and in the CD3+ cell population (f) of human bone marrow. (K-L) Percentage of CD53bright 
cells in the CD20+ cell population in the B cell follicle and red pulp (k) and in the CD3+ cell population in the T cell zone 
and red pulp (l) of human spleen. (Q-R) Percentage of CD53bright cells in the CD20+ cell population (q) and in the CD3+ 
cell population (r) in the B cell follicles and lamina propria of human appendix. Each dot represents data of one 20x image 
from the lymphoid tissue. The red line represents the mean. *P<0.05, ****P<0.0001.
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Figure 7: Localization and expression of CD53.
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Discussion
Here, we provide the quantitative expression of tetraspanins directly linked to tissue distribution 
in human lymphoid organs using multispectral imaging. Tetraspanin proteins are important in 
controlling cellular immune responses which is evidenced by the defects in the immune system 
of different tetraspanin-deficient mice [10,21–24]. 
We demonstrate abundant expression of CD53 on lysosomes and of both tetraspanins on 
endosomes in human monocytes. The presence of tetraspanin proteins in intracellular vesicles 
has been linked to their function to regulate the trafficking of their partner proteins through 
the cell [7,25]. In B cells, both CD37 and CD53 can be found in multivesicular endosomes, 
called MHC class II-enriched compartments [26]. Furthermore, it has been described that CD37 
contains a tyrosine-based sorting motif which targets this protein to endocytic vesicles [25].
The predominant expression of CD37 observed on B lymphocytes and in B cell follicles is in 
line with former studies reporting an important role for CD37 in B cell function [11,12,21,27]. 
In the cytoplasmic tails of CD37 “ITIM-like” and “ITAM-like” motifs have been reported that 
regulate B cell death and survival respectively [27]. Interestingly, the dynamic process of B cell 
differentiation and selection in GCs coincides with lower CD37 expression towards plasma 
cell differentiation [28]. Tetraspanins play a well-established role in cancer development and 
progression [29], and CD37-directed targeted therapies are currently under investigation in 
clinical trials in patients with B cell malignancies [30–32].
We observed primary myeloid and plasmacytoid DCs in human blood to express CD37 
protein suggesting that CD37 may be involved in human DC function. This is supported by 
studies with DCs of CD37-deficient mice which show that CD37 promotes cell migration [33] 
and inhibits antigen presentation via MHC class II molecules [10]. T cells present in lymphoid 
organs were mostly CD37bright, which may be linked to the reported function of CD37 in T cell 
proliferation, which predominantly takes place in lymphoid organs upon antigen presentation 
by DCs. T cells that are deficient in CD37 have disturbed regulation of T cell receptor signaling 
leading to increased proliferation [8]. Remarkably, lymphocytes in various tissue regions within 
spleen and appendix often expressed significantly different levels of CD37 and CD53. For 
example, significantly more T cells in the red pulp were CD37bright compared to T cells in the T 
cell zone, suggesting that CD37 expression correlates with immune cell localization though it 
is also possible that these represent different T cell subsets.
The role of CD53 in the immune system has not been clearly defined although a CD53-
deficient family has been reported that suffered from recurrent infections [13]. Our study now 
demonstrates that CD53 in blood is expressed on all immune cells with the highest expression 
on B cells, monocytes and mDC and pDC subsets. Within the secondary lymphoid tissues spleen 
and appendix, CD53 was highly expressed on both CD20+ and CD3+ cells. Surprisingly, we 
found CD20+ B lymphocytes in bone marrow to be mostly CD53dim which may be related to the 
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finding that CD53 is under the control of the transcription factor early B cell factor-1 (EBF-1) 
[34]. EBF-1 is essential for B cell development by inducing expression of the genes encoding the 
(pre-)BCR, from which production is started in pre-B cells. CD53 has also been shown to interact 
with protein kinase C (PKC) (Zhang et al 2001; personal communication), a central signaling 
molecule important in cell proliferation, differentiation, and apoptosis. We anticipate that CD53 
may only be expressed during later stages of B cell development in the bone marrow when 
the (pre-)BCR is expressed, which is in line with an earlier study showing lower levels of CD53 
in earlier maturation stages of B cells within bone marrow [28]. Furthermore, we demonstrate 
abundant CD53 expression on T cells within blood and lymphoid organs. Although CD53 
function in T cells is largely unknown to date, a strong correlation between CD53 expression 
on murine thymocytes and positive selection has been reported in the thymus [36].
In conclusion, we demonstrate the differential expression of tetraspanins CD37 and CD53 in 
the human immune system. Multispectral imaging allowed us to obtain quantitative expression 
data that is directly linked to tissue distribution. This study offers guidance for further exploring 
tetraspanin function in the human immune system using this novel imaging technique.
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Supplementary figure 1: Flow cytometry gating strategy of immune cell subsets in PBLs. 
(A-H) Live cells were gated on FSC-SSC plots (a). From the live cells, CD4+ T cells (b), CD8+ (CD3+CD56-) T cells (c), CD20+ B 
cells (d), CD14+ monocytes (e), CD56+ (CD3-CD8-) NK cells (f), BDCA1+CD19- mDCs (g) and BDCA2+ pDCs (h) were gated.
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Supplementary figure 2: Scatter plots of CD3 or CD20 and CD37 expression in human bone marrow, spleen and 
appendix. 
(A-B) Expression of CD3 and CD37 (a) and CD37 alone (b) in human bone marrow. (C) Expression of CD37 alone in 
human spleen (scatter plots of CD3 and CD37 shown in Fig. 5I-L). Black = B cell follicle, gray red pulp & T cell zone. (D-E) 
Expression of CD3 and CD37 (d) and CD37 alone (e) in human appendix. Black = B cell follicle, gray = lamina propria. 
Dotted lines represent threshold used for analysis of scoring CD3 positive and negative cells (horizontal line) or CD37dim 
and CD37bright cells (vertical line) in inForm software. Data shown of 2000 representative cells per tissue region.
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Supplementary figure 3: Scatter plots of CD3 or CD20 and CD53 expression in human bone marrow, spleen and appendix. 
(A-B) Expression of CD3 (a) or CD20 (b) and CD53 in human bone marrow. (C) Expression of CD3 and CD53 in human 
spleen (scatter plots of CD20 and CD53 shown in Fig. 4J-L). Dark gray = T cell zone, black = B cell follicle, gray = red 
pulp. (D-E) Expression of CD3 (d) or CD20 (e) and CD53 in human appendix. Black = B cell follicle, gray = lamina propria. 
Dotted lines represent threshold used for analysis of scoring CD3 or CD20 positive and negative cells (horizontal line) or 
CD53dim and CD53bright cells (vertical line) in inForm software. Data shown of 2000 representative cells per tissue region.
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Supplementary table 1: Number of 20x images used for quantification and statistical analysis of CD37 and CD53 dis-
tribution. 
Figure # Organ # of images used for quantification 
and statistical analysis
6E Bone marrow 35
6F Bone marrow 40
7E Bone marrow 41
7F Bone marrow 38
B cell follicle or T cell zone Red pulp
6K Spleen 296 311
6L Spleen 174 273
7K Spleen 233 325
7L Spleen 182 298
B cell follicle Lamina propria
6Q Appendix 94 120
6R Appendix 50 112
7Q Appendix 65 124
7R Appendix 69 107
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Abstract
Dendritic cell (DC) subsets respond differently to pathogens  and differ in their 
ability to ingest, process and present antigens. These processes are mediated 
through multiple different receptors (pattern recognition receptors, integrins, 
MHC and other immunoreceptors) which are coordinated at the level of the 
plasma membrane. Tetraspanins organize cell membranes by facilitating (receptor) 
protein-protein interactions within the so called tetraspanin web. In this study we 
compared expression of the complete tetraspanin superfamily in primary murine 
and human DC subsets at the RNA and protein level. We observed different 
RNA and protein expression profiles for the tetraspanin genes across human and 
murine DC subsets. A select group of tetraspanins (CD9, CD37, CD53, CD81, 
CD82, CD151 and Tspan31) was analyzed in more depth on human DCs. RNA 
expression levels of CD37 and CD82 were not significantly different between 
human DC subsets. In human pDCs, CD9 RNA was expressed at relatively high 
levels compared to CD1c+ or CD141+ DCs, while CD9 protein expression was 
lower. This indicates that relative RNA and protein expression levels are not always 
in agreement. Both murine CD8α+ DCs and its presumed human counterpart, 
CD141+ DCs, displayed relatively high protein levels of CD81. CD53 protein was 
highly expressed on human pDCs which was in contrast to the relatively low protein 
expression of most other tetraspanins. This CD53 protein expression pattern was 
not conserved between human and mouse, as CD53 was expressed lower on 
murine pDCs compared to CD8α+ and CD4+ DCs. The functional implications 
of this differential tetraspanin expression was illustrated by the hampered IL-6 
secretion by CD53-deficient murine bone marrow derived DC upon stimulation. 
This report provides a valuable resource that will aid the understanding of 
tetraspanin function in DC biology.
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Introduction 
Dendritic cells (DCs) are highly specialized immune cells that can sense tumor and microbial 
antigens and initiate both cellular and humoral immune responses. The complexity of the 
DC network has expanded enormously in the last decade by the identification of multiple 
different DC subsets. These subsets have been characterized by ontogeny, anatomical location, 
phenotypical markers, gene expression programs, and functionality [1,2]. The remarkable 
heterogeneity in DC subtypes may underlie a broad variety in the type, strength and duration 
of immune responses that may lead to either immunity or tolerance.
The DC network is largely conserved between mouse and human, although subset-
discriminatory (cell surface) markers are different between the two species. In human peripheral 
blood, DC subsets are classified into plasmacytoid DCs (pDCs, BDCA4+) and two myeloid DC 
subsets: CD141+ (BDCA3+) and CD1c+ (BDCA1+) cells, also referred to as classical DC1 (cDC1) 
and cDC2, respectively [3]. These DC subsets are not only present in blood but have also 
been detected in different human lymphoid and non-lymphoid organs. In contrast to humans, 
murine DCs have mostly been studied in lymphoid organs, rather than in blood, and include 
plasmacytoid DCs (pDCs, CD11c int, B220+) and two myeloid DC subsets: CD8α+ (CD11b- 
CD11c+) DCs and CD4+ (CD11b+ CD11c+) DCs [4,5]. Although there are both phenotypical 
and anatomical differences between these murine and human DC subsets, they share many 
functional properties [6]. Both human and murine pDCs have the capacity to produce vast 
amounts of type I interferons (IFNα and IFNβ) and as such are important in the induction 
of antiviral immune responses. The cDC1 subsets (human CD141+ and murine CD8α+ DCs) 
share the ability to mediate efficient antigen cross-presentation leading to activation of CD8+ 
T cells, whereas the cDC2 subsets are more efficient in stimulating CD4+ T cell responses and 
polarization towards Th2 and Th17 responses [2]. 
DCs interact with their environment (i.e. tissue surroundings, pathogens/tumor cells and 
other immune cells) through immunoreceptors that are embedded in the plasma membrane. 
It is well-established that these immunoreceptors (including major histocompatibility complex 
(MHC) molecules, pattern-recognition receptors (PRRs) and adhesion proteins) are often 
non-randomly distributed at the cell surface and organized in domains. This organization not 
only increases receptor avidity, but also allows for receptor cross-talk and spatial regulation of 
receptor signaling. For example, MHC-peptide complexes on DCs are pre-clustered, permitting 
simultaneous engagement of multiple T cell receptors (TCRs) to overcome the required 
signaling threshold for T cell activation [7–10]. Clustering of immunoreceptors in DCs occurs 
in several specialized membrane domains, including caveolae, lipid rafts, and tetraspanin-
enriched microdomains that each have a distinct organization and function [11–14][Chapter 
1 [15],Chapter 4 [16]]. In this study, we focused on the organizers of the latter domain, the 
tetraspanins, which are widely expressed but so far only little studied in DC subsets.   
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Tetraspanins belong to the superfamily of four-transmembrane proteins that share a CCG 
motif and conserved cysteine residues in the large extracellular loop [17,18]. They are expressed on 
the plasma membrane as well as on intracellular membranes. Tetraspanins are not classical ligand-
binding receptors that bind ligands in trans, instead they mostly interact with other proteins in 
cis. Documented binding partners are different immunoreceptors (MHC, CD4, CD8, C-type lectin 
receptors, and others), integrins and signaling proteins, and tetraspanins regulate their lateral 
organization [14,19]. It has been estimated that DCs express approximately 20 tetraspanins of the 
33 different family members that have been identified in mammalian cells [20,21]. Despite the 
essential role of cell surface receptors for DC function, studies on the role of tetraspanin proteins 
in regulating DC receptors have only recently been initiated. We and others have shown that 
DC migration is regulated by tetraspanins CD37 and CD81. CD81 was found to be required for 
the formation of membrane protrusions during adhesion-dependent DC migration, and CD37-
deficiency leads to impaired DC migration from skin to lymph nodes in mice [22,23]. In contrast, 
the predominantly intracellular expressed tetraspanin CD63 may slow down DC migration 
via a mechanism that is yet unclear [24]. Other studies have reported on the involvement of 
tetraspanins (CD37, CD151, CD9, CD81, CD82) in antigen presentation by DCs by regulating 
MHC interactions, the formation of the immune synapse or through exosomes [25–29]. 
Together these studies underscore that tetraspanins play an important role in regulating DC 
surface receptor function. The different DC subsets differ greatly in the set of surface receptors 
they express [30], and consequently may require a distinct set of tetraspanins for receptor 
regulation. Moreover, differential expression of tetraspanins between DC subsets could equip 
DCs with cell specific functions by regulation of the same cell surface receptor in one DC subset 
with respect to  other subsets. Here, we directly compared the differential expression of the 
complete tetraspanin superfamily in primary murine and human DC subsets at the RNA and 
protein level and discuss potential implications for DC biology.
Materials and Methods
Microarray data
For RNA analysis, publically available affymetrix CEL files containing expression data of resting 
human pDCs, CD1c+ and BDCA3 (CD141+) mDCs were downloaded from ArrayExpress 
(accession: E-TABM-34). For mouse DCs, files containing expression data of resting spleen-pDCs 
(GSM605840-GSM605842), spleen-CD8α DCs (GSM538258-GSM538260) and spleen-CD4+ 
DCs (GSM538248-GSM538250) were downloaded from the Gene Expression Omnibus. The raw 
files were processed in the R programming environment and intensity values were normalized 
using the RMA normalization function of the affy package [31]. The normalization was evaluated 
by boxplots (Fig. S1). Specific annotation packages for human and mouse were used to map 
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array probe identifiers to corresponding species specific Gene Symbols. In case of redundant 
probes, the probe with highest summed intensity of all samples was considered. From the curated 
tetraspanin genes sets (http://www.genenames.org/genefamilies/TSPAN) we were able to retrieve 
32 tetraspanins in the human dataset and 31 tetraspanins in the mouse dataset. ANOVA was 
applied on the 2log-transformed values of the retrieved tetraspanins for human and mouse data 
separately. For the genes that had an expression level below 5 we did not find any ANOVA 
significant differences. Because of the increasing influence of background noise these data were 
considered less reliable. Therefore genes that had expression levels below 5 in 2-out-of-3 donors in 
all DC subsets were only included in Supplementary Table 1.  p-values were corrected for multiple 
testing using the Benjamini & Hochberg correction. Genes with a resulting p-value <0.05 were 
considered as differentially expressed. For the generation of heat maps, the human and murine 
datasets were separately z-scored (setting the data to a mean=0 and a variance=1), and heat 
maps were generated using freely availably GeneE program (http://www.broadinstitute.org/). 
Cells
Human blood peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of 
healthy individuals by Ficoll density centrifugation (Lucron Bioproducts). Buffy coats were obtained 
with informed consent in accordance with institutional guidelines. Single cell suspensions of 
murine spleens were made by DNAse and collagenase treatment, after which DCs were enriched 
by Nycodenz density centrifugation as described in [32]. Bone marrow cells were isolated and 
cultured in the presence of 200ng/ml rFlt3L (eBioscience) in RPMI supplemented with 10% FCS, 1% 
glutamine (Cambrex), 0.5% antibiotic/antimycotic (Invitrogen) and 50mM beta-mercaptoethanol 
at 37°C, 10% CO2 for 9 days. Differentiated cells were analysed for purity and composition by 
flow cytometry or stimulated with 400ng/ml R848 or 100ng/ml CpG (both Enzo Life Sciences) 
for 24 hours, after which supernatant was collected for analyses of cytokine production. Cd53-
/- mice (C57Bl/6J background) and C57Bl/6J wild-type mice were bred at the Central Animal 
Laboratory Nijmegen (The Netherlands). All murine studies complied with European legislation 
(directive 2010/63/EU of the European Commision) and were approved by local authorities (CCD, 
The Hague, the Netherlands) for the care and use of animals with related codes of practice.
Flow cytometry 
Antibodies used in this study are listed in Supplementary Table 2. Human PBMC were stained 
with viability dye e780 in PBS before fixation with 2% PFA in PBS.  Murine cells were fixed with 
4% PFA. Cells were permeabilized with 0.5% saponin (Sigma) in PBA. Cells were blocked and 
stained in 1% human serum (human cells) or 2% goat serum (murine cells), 0.5% saponin in PBA. 
First, cells were stained with anti-tetraspanin antibodies or isotype controls, followed by labelled 
secondary antibodies. Next, free arms of bound secondary antibodies were blocked with mouse 
or rabbit serum, and subsequently stained with antibodies for DC subset identification. Human 
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PBMC were analyzed on the FACSVerse (BD Biosciences) and murine cells on the FACSCalibur (BD 
Biosciences). Data analysis was done using FlowJo software (version 9.7, TreeStar Inc.).
Cytokine production
IL-6 present in supernatants of stimulated bone marrow derived DC cultures were analyzed by 
sandwich ELISA using MaxiSorp 96-wells plates (Nunc, Roskilde, Denmark). Anti-IL-6 (MP5-20F3, 
Biolegend) was coated overnight at 4°C, plates were blocked with 1% FCS and 1% BSA in PBS, 
and supernatants were added for 1 h at 37°C. Plates were incubated with biotinylated anti-IL-6 
(MP5-32C11, BD Biosciences), followed by Streptavidin-HRP (eBioscience) and detection with 
TMB. Absorbance was read at 450 nm. ELISA to detect murine IL-10 was performed according 
to the manufactures instructions (Ready-SET-Go!, eBioscience).
Results
Tetraspanins are differentially expressed by human DC subsets
RNA expression data of tetraspanins in human DCs subsets was retrieved from a publically 
available dataset [33], which provides relative mRNA expression levels of tetraspanin superfamily 
members in CD1c+ DCs, CD141+ DCs and pDCs derived from 3 healthy donors. From these 
files we were able to analyse expression data of 26 different human tetraspanins of which 16 
appeared differentially transcribed between the DC subsets (Fig. 1A; Table S1). Information 
on tetraspanins that were only detected at low expression levels (which prevented reliable 
assessment of differential expression between subsets) is included in Supplementary Table 1. 
The expression profiles differed greatly between the tetraspanin genes: CD9, CD53, TSPAN1, 
TSPAN3, TSPAN13 and TSPAN31 were relatively high expressed in pDCs compared to CD1c+ 
DCs and CD141+ DCs, whereas the other tetraspanin genes displayed higher mRNA levels in 
mDC subsets compared to pDCs (CD63, CD151, TSPAN17). In addition, several tetraspanin 
genes were differentially transcribed between mDC subsets CD1c+ and CD141+ DCs (e.g. 
CD53, CD81, TSPAN2, TSPAN4, TSPAN14). Of the tetraspanin genes depicted in Figure 1B no 
significant differences in their mRNA expression levels between the different DC subsets were 
found. Based on the microarray data, our specific interest and the availability of antibodies, 
we selected 7 tetraspanin genes for in-depth analysis. Plotting of the untransformed RNA 
expression levels of these tetraspanins highlighted that although CD9 was remarkably high 
expressed in pDCs compared to the other subsets, differences in expression levels between 
the DC subsets were generally small, but consistent between the different donors (CD53, 
CD81, CD151 and TSPAN31). mRNA expression levels of CD37 and CD82 were not significantly 
different between DC subsets, but are of interest for further analysis because of their potential 
roles in antigen presentation and/ or DC migration that are key to DC function [22,23] (Fig. 1C).
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Next, for the selected set of 7 tetraspanins on human DC subsets, we investigated  whether 
RNA expression values were indicative of protein expression levels. Total protein expression 
levels were measured on CD1c+ DCs, CD141+ DCs and pDCs by flow cytometry. For most 
tetraspanins, the observed differential expression between the DC subsets at the mRNA level 
was confirmed at the protein level (Fig. 2A; Table 1). The protein data, however, was not 
always in agreement with the RNA expression data. We observed a lower CD9 and CD82 
protein expression on pDCs compared to CD1c+ or CD141+ DCs and equal levels of TSPAN31 
(Fig. 2B), which was in contrast to their relative mRNA expression levels in pDCs. These results 
indicate that CD9, CD82 and TSPAN31 protein expression in pDCs is possibly modulated by 
decreased mRNA stabilisation and/or increased protein degradation  For the other tetraspanins 
studied, mRNA and protein levels were largely in agreement (Table 1). Although CD37 protein 
expression varied greatly between donors, similar expression levels were found between the 
DC subsets of each donor. CD53 was highly expressed in pDCs which was in sharp contrast to 
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Figure 1: Relative mRNA expression levels of tetraspanins in human DC subsets. 
Z-scored values of (A) differentially expressed genes (ANOVA p<0.05) and (B) non-differentially expressed genes (ANOVA 
p>0.05 and expression >25 in at least two donors in one DC subset). Asterisks mark genes that were selected for further 
analysis. See Supplementary Table 1 for selected probes and statistics on expression data of all members of the tetraspanin 
family. (C) Gene expression levels of tetraspanins in DC subsets, normalized probe intensities are plotted, error bars 
indicate SEM. Data from 3 healthy donors.
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the relatively low protein expression levels of most other tetraspanins on pDCs (CD9, CD81, 
CD82 and CD151). CD81 was markedly higher expressed on CD141+ DCs compared to the 
other DC subsets, and  CD151 protein expression was highest on CD1c+ DCs closely followed 
by CD141+DCs and much lower on pDCs. 
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Figure 2: Protein expression of tetraspanins on human DC subsets.
(A) Flow cytometric analysis of total tetraspanin protein expression on fixed permeabilized DC subsets. Far left: dot plots 
of viable Lin-MHC II+ cells. CD1c+ DCs were identified as BDCA1+, CD141+ DCs as BDCA3+, and pDCs as BDCA4+ cells. 
See Supplementary Figure 2 for full gating strategy. Histograms of tetraspanin expression (black curve) and isotype control 
staining (grey curve) on gated cells depicted in the dot plots. (B) Tetraspanin expression of 3 healthy donors, geometric 
mean fluorescent intensity (gMFI) normalized for isotype control binding, error bars indicate SEM, each symbol represents 
one donor.
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To investigate the conservation of tetraspanin expression in the murine DC-subset equivalents, 
we next retrieved mRNA expression data of tetraspanins for CD11b+CD4+DCs, CD11b-CD8α+ 
DCs and pDCs from the public ImmGen repository [34]. Within the DC subset data containing 
mRNA expression from 3 mice, 17 tetraspanin genes were found to be differentially transcribed 
between the different DC subsets (Fig. 3A; Table S1). Similar to their human counterparts, 
these murine tetraspanin genes showed different expression profiles across the DC subsets. 
Cd37, Cd53, Tspan5, Tspan13, Tspan14 and Tspan31 were relatively high expressed in pDCs, 
whereas many other tetraspanin genes demonstrated higher mRNA levels in mDCs compared 
to pDCs (Fig. 3A). Interestingly, differences in relative tetraspanin expression between CD4+ and 
CD8α+ DCs seemed less pronounced than the differences observed between the human mDC 
counterparts. The tetraspanin genes depicted in Figure 3B were not found to be differentially 
expressed between the DC subsets. In contrast to the human RNA profile, but in line with the 
human protein data, Cd9 was expressed at relatively low levels on pDCs compared to CD4+ and 
CD8α+ DCs (Fig. 3C). Cd53 was expressed at relatively high levels on murine pDCs and Cd81 
on CD8α+ DCs, which matched the human CD53 and CD81 expression profiles.
Table 1. Tetraspanin protein expression on DC subsets.
Human Mouse
CD9 D pDC low A CD8α+ DC high, pDC very low
CD37 A Similar expression N.A.
CD53 A pDC high D pDC low
CD81 A CD141+ DC high, pDC very low A CD8α+ DC high, pDC very low
CD82 D pDC low N.A.
CD151 A pDC low D CD4+ DC low, CD8α high
Tspan31 D Similar expression N.A.
D: RNA and protein expression profile disagree. A: RNA and protein expression profile agree. N.A.: not analyzed. Remarks 
on the relative protein expression profile of each tetraspanin are described.
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Subsequently we measured  the protein expression levels of selected tetraspanins for the 
murine DC subsets. Due to limited availability of antibodies recognizing mouse tetraspanins 
the analysis was restricted to total protein expression of CD9, CD53, CD81 and CD151 (Fig. 
4A). Notably,  CD9 and CD81 were absent on pDCs which is line with the human data (Fig. 2). 
In contrast, CD8α+ DCs displayed relatively high protein levels of these tetraspanins (Fig. 4B), 
which was again similar to our observations in human CD141+ mDCs. On the other hand, the 
expression pattern of CD53 differed greatly between murine mRNA and protein data as well 
as between murine and human protein data. Opposite to the relatively high Cd53 mRNA levels 
observed in murine pDCs and the high expression of CD53 protein on human pDCs, lower 
protein levels of CD53 were observed on murine pDCs, compared to CD4+ and CD8α+ DCs. 
This indicated that also CD53 protein expression levels are not solely regulated by the amount 
of mRNA. Similarly, CD151 protein expression on murine pDCs was in the same range as CD151 
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Figure 3: Relative mRNA expression levels of tetraspanins in murine DC subsets. 
Z-scored values of (A) differentially expressed genes (ANOVA p<0.05) and (B) non-differentially expressed genes (ANOVA 
p>0.05 and expression > 25 in at least two mice in one subset). Asterisks mark genes that were selected for further 
analysis. See Supplementary Table 1 for selected probes and statistics on expression data of all members of the tetraspanin 
family. (C) Gene expression levels of tetraspanins in DC subsets, probe intensities are plotted, error bars indicate SEM. 
Data from 3 mice.
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expression on the other DC subsets, which was in contrast to the low Cd151 expression levels 
on pDCs measured at the mRNA level and in human DCs.
DCs from Cd53-/- mice produce more IL-6
As tetraspanin CD53 was found to be expressed on all DC subsets (Fig. 1 and 3), we decided 
to further investigate the function of this tetraspanin on DCs of CD53-deficient (Cd53-/-) mice 
by studying their response to Toll-like receptor (TLR) stimulation. Bone marrow cells from wild 
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Figure. 4. Protein expression of tetraspanins on murine DC subsets.
(A) Flow cytometric analysis of total tetraspanin protein expression on DC subsets. Cells from spleen were enriched for 
DCs as described in the materials and methods. Far left: dot plots of viable CD11c+ cells (CD4+ and CD8α+ DCs) or viable 
pDCs. CD4+ DCs were identified as CD4+CD11b+, CD8α+ DCs as CD8α+CD11b-, and pDCs as B220+CD11cint cells. See 
Supplementary Figure 3 for full gating strategy. Histograms of tetraspanin protein expression on gated cells depicted in the 
dot plots (black line) and isotype controls (grey line). (B) Average tetraspanin expression of 3 individual mice, geometric 
mean fluorescent intensity (gMFI) normalized for isotype control binding, each symbol represents one mouse.
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type (WT) and Cd53-/- mice were differentiated to pDCs and mDCs by culturing cells in the 
presence of Flt3L. Similar ratios of pDCs (21%) and mDCs (77%) were generated from WT and 
Cd53-/- cells (Fig. 5A). Interestingly, when DCs were stimulated with TLR ligands R848 or CpG, 
Cd53-/- DCs produced significantly more IL-6 than WT DCs. In contrast, IL-10 was produced at 
comparable levels by DCs from WT or Cd53-/- mice (Fig. 5B) indicating a specific role for CD53 
in TLR-driven IL-6 production.
Discussion
Here, we for the first time provide a complete overview of expression of members of the 
tetraspanin superfamily in human and murine DC subsets at both the mRNA and protein 
level. We demonstrate that many tetraspanins are differentially expressed between cDC1s, 
cDC2s and pDCs, indicating they may have a role in sustaining subset identity or functional 
differences. Moreover, different expression profiles were found between individual tetraspanin 
genes, which may reflect the reported non-redundant functions of members of the tetraspanin 
superfamily [14,19,35]. 
Although DC subsets share their function as professional antigen presenting cells, they are 
highly specialized when it comes to pattern recognition, antigen uptake and processing, T cell 
co-stimulation, cytokine secretion and migratory routes. All these processes are to some extend 
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Figure 5: Cytokine secretion by Cd53-/- BMDCs.
(A) The differentiation of BMDCs (day 9) from WT and Cd53-/- mice was analyzed by flow cytometry. Dead cells were 
excluded based on forward and side scatters and cells were gated on CD11c positivity. (B) Mean cytokine production of 
BMDCs from WT and Cd53-/- mice determined by ELISA. BMDCs were stimulated with 400ng/ml R848 or 100ng/ml CpG 
for 24 hr and analyzed for production of IL-6 and IL-10 in supernatants. Error bars indicate SEM, data from 3 mice. ** 
p=0.002.
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regulated by transmembrane proteins and downstream intracellular signalling cascades. After 
antigen uptake, DCs migrate towards lymph nodes to activate naïve T lymphocytes. Within 
the lymph node DCs present non-self peptides to CD4+ T cells on MHC class II, or to CD8+ 
T cells on MHC I molecules. The interaction between MHC class II and tetraspanins (CD9, 
CD37, CD53, CD63, CD81 and CD82) is well documented [15]. It has been suggested that 
tetraspanins regulate both plasma membrane stability and intracellular trafficking and loading 
of MHC molecules [36,37]. The relative low expression of tetraspanins (CD9, CD81, CD82) on 
pDCs may reflect a regulatory role for these tetraspanins in processes that are important in cDC 
function, such as phagocytosis [38], antigen processing [39] or MHC II trafficking [40].
Although CD141+ DCs are able to present antigen via MHC class II to CD4+ T cells, they 
stand out in their ability to efficiently cross-present antigens from dying or virus infected cells 
via MHC class I to CD8+ T cells. CD53, CD81 and CD82 have been reported to interact with 
MHC class I [41], and it will be interesting to study the role of these tetraspanins in antigen 
cross-presentation or receptor mediated uptake of remnants of dying cells by CD141+ DCs 
and CD8α+ DCs. In particular CD81, that we observed to be highly expressed in both human 
CD141+DCs and murine CD8a+ DCs. 
pDCs differ from the other DC subsets by their unique expression of virus recognising PPRs, 
their ability to secrete high amounts of type I interferon, and their unique migratory and adhesive 
properties. We observed that pDCs expressed relatively low protein levels of many tetraspanins, 
even though mRNA levels were high (CD9, CD81, CD82). It is possible that pDCs, more than 
the other DC subsets, regulate tetraspanin protein expression via additional mechanisms like 
posttranslational modifications, protein and/or RNA degradation or microRNAs. In colorectal 
carcinoma, Tspan1 mRNA is targeted by microRNA-638 suggesting that some tetraspanins 
are prone to this latter regulatory mechanism [42]. Moreover, tetraspanin expression levels 
have been reported to change upon activation and differentiation of other immune cells [43], 
thus it would be valuable to investigate differential expression of tetraspanins in DCs during 
differentiation and activation. This is illustrated by a recent study on CD37 and CD82 expression 
and function on immature and mature murine BMDCs. CD37, which promotes migration but 
restrains antigen presentation, is down-regulated upon DC maturation, whereas CD82, which 
restrains migration but promotes antigen presentation, is up-regulated in mature DCs [44].
The expression pattern of tetraspanins in DC subsets was not always conserved between 
human and mouse, as shown here for CD53 and CD151. This may be due to the different 
anatomical location the subsets were obtained from (i.e. blood versus spleen) and the 
differential need for integrin activity. Tetraspanins are known to control integrin avidity, as well 
as downstream signaling events [22,45]. On B cells, CD37 controls integrin α4β1 clustering 
and function, leading to defective AKT kinase signaling and increased apoptosis of B cells in 
the absence of CD37 [46]. Moreover, CD37-deficient dermal DCs show impaired directional 
migration to draining lymph nodes, which contributes to the poor cellular immune responses 
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observed in Cd37-/- mice [23]. CD151 strongly interacts with and modulates the function 
of laminin-binding integrins, thereby affecting cell adhesion and migration [47,48]. This is 
apparent in Cd151-/- mice that are impaired in wound healing [49] and show less tumor cell 
metastasis [50]. It would be interesting to investigate whether differential expression of CD151 
in DC subsets influences integrin-dependent DC adhesion and migration. 
Notable was the relative high protein expression of tetraspanin CD53 on all human DC subsets 
and in particular on human pDCs. The specific role of CD53 on DCs is currently unknown. CD53 
is exclusively expressed on cells of the hematopoietic system and highly expressed on antigen 
presenting cells [Chapter 2 [51]]. We here show that CD53 dampens IL-6 production after 
TLR stimulation of BMDCs, while IL-10 production is unaffected by the absence of CD53. The 
secretion of cytokines by DC subsets may thus be regulated by tetraspanins like CD53, possibly 
by modulation of the signalling cascades resulting from TLR engagement. For example, IL-6 and 
IL-10 production are differentially regulated by the MAPK signaling pathways [52]. Alternatively, 
tetraspanins could directly regulate the function and stabilization of PRRs within the membrane. 
This would be in line with the function of CD37, which is reported to modulate the secretion 
of IL-6 upon Dectin-1 ligation in macrophages [53,54].
Due to their interactions with various immune receptors and adhesion molecules, 
tetraspanins play important and diverse roles in many immunological processes including 
antigen presentation, cell adherence and cytokine production. The here obtained knowledge on 
tetraspanin expression on the different DC subsets, combined with our increasing understanding 
specific functions of DC subsets provides a highly valuable resource to derive which biological 
processes are regulated by individual tetraspanins. 
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Supplementary table 2: Antibodies.
Anti-human antibodies
CD9 M-L13 BD, 555370
CD37 WR17 Home made
CD53 Mem53 Serotec, MCA7236
CD81 JS-81 BD, 555675
CD82 BL-2 Novus Bio, NB600-1283
CD151 11G5a Serotec, MCA1856
Tspan31 Rabbit polyclonal Abgent, AP8587c
lineage-FITC Lin 1 cocktail BD, 340546
BDCA4-PerCP-Cy5.5 12C2 BioLegend, 354509
BDCA3-PE - Miltenyi
BDCA3-APC AD5-14H12 Miltenyi, 130-090-907
BDCA1-BV421 L161 BioLegend, 331526
MHC class II-BV510 G46-6 BD, 563083
Anti-mouse antibodies: 
CD9 KMC8 eBioscience, 14-0091-82
CD53-FITC OX-79 BioLegend, 124705
CD81 Eat-2 BioLegend, 104902
CD151 455807 R&D, MAB4609
CD11c-PerCP N418 BioLegend, 117326
B220-PE RA3-682 BD, 553089
CD11b-PE M1/70 BioLegend, 101208
CD8α-FITC 53-6.7 BD, 553031
CD8α-APC 53-6.7 BioLegend, 100712
CD4-FITC RM4-5 BioLegend, 100510
CD4-APC RM4-5 BioLegend, 100516
Siglec-H-alexa647 551 Biolegend, 129608
Isotype control antibodies:
Mouse IgG1 MOPC-21 BioLegend, 400102
Mouse IgG2a MOPC-173 BioLegend, 400202
Rabbit IgG polyclonal Jackson IE, 011-000-003
Rat IgG2a eBR2a eBioscience, 14-4321-85
Armenian Hamster IgG eBio299Arm eBioscience, 14-488-81
Secondary antibodies:
anti-mouse-PE
Goat anti-rabbit-alexa647 polyclonal Life Technologies, A-21245
Goat-anti-rat-alexa647 polyclonal Life Technologies, A-21247
Goat anti-hamster (Armenian)-biotin Poly4055 BioLegend, 405501
Streptavidin-alexa647 Life Technologies, S-32357
Fixable Viability dye eFluor780 eBioscience, 65-0865-14
91
Expression of tetraspanins in DC subsets
3
Supplementary fi gure 1: Data normalization.
Box plots of normalized probe intensity distributions. Complete data set of expression values of human blood DC subsets 
(A), and murine spleen DC subsets (B) were normalized using the RMA normalization function and 2log transformation
A B
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Supplementary figure 2: Gating strategy human DC subsets.
PBMCs were stained with specific antibodies and analysed by flow cytometry. (A) Cell debris (left) and cells positive for 
dead cell marker were excluded (middle). DCs positive for MHC class II and negative for lineage markers CD3, CD14, 
CD16, CD19, CD20 and CD56 were selected (right). (B) CD1c+ DCs were gated on MHC class II and BDCA1 positivity 
(left). Cells positive for BDCA3 and BDCA4 were excluded (right) from tetraspanin expression analysis. (C) CD141+ DCs 
were gated on MHC class II and BDCA3 positivity (left). Cells positive for BDCA1 and BDCA4 were excluded (right) from 
tetraspanin expression analysis. (D) pDCs were gated on MHC class II and BDCA4 positivity (left). Cells positive for BDCA1 
and BDCA3 were excluded (right) from tetraspanin expression analysis. 
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Supplementary figure 3: Gating strategy murine DC subsets.
Splenic cells were enriched for DCs, stained with specific antibodies and analyzed by flow cytometry. Dead cells were 
excluded based on forward and side scatter characteristics. Upper: CD11c+ cells were gated on CD11b+ CD4+ to 
determine tetraspanin expression on CD4+ DCs. Middle: CD11c+ CD11b- CD8α+ cells were selected for tetraspanin 
expression analyses. Lower, pDCs: B220+ CD11cint. cells were gated on CD8α+ for tetraspanin expression analyses.
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resolution microscopy
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Abstract
The spatial organization of membrane proteins in the plasma membrane is 
critical for signal transduction, cell communication and membrane trafficking. 
Tetraspanins organize functional higher-order protein complexes called 
‘tetraspanin-enriched microdomains (TEMs)’ via interactions with partner 
molecules and other tetraspanins. Still, the nanoscale organization of TEMs in 
native plasma membranes has not been resolved. Here, we elucidated the size, 
density and distribution of TEMs in the plasma membrane of human B cells and 
dendritic cells using dual color stimulated emission depletion (STED) microscopy. 
We demonstrate that tetraspanins form individual nanoclusters smaller than 120 
nm and quantified that a single tetraspanin CD53 cluster contains less than ten 
CD53 molecules. CD53 and CD37 domains were adjacent to and displayed only 
minor overlap with clusters containing tetraspanins CD81 or CD82. Moreover, 
CD53 and CD81 were found in closer proximity to their partners MHC class II and 
CD19 than to other tetraspanins. Although these results indicate that tetraspanin 
domains are adjacently positioned in the plasma membrane, they challenge the 
current view of the tetraspanin web of multiple tetraspanin species organized 
into a single domain. This study increases the molecular understanding of TEMs 
at the nanoscale level which is essential for comprehending tetraspanin function 
in cell biology.
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Introduction 
The organization of proteins and lipids in the plasma membrane is crucial for fundamental 
cellular functions, including cell communication, signal transduction and trafficking. Specialized 
tetraspanin-enriched microdomains (TEMs) in the plasma membrane are implicated in the 
compartmentalization of specific lipids, receptors and signaling molecules into multi-molecular 
complexes [1]. Tetraspanins are small hydrophobic proteins with four transmembrane domains, 
a small and a large extracellular loop and two short cytoplasmic tails [2]. Tetraspanins are 
characterized by their ability to laterally organize membrane proteins by interacting in cis with 
transmembrane receptors, adhesion molecules, enzymes, signaling proteins and with each 
other. By this means, they have been proposed to organize functional TEMs in the plasma 
membrane that contain different tetraspanins and their interacting partner proteins [3,4]. 
The interaction of tetraspanins with their partner proteins can be direct (primary) or indirect 
(secondary to tetraspanin-tetraspanin interactions). The large number of different partner 
molecules may underlie the involvement of tetraspanins in a wide variety of essential cellular 
processes, including cell proliferation, differentiation, and migration [5]. 
The expression profile of certain tetraspanin proteins is tissue-restricted, for example 
CD53 and CD37 are exclusively expressed on immune cells where they interact with various 
immunoreceptors [6]. In particular, many tetraspanins have been reported to associate with 
major histocompatibility complex (MHC) class II molecules, central receptors expressed on 
antigen-presenting cells (APCs; B cells, dendritic cells) that allow presentation of antigenic 
peptides to T cells [7–9]. It has been proposed that clustering of MHC class II molecules in the 
plasma membrane of APCs is crucial to efficiently activate T cells [10], and the stability of MHC 
class II clusters on the plasma membrane may be increased by participation into microdomains, 
such as TEMs or lipid rafts [11,12].  In B cells, the interaction between tetraspanin CD81 and 
CD19 is crucial for cell surface expression of CD19 and B cell activation. CD81-deficiency in 
mice and humans leads to aberrant CD19 expression and impaired humoral immune responses 
indicating that tetraspanin-partner interactions are biologically relevant [13,14].
The assembly of TEMs is complex and has been hypothesized to involve both tetraspanin-
partner interactions and tetraspanin-tetraspanin interactions. This concept of a TEM was initially 
studied by biochemical approaches including isolation of detergent resistant membranes, 
co-immunoprecipitation, protein crosslinking and proteomics [15–17]. While these techniques 
have been instrumental to the original identification of TEMs, they do not provide insight in the 
spatiotemporal characteristics of TEMs in the plasma membrane. Although advanced imaging 
techniques have recently been applied to investigate the organization of TEMs [8,18–21], many 
basic physical properties of TEMs including their size, distribution and architecture in native 
plasma membranes are still unknown. Given the essential role of TEMs for many important 
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cellular processes, this is surprising. Super-resolution microscopy techniques allow to resolve 
individual TEMs and thereby enable the quantification of these physical properties [22,23]. 
In this study, we visualized the tetraspanin web on the cell surface of human antigen-
presenting cells using dual color stimulated emission depletion (STED) microscopy [24–26]. We 
demonstrate that tetraspanins CD37, CD53, CD81 and CD82 form individual clusters on the 
plasma membrane of a size below 120 nm. These small nanoclusters are distributed on the 
plasma membrane at densities of 1-5 domains per μm2. Whereas TEMs containing tetraspanin 
CD53 or CD81 are in proximity to their interaction partners MHC class II or CD19, these TEMs 
show surprisingly little overlap with other tetraspanin proteins. Finally, we quantified that a 
single TEM contains on average only about 3.5 molecules of CD53. Based on these data we 
propose a new view on the tetraspanin web.
Materials and methods
Antibodies
Two antibodies were used for the detection of CD53: a monoclonal rabbit antibody against 
the C-terminus of human CD53 (EPR4342(2), LifeSpan BioSciences, referred to as CD53(Rab)) 
and a mouse antibody against the extracellular loop of human CD53 (referred to as CD53(Mo), 
both unlabeled (mem53, Serotec) and FITC-labeled (mem53-FITC, Abcam)). Mouse primary 
antibodies against human CD9 (M-L13, BD Biosciences), CD37 (WR-17, in house produced), 
CD81 (JS-81, BD Biosciences), CD82 (B-L2, Serotec), CD82(Rab) (AHP1709, Serotec), CD55 
(143-30, eBioscience), CD19 (#3574, Cell Signaling Technology) and MHC class II (Q5/13, in 
house produced) were used. Isotype control antibodies were mouse IgG1(X40, BD Biosciences) 
and rabbit IgG (Jackson ImmunoResearch). Alexa488 or Alexa647 goat anti-mouse IgG 
(Invitrogen) was used for detection by flow cytometry. Goat anti-rabbit and anti-mouse F(ab) 
fragments (111-007-003 and 115-007-003, Echelon) were labeled by incubating 200 μl of 50 
μM F(ab) fragment with a 50-fold molar excess of Atto594 NHS-ester (Attotec). Unconjugated 
dye molecules were removed by size exclusion chromatography with sephadex G50 to 10 
mM Na-phosphate buffer with 250 mM NaCl at pH 7.6. Goat anti-rabbit, sheep anti-mouse 
and goat anti-mouse antibodies (Dianova) were labeled with Atto594 or KK114 (Abberior 
Red, Abberior). For experiments in Fig. 3b, goat anti-mouse IgG1-Atto590 (Enzo Life Sciences) 
was used, and rat anti-mouse IgG2a (R19-15, BD Biosciences) was labeled by incubating 70 
μl of 0.5 mg/ml antibody with a 40-fold molar excess of KK114-NHS-ester (Abberior) at pH 
8. Unconjugated dye molecules were removed on 40K MWCO Zeba Spin desalting columns 
(Thermo Scientific) at pH 7. Cortical actin was stained with phalloidin-Alexa546 (Invitrogen). 
99
The tetraspanin web revisited by STED microscopy
4
Cell culture and preparation of human DCs
The human B cell line JY was maintained in RMPI1640 medium with 10% Fetal Bovine Serum 
(Greiner Bio One), stable Glutamine (PAA) and Antibiotic-Antimycotic (Gibco). Where indicated, 
JY cells were stimulated with 1 μg/ml anti-BCR antibody for 8 hours, 10 μg/ml for 5 min, 
or treated with 5 μM Latrunculin A (LatA) for 15 min at 37°C. DCs were generated from 
peripheral blood mononuclear cells as described previously [27]. Plastic-adherent monocytes 
were cultured in RMPI1640 medium with 10% Fetal Bovine Serum, stable Glutamine and 
Antibiotic-Antimycotic, IL-4 (300 U/ml) and GM-CSF (450 U/ml) for 7 days. At 6 days of culture, 
immature DCs were stimulated with 100 ng/ml LPS for 24 hours.
Membrane sheet production and antibody staining
For the preparation of the membrane sheets, JY B cells were kept at 4°C until membrane fixation 
to prevent antibody induced clustering of membrane proteins. Stimulated or unstimulated cells 
were washed with cold PBS and blocked in 3% BSA, 1% filtered human serum and 10 mM 
glycine in PBS. Extracellular epitopes on cells were stained with mouse primary antibodies, 
followed by staining with anti-mouse secondary antibodies in blocking solution at 4°C. 
Coverslips were cleaned in 1% Hellmanex III (Hellma) and sonified for 15 min at RT, rinsed 
with ultrapure water, blow dried, and coated with poly-L-lysine. Thoroughly washed cells were 
seeded on the coverslips for 15 min at 4°C. Non-adhered cells were removed by a gentle 
wash step with cold PBS. Coverslips were covered with cold PBS and a sonic pulse of 0.1 s at 
10% power was applied (sonifier, Branson). Cell debris was washed away with cold PBS and 
membrane sheets were immediately fixed in 2% PFA in PBS. Sheets were washed with PBS and 
blocked, and stained with CD53(Rab), CD19 or CD82(Rab) (intracellular epitopes) followed 
by staining with anti-rabbit secondary antibodies. Coverslips were washed and embedded in 
Mowiol (Sigma). As the mouse antibodies used in this study recognize extracellular domains 
of membrane proteins and the rabbit antibodies bind intracellular domains, we can rule out 
binding artifacts due to steric hindrance. Note that no detergent was used for the preparation 
of the membrane sheets.
Whole cell immunostaining
Raji B cells were adhered to poly-L-lysine coated coverslips and fixed in 2% PFA. Cells were 
blocked in 3% BSA, 1% filtered human serum and 10 mM glycine in PBS. Membranes were 
permeabilized with 0.5% saponin, 3% BSA, 1% filtered human serum and 10 mM glycine 
in PBS. Cells were stained with CD53(Mo) in saponin containing block buffer and washed, 
followed by staining with sheep-anti-mouse Ig-KK114. Coverslips were washed with saponin 
buffer, PBS and ultrapure water, and embedded in Mowiol. 
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Dual color STED and confocal imaging
The dual color STED setup is described in detail in [26]. In short, excitation of the Atto594 and 
KK114 dyes was performed with two pulsed diode lasers at 595 nm and 640 nm (PicoQuant). 
STED was performed using a frequency-doubled fiber laser (ELP-5-775-DG, IPG Photonics 
Corporation) emitting at 775 nm at a repetition rate of 20 MHz. Excitation pulses were 
synchronized to the STED pulses. The excitation beams and the donut shaped STED beam 
were co-aligned and coupled into a 1.4 numerical aperture oil immersion lens (NA 1.4 HCX PL 
APO, 100x, Leica Microsystems). The fluorescence was collected by the same lens, spectrally 
separated and filtered into two ranges: 600-640 nm and 650-690 nm. The fluorescence was 
detected by fiber-coupled single-photon-counting modules (SPCMAQRH13, Perkin Elmer), with 
their fiber cores acting as confocal pinholes. Images with 20 nm sized pixel steps were acquired 
and the hardware and data acquisition was controlled by the software ImSpector (http://www.
imspector.de).
Image analysis
All image analysis was performed using Fiji software [28]. Edges of sheets were excluded from 
analysis. For determination of the cluster size, random clusters were selected from representative 
sheets and an intensity profile was plotted for each cluster. The width of the profile at half-
maximal intensity was measured as cluster size. For area and circularity measurements, regions 
of interest were created corresponding to tetraspanin clusters by applying a threshold to STED 
images of membrane sheets. Of these regions the area and circularity was determined. To 
annotate the location of tetraspanin clusters on a sheet, a simple intensity threshold was 
applied to the STED images followed by a blob detection algorithm. The x/y positions of the 
centers of the tetraspanin clusters were then used to determine the distances to the nearest 
neighboring clusters. These nearest neighbor distances to tetraspanin clusters of the same 
species were fitted with random distance distribution curves (Originlab). Assuming uncorrelated 
cluster distributions, the probability distribution dp for finding the nearest neighbor at a 
distance r ± dr is given by: dp / dr (r) = 2 π ρ r exp(-π ρ r2). For the fitting, the density ρ was 
independently determined from the images (i.e. by dividing the number of domains over the 
area of analyzed plasma membrane). To obtain nearest neighbor distance distributions for 
two different tetraspanin species (or from CD53 to CD55 or MHC class II), mock images were 
generated by a custom program in VB.NET. In these mock images, domains were randomly 
placed with the densities and size distributions determined from the STED images. For obtaining 
the nearest neighbor histogram, these mock images were then analyzed identical to the STED 
images as described above.
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Immunoprecipitation
JY B cells were lysed in lysisbuffer containing  1% detergent (Brij97), 10 mM Tris (pH 7.5), 
150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM NaF, 1 mM Na3VO4 with protease inhibitors 
(EDTA free, Roche). Cell lysates were precleared with bare protein G sepharose beads (GE 
Healthcare) and isotype control antibody-bound beads. Immunoprecipitation was performed 
with CD53(Mo)-bound beads and isotype control antibody-bound beads. After incubating 
with the lysate for 2 hours at 4°C, beads were washed in lysis buffer. A fraction of the 
beads was incubated with 1% Triton X-100 to elute weak interaction partners from CD53 
immunocomplexes, and eluted proteins were acetone precipitated. Samples were boiled at 
95°C, separated by SDS-PAGE under non-reducing conditions and blotted on polyvinylidene 
difluoride (PVDF) membranes (Millipore). Membranes were blocked with 3% BSA and 1% skim 
milk powder in TBS and probed with CD53(Mo) (mem53) and MHC class II (Q5/13) antibodies 
overnight at 4°C. Detection was performed with IRDye-conjugated secondary antibodies and 
the Odyssey infrared detection system (LI-COR). 
Flow cytometry
Stimulated and unstimulated DC and JY B cells were stained with primary antibodies against 
tetraspanin proteins or MHC class II or isotype control antibody and subsequently stained with 
Alexa488-labeled goat anti-mouse-IgG in PBS containing 1% BSA and 0.01% NaN3 (PBA) with 
2% human serum. Geometric mean fluorescence intensity was measured using flow cytometry 
(FACS Calibur, BD Biosciences) and analyzed using FlowJo. To determine the plasma membrane 
fraction of CD53, JY cells were first stained with CD53(Mo) or isotype control antibody followed 
by staining with Alexa488 labeled goat-anti-mouse IgG in 2% human serum PBA at 4°C. To 
determine total CD53 expression, cells were fixed in 2% PFA, permeabilized in 0.5% saponin 
PBA, and stained with CD53(Mo) or isotype control antibody and Alexa488-labeled goat anti-
mouse-IgG in 2% human serum 0.5% saponin PBA at 4°C. 
Quantitative Western Blotting
JY cells were lysed at 20x106 cells/ml in Laemmli sample buffer containing 5% β-mercaptoethanol. 
Human CD53 recombinant protein (Abnova) was titrated in sample buffer. Samples were 
boiled at 95°C, separated by SDS-PAGE and blotted on PVDF membranes. Membranes were 
blocked with 3% BSA and 1% skim milk powder in TBS and probed with CD53(Rab) antibodies 
overnight at 4°C. This was followed by IRDye-conjugated secondary antibodies and Odyssey 
infrared detection. 
Confocal microscopy to determine surface membrane area
JY cells were seeded in Willco dishes (Willco Wells) in 281 mOsm PBS, and treated with 5 μM 
Latrunculin A for 15 min at 37°C. Plasma membranes were stained with fluorescent lipophilic 
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tracer DiI (1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindocarbocyanine Perchlorate (DiIC18(3), 
Molecular Probes) (100μM, DiI was stored at 10mM in EtOH). A solution of 10 mM NaPO4 was 
titrated to the cell suspension to obtain a hypotonic cell environment of 196 mOsm and to 
eliminate plasma membrane ruffles. Spherical cells were imaged on a SP8 confocal microscope 
equipped with a 60× water 1.2 NA objective (Leica, Wetzlar, Germany) using appropriate laser 
lines and settings. Osmolarities were determined by freezing point depression (Osmomat 3000, 
Gonotec).
Modelling 
Model images of the tetraspanin domains were generated with POVray. The predicted structure 
of CD81 [29] (protein database accession number 2AVZ) and the crystal structure of MHC class 
II [30] (protein database accession number 4IS6) were used. 
Statistics
Statistical analysis was carried out with Graphpad Prism. Data are presented as mean ± standard 
deviation for column scatter plots and median ± interquartile range for box plots (with whiskers 
representing the smallest and largest value). Student T-tests were used to compare two groups 
and an one-way analysis of variance (ANOVA) with a post hoc Bonferroni’s multiple comparison 
test was executed to compare the means of more than two groups. Data that did not pass the 
Kolmogorov-Smirnov normality test were compared with a Mann Whitney test (for two groups) 
or a Kruskal-Wallis test followed by Dunn’s multiple comparison testing. Statistical significance 
was defined as * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001. 
Results
We employed dual color STED microscopy to analyze the organization of endogenously-
expressed tetraspanin proteins at super-resolution in native plasma membranes. By applying 
an ultrasound pulse to attached cells, we created flat membrane sheets, which allows for 
antibody binding of intracellular epitopes without the need of detergents [31,32]. Since 
intracellular membranes are removed, this method permits plasma membrane visualization 
by STED microscopy without interference from background signal arising from intracellular 
structures or the apical membrane. This procedure does not change the spatial localization of 
membrane proteins [33,34], as the nanoscale distribution and size of the tetraspanin CD53 
clusters in membrane sheets was comparable to those found in whole cells when we used an 
antibody recognizing an extracellular epitope of CD53 (Fig. S1A). The density and size of CD53 
clusters were similar (whole cell: 5.01 clusters/μm2 and 111.5 ± 29.58 nm, membrane sheet: 
5.34 clusters/μm2 and 102.0 ± 30.89 nm). Moreover, the cortical cytoskeleton remained at least 
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partially intact in membrane sheets (Fig. S1B), and disruption of F-actin with Latrunculin A did 
not affect tetraspanin cluster distribution (Fig. S1C).  
We first focused on the archetypical tetraspanin CD53 (also known as Tspan25), which is 
expressed exclusively in the immune system and highly abundant on antigen-presenting cells. 
Conventional confocal microscopy analyses revealed that CD53 was clustered on the plasma 
membrane of B cells, in line with the concept of tetraspanin-enriched microdomains. As the 
limited resolution of conventional optical microscopy does not allow to distinguish individual 
domains adequately, we performed STED microscopy to determine the size and distribution of 
individual clusters enriched in tetraspanin CD53 at the nanoscale level (Fig. 1A). With the super-
resolution obtained by STED microscopy, it became apparent that many of the larger CD53 
clusters observed with conventional confocal microscopy were actually multiple smaller CD53 
clusters in close proximity. We employed two different CD53 antibodies in our studies; a CD53 
monoclonal rabbit antibody (Rab) directed against the intracellular C-terminus of CD53, and a 
monoclonal mouse antibody (Mo) which recognizes the large extracellular loop of CD53. Using 
dual color STED microscopy, CD53 was recognized by both antibodies in clusters that clearly 
co-localized, showing that the antibodies bound the same target protein (Fig. 1B), in contrast to 
isotype control antibodies that were hardly detectable (Fig. S1D). The specificity of the CD53(Rab) 
antibody was confirmed in control stainings of membrane sheets of different CD53-negative 
cells (Fig. S1E), and the sensitivity of the two antibodies was comparable (Fig. S1F). These 
experiments indicate that the CD53(Mo) antibody labeled a subpopulation of CD53 proteins 
expressed in larger domains that were also positively stained with the CD53(Rab) antibody. 
This is most likely due to epitope masking by the molecular configuration in a subpopulation 
of CD53 molecules. As control, B cells were labeled with an antibody that recognizes the GPI-
anchored protein CD55, a regulator of complement activation, which is reported not to interact 
with tetraspanins [35]. Indeed, CD55 labeling was found to be excluded from CD53-enriched 
domains (Fig. 1B). 
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Figure 1: Membrane clusters enriched in tetraspanin CD53 visualized by STED microscopy.
(A) Left images: a representative JY B cell membrane sheet stained with antibodies against CD53 and imaged with 
conventional confocal (upper) or STED microscopy (lower). Right images: magnification of the area indicated in the left 
images. Scale bars represent 5 (left) and 1 μm (right). Graphs show intensity profiles of CD53 depicted in the right images. 
(B) B cell membrane sheets were stained for CD53(Rab) and CD53(Mo) (upper), or CD53(Rab) and CD55 (lower) and 
imaged with conventional confocal microscopy or by STED microscopy. Most right image: merged image of CD53(Rab) 
(red) and CD53(Mo) or CD55 (green). Scale bars represent 5 μm in whole sheet images and 0.5 μm in zoomed images. 
(C) Nearest neighbor analysis. Distance distributions of CD53(Mo) (blue) or CD55 (pink) clusters to the nearest CD53(Rab) 
clusters from at least 10 sheets. (D) Left: For every sheet the percentage of clusters within 100 nm from the nearest 
CD53(Rab) cluster was plotted. ANOVA ***, significance by post hoc analysis (Bonferroni) is shown. Right: for every sheet 
the Pearson correlation coefficient was determined and plotted. Kruskal-Wallis ***. Significance by post hoc analysis 
(Dunn) is shown. CD53(Mo) Atto594 or CD55 Atto594: sheets were stained with CD53(Mo) or CD55 which was detected 
by anti-mouseAtto594, and CD53(Rab) was detected by anti-rabbitKK114. CD53(Mo) KK114 or CD55 KK114: secondary 
antibody dyes were swapped. At least 10 sheets were analyzed for each condition.
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To quantify the distance between clusters, we first annotated their positions by identifying 
all individual clusters in the STED images with a simple fluorescence intensity offset. The x/y 
coordinates of the center of each individual domain were then annotated by blob detection 
(Fig. S2A). We then performed a nearest neighbor analysis to calculate the distances between a 
CD53(Mo) or CD55 cluster to the nearest CD53(Rab) cluster. Clusters of which their center was 
within a distance of 100 nm from the center of the nearest CD53(Rab) cluster were considered 
as (partly) overlapping with CD53 (Fig. 1C). By using this criterion, 55% of clusters recognized 
by CD53(Mo) were overlapping with CD53(Rab) clusters. This value is an underestimate, since 
CD53(Mo) recognizes larger clusters than CD53(Rab) and the centers of merged CD53 clusters 
may thus not always overlap. In comparison, only 22% of the CD55 clusters overlapped 
with CD53(Rab) clusters (Fig. 1D). To confirm these findings, we employed an alternative 
analysis were we calculated Pearson’s correlation coefficients for every membrane sheet. Here 
we obtained average values of 0.5 for CD53(Mo) and CD53(Rab), and 0.2 for CD55 and 
CD53(Rab) (Fig. 1D) validating the nearest neighbor analyses. Swapping the dye colors of the 
anti-mouse and anti-rabbit secondary antibodies did not affect the nearest neighbor distances 
of CD53(Mo), or CD55, to CD53(Rab) (Fig. S2B and 1D). Furthermore, secondary-antibody 
related clustering artifacts can be excluded [36], because similar cluster sizes and distributions 
of CD53 were observed by comparing whole secondary antibodies with labeled F(ab) fragments 
(Fig. S3A and B). F(ab) fragments contain only a single paratope, and therefore cannot induce 
protein clustering [32]. Moreover, we can exclude crowding effects due to the use of secondary 
antibodies, because the staining intensity of the secondary anti-mouse antibody correlated 
linearly with the intensity of the directly labeled CD53 antibody (Fig. S3C), and labeling multiple 
tetraspanin species did not reduce staining intensities of the individual antibodies (Fig. S3D).
Characterization of individual tetraspanin clusters
Next, we characterized the distribution and size of clusters that contain different members of the 
tetraspanin superfamily (CD53, CD37, CD81 and CD82) that are endogenously expressed on 
the plasma membrane of B cells (Fig. 2A). CD53 was present in clusters with an average size of 
96 nm (± 35 nm; standard deviation) (Fig. 2B). CD37-containing clusters had on average larger 
diameters than clusters of other members of the tetraspanin family (171 ± 82 nm). However, 
this was caused by a small population of relatively large domains and the majority of clusters of 
CD37 had sizes ranging between 100 and 150 nm, similar to the size of CD53, CD81 (114 ± 
39 nm) and CD82 (124 ± 47 nm) domains. These data indicate that most tetraspanin proteins 
were present in clusters of a typical size of around 120 nm in the plasma membrane. This 
value is an upper estimate, as it is still convoluted with the resolution of our STED microscope 
(full-width at half-maximum intensity below 50 nm), and at super-resolution the size of the 
primary and secondary antibodies add to the domain sizes. Next, we determined the circularity 
of the tetraspanin clusters, and observed that clusters with a large area (≥ 0.025 μm2) were 
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less circular than small clusters (Fig. 2C), suggesting that individual tetraspanin clusters can 
coalesce into larger clusters. Quantification of the density of tetraspanin clusters revealed 
that B cells contained more CD53-containing clusters on the plasma membrane than clusters 
containing CD37, CD81 or CD82 (Fig. 2D; on average 4.4 clusters per μm2 for CD53 versus 
approximately 0.5-1 clusters per μm2 for the other tetraspanins). These differences in densities 
of the tetraspanin clusters on the plasma membrane were in line with the expression levels of 
these tetraspanins as determined by flow cytometry (Fig. S4). 
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Figure 2: Physical characteristics of tetraspanin clusters.
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Next, we investigated whether the distributions of the individual tetraspanin clusters 
on the plasma membrane were randomly organized at the mesoscale level (i.e. relative to 
each other). The locations of individual tetraspanin clusters were annotated and the nearest 
neighbor distances to adjacent clusters (i.e. of the same tetraspanin species) were calculated. 
The distributions of these distances were compared to the theoretical distributions when the 
domains would be completely randomly distributed. The experimental distance distributions 
of CD53, CD37, CD81 or CD82 clusters could be well fitted with random distributions (Fig. 
2E). Thus, we did not obtain evidence for a non-random mesoscale organization of clusters of 
individual tetraspanin species on the plasma membrane. 
Dual color STED microscopy of the tetraspanin web
Mainly based on co-immunoprecipitation studies [15], it is widely acknowledged that 
tetraspanin proteins can interact with other members of the tetraspanin family. We therefore 
analyzed the distribution of tetraspanin clusters enriched in CD37, CD81 or CD82 relative 
to clusters containing the tetraspanin CD53 using dual color STED microscopy. As shown in 
Figure 1B, CD53(Mo) was overlapping with CD53(Rab) clusters. Surprisingly, other members 
of the tetraspanin family did not co-localize with CD53 (Fig. 3A). Similarly, clusters detected 
by anti-CD82 rabbit antibodies (CD82(Rab)) were overlapping with clusters detected by anti-
CD82 mouse antibodies, in contrast to CD82(Rab) clusters which did not co-localize with 
CD53(Mo) clusters (Fig. S5A and B). Next, we investigated the localization of tetraspanin CD37 
clusters relative to clusters containing CD53, CD81 and CD82. Notably, CD37 clusters showed 
more overlap with CD81 and CD82 than with CD53 clusters (Fig. 3B). As expected, distances 
between clusters identified with CD53(Mo) and CD53(Rab) antibodies were shorter than 
distances between CD53 clusters and clusters containing other tetraspanin family members. 
In fact, CD53 was not closer to tetraspanins CD37, CD81 and CD82 than to CD55, a GPI-
protein that is excluded from the tetraspanin web (Fig. 3C and 1D). In contrast, more CD81 
and CD82 clusters were within 100 nm from CD37 compared to CD53 clusters, indicating that 
these tetraspanins may at least partially co-cluster (Fig. 3D). These findings question the current 
←	Figure 2: Physical characteristics of tetraspanin clusters. 
(A) JY B cell membrane sheets were stained for CD37, CD81 or CD82 and imaged by STED microscopy. Right images: 
magnification of the area indicated in left images. Scale bars represent 5 μm in whole sheet images and 0.5 μm in 
zoomed images. (B) The diameter of tetraspanin clusters measured from intensity profiles by the full-width at half-maximal 
intensity (FWHM). At least 120 random clusters were measured derived from at least 3 sheets per condition. Kruskal-Wallis 
***. Significance by post hoc analysis is shown (Dunn’s multiple comparison tests between CD53 and other tetraspanins). 
(C) Masks were made for individual CD37 clusters by applying a local threshold on STED images, and of each cluster the 
circularity was plotted against the area. 405 clusters were analyzed from 3 sheets. Left: dot plot of individual clusters, 
right: boxplot, Kruskal-Wallis ***, significance by post hoc analysis (Dunn) is shown. (D) Density of tetraspanin clusters. 
For every sheet the analyzed surface area and the number of annotated clusters were determined and the number of 
clusters per μm2 calculated. At least 7 sheets were analyzed per condition. Kruskal-Wallis ***, significance by post hoc 
analysis (Dunn) is shown. (E) Distances from the center of annotated clusters to the center of their nearest neighbor were 
determined. The red dashed curves show fits of the nearest neighbor curves with random cluster distributions and the 
average densities from panel D. Clusters of at least 7 sheets were analyzed per condition. 
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model of tetraspanin-enriched microdomains containing multiple different members of the 
tetraspanin superfamily, at least for CD53.
To further investigate the architecture of the tetraspanin web, we analyzed the distances 
between different tetraspanin clusters in more detail. Notably, clusters containing tetraspanin 
CD53 were not overlapping with CD37, CD81 or CD82 clusters, indicating the presence of 
distinct 120 nm sized clusters that contain only this single member of the tetraspanin family (Fig. 
4A). Such clusters were also found when B cells were stimulated implying that this distribution 
is independent of cell activation (data not shown). Although CD37 domains overlapped partly 
with CD81 or CD82, most CD37 domains were isolated and not enriched in other tetraspanins 
(Fig. 4B). We investigated the positioning of CD53, CD81 and CD82 clusters to the CD37 
clusters. For this analysis, we generated 2-color images in which we completely randomly 
positioned clusters with the densities and size distributions of CD37, CD53, CD81 or CD82 
clusters (Fig. S6A). We then performed the same nearest neighbor analyses on these random 
and uncorrelated mock images as with the experimental STED micrographs and compared the 
distance distributions (Fig. 4C). We found that a large population of CD53, CD81 or CD82 
clusters had much shorter distances to CD37 clusters than expected when the domains would 
be randomly distributed relative to each other. This indicates that tetraspanin clusters are 
organized at a larger scale and that although clusters of different individual tetraspanin family 
members are not or only slightly overlapping, they are often located in close proximity to each 
other (Fig. 4D).
Figure 3: The tetraspanin web revealed by dual color STED microscopy. →
(A-B) JY B cell membrane sheets double stained for CD53 (red) and CD37, CD81 or CD82 (green) (a), or double stained 
for CD37 (red) and CD53, CD81 or CD82 (green) (b) were imaged by STED microscopy. Middle images: magnification of 
the area indicated in whole sheets images (most left). Blob detection images (most right) show annotated clusters used 
for further analysis. Scale bars represent 5 μm in whole sheet images and 0.5 μm in zoomed and blob detection images. 
(C-D) Percentage of clusters of which the distance from their center to the center of the nearest CD53 (c) or CD37 (d) 
cluster was within 100 nm. Clusters of at least 7 sheets were analyzed per condition. ANOVA ***, significance by post 
hoc analysis (Bonferroni) is shown.
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Figure 3: The tetraspanin web revealed by dual color STED microscopy.
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Figure 4: Tetraspanin clusters are organized at a higher spatial scale.
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←	Figure 4: Tetraspanin clusters are organized at a higher spatial scale.
(A-B) Images: zoom of JY B cell membrane sheets double stained for CD53(Rab) (red) and CD53(Mo), CD37, CD81 or 
CD82 (green) (a) or CD37 (red) and CD53, CD81 or CD82 (green) (b) imaged by STED microscopy. Scale bars represent 
0.5 μm. Graphs: intensity profiles of CD53(Rab) or CD37 (red curves) and CD53(Mo), CD37, CD81 or CD82 (filled green) 
as depicted in the corresponding images. (C) Distances from the center of annotated clusters to the center of their nearest 
CD37 clusters were determined. The nearest neighbor curves were compared to distance curves (red dashed curves) 
determined from mock images generated with the corresponding cluster densities and sizes, but with completely random 
and uncorrelated cluster distributions. Clusters of at least 10 sheets were analyzed per condition. (D) Zoom of a B cell 
membrane sheet double stained for CD53 and CD37. Yellow ellipses indicate CD53 and CD37 clusters that are in close 
proximity to each other. Scale bar represents 1 μm.
Tetraspanin-partner interactions resolved by super-resolution microscopy 
Since the interaction between CD19 and CD81 is crucial for efficient B cell activation via the 
B cell receptor (BCR), we investigated the nanoscale distribution of CD19 and CD81 clusters 
on the plasma membrane of B cells under resting conditions and upon BCR activation (Fig. 
5A). The organization of CD81 and CD19 clusters relative to each other did not seem to 
change upon BCR crosslinking. In addition, the density of clusters remained unchanged upon 
B cell stimulation (Fig. 5B), and CD81 and CD19 did not become more co-localized into single 
domains (Fig. 5C). Still, CD81 clusters were in closer proximity to CD19 clusters than expected 
when the distribution of these clusters would be random (Fig. 5D). Notably, we observed CD81 
clusters to be in closer proximity to clusters of its interaction partner CD19 than to clusters of 
tetraspanin CD53 (Fig. 5E and 3C).
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Next, we investigated the localization of tetraspanin CD53 on antigen-presenting cells in relation 
to another well-known interacting protein of tetraspanins, namely MHC class II [7,8,37,38]. In 
accordance with the reported interaction between CD53 and MHC class II we were able to 
pull down endogenous MHC class II in protein complexes precipitated from lysates of B cells 
using antibodies against CD53 (Fig. 6A) in conditions that preserve tetraspanin-tetraspanin 
interactions (Brij97). This interaction was lost under conditions in which a strong detergent 
(Triton X-100) was used, often interpreted as an indirect interaction in the tetraspanin field. To 
investigate the nanoscale organization of endogenous MHC class II molecules, we visualized 
CD53 and MHC class II clusters on the plasma membrane of B cells with dual color STED 
microscopy (Fig. 6B). Upon activation of B cell via the BCR, the density and sizes of CD53 
clusters remained unchanged. The density of MHC however decreased, while the determined 
average size of MHC clusters increased from 77 to 87 nm (Fig. 6C and D). This is likely due 
to coalescence of smaller clusters of MHC class II into larger clusters, since flow cytometry 
showed that the expression level of MHC on the plasma membrane of B cells did not change 
upon B cell activation (Fig. 6E). We investigated the proximity of MHC class II to CD53 clusters 
by comparing nearest neighbor distances of MHC class II to CD53, with distances calculated 
from computer generated mock images with a random distribution of both MHC class II and 
CD53 clusters (Fig. S6b). Both before and after B cell stimulation, MHC class II clusters were in 
slightly closer proximity to CD53 clusters than predicted from completely randomly positioned 
clusters (Fig. 6f and g). Moreover, a higher percentage of CD53 clusters was overlapping with 
MHC class II clusters than with clusters enriched in CD37, CD81 or CD82 (Fig. 3C, 4A, 6G and 
H). These findings indicate that CD53 is in closer proximity to its interaction protein MHC class 
II than to other members of the tetraspanin family. 
← Figure 5: Organization of CD19 relative to CD81 on the plasma membrane of B cells.
(A) JY B cells were untreated or stimulated with anti-BCR for 5 min. Membrane sheets double stained for CD19 (red) and 
CD81 (green) were imaged by STED microscopy. Blob detection images (most right) show annotated clusters used for 
further analysis. Scale bars: 5 μm in whole sheets and 0.5 μm in zoomed and blob detection images. (B) Surface density 
of the clusters from panel A. ≥15 sheets were analyzed per condition. Significance was tested with a Student T-test. (C) 
Images: zoom of B cell membrane sheets double stained for CD19 (red) and CD81 (green), imaged by STED microscopy. 
Left: untreated B cells. Right: BCR-stimulated B cells. Scale bar: 0.5 μm. Graphs: intensity profiles of CD19 (red line) and 
CD81 (filled green) as depicted in the corresponding images. (D) Distances from the center of annotated CD81 clusters 
to the center of their nearest CD19 cluster were determined. The nearest neighbor distance distributions were compared 
to distributions generated from 10 mock images with similar cluster densities and sizes but with completely random and 
uncorrelated cluster distributions. Clusters of ≥15 sheets were analyzed per condition. (E) Percentage of MHC clusters 
of which the distance from their center to the center of the nearest CD53 cluster was within 100 nm. Per sheet the 
percentage of clusters overlapping CD53 clusters was plotted for unstimulated and BCR-stimulated cells. Clusters of ≥15 
sheets were analyzed per condition.
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Figure 6: Organization of MHC class II relative to CD53 on the plasma membrane of B cells.
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← Figure 6: Organization of MHC class II relative to CD53 on the plasma membrane of B cells. 
(A) CD53 was immunoprecipitated from JY B cell lysates as described in the Methods. The different fractions were 
investigated for the presence of CD53 (multiple bands as CD53 is glycosylated) and MHC II (arrow) by immunoblotting. 
(B) B cells were untreated or stimulated with anti-BCR for 8 hours. Membrane sheets double stained for CD53 (red) and 
MHC II (green) were imaged by STED microscopy. Blob detection images (most right) show annotated clusters used for 
further analysis. Scale bars: 5 μm (whole sheets) and 0.5 μm  (zoomed and blob detection images). (C) Surface density 
of the clusters from panel B. ≥20 sheets were analyzed per condition. Significance was tested with a Mann Whitney test, 
p = 0.0079. (D) The full-width at half-maximal intensity (FWHM) of CD53 and MHC II clusters. ≥120 random clusters 
were measured derived from 3 sheets per condition. Significance was tested with a Mann Whitney test, p = 0.0021. (E) 
Unstimulated (filled gray) and stimulated B cells (black curve) were stained with MHC II or isotype control antibodies (light 
gray curves). Plasma membrane expression was analyzed by flow cytometry. (F) Distances from the center of annotated 
MHC II clusters to the center of their nearest CD53 cluster were determined. The nearest neighbor distance distributions 
were compared to distributions generated from 10 mock images with similar cluster densities and sizes but with completely 
random and uncorrelated cluster distributions. (G) Percentage of MHC clusters of which the distance from their center to 
the center of the nearest CD53 cluster was within 100 nm. Per sheet the percentage of clusters overlapping CD53 clusters 
was plotted for unstimulated and BCR-stimulated cells. F+G: Clusters of ≥20 sheets were analyzed per condition. (H) 
Images: zoom of membrane sheets double stained for CD53 (red) and MHC II (green), imaged by STED microscopy. Scale 
bar: 0.5 μm. Graphs: intensity profiles of CD53 (red line) and MHC II (filled green) as depicted in the corresponding images.
To further address the nanoscale distribution of MHC class II relative to CD53 in primary cells, 
we studied human monocyte-derived dendritic cells (DCs) under resting and stimulatory 
conditions (Fig. 7A; stimulation with LPS). In line with B cells, clusters of individual members 
of the tetraspanin family, including CD9, did not co-localize with each other (Fig. S7A and B). 
Moreover the density and sizes of CD53 clusters on the plasma membrane of DCs remained 
unchanged upon activation with LPS (Fig. 7B and C). However, we observed that in DCs not 
only the size but also the density of MHC class II clusters increased upon cell activation (Fig. 7B 
and C). These data corroborate the finding that in DCs the plasma membrane expression of 
MHC class II was increased upon activation (Fig. 7D). To investigate the proximity of MHC class 
II clusters to CD53 in DCs, we generated mock images with random and uncorrelated cluster 
organizations based on the cluster sizes and densities obtained from the STED images (Fig. 
S6C). In line with the data obtained in B cells, MHC class II clusters were in closer proximity to 
CD53 compared to random distributions in both resting and activated DCs (Fig. 7E), and this 
proximity of MHC class II clusters to CD53 clusters did not significantly alter upon cell activation 
(Fig. 7F). 
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Figure 7: Organization of MHC class II relative to CD53 on the plasma membrane of DCs.
Monocyte-derived DCs were untreated or stimulated with LPS for 24 hours. (A) DC membrane sheets double stained for 
CD53 (red) and MHC class II (green) were imaged by STED microscopy. Middle images: magnification of the area indicated 
in whole sheets images (most left). Blob detection images (most right) show annotated clusters used for further analysis. 
Scale bars represent 5 μm in whole sheet images, and 0.5 μm in zoomed and blob detection images. (B) Density of CD53 
and MHC class II clusters from panel A. At least 16 sheets were analyzed per condition. Significance was tested with a 
Student T-test, p = 0.0236. (C) The full-width at half-maximal intensity (FWHM) of CD53 and MHC II clusters. At least 120 
random clusters were measured derived from 3 sheets per condition. Significance was tested with a Mann Whitney test, 
p = 0.0254. (D) Unstimulated (filled gray) and stimulated monocyte-derived DC (black curve) were stained with MHC II or 
isotype control antibodies (light gray curves). Plasma membrane expression was analyzed by flow cytometry. (E) Distances 
from the centers of annotated MHC class II clusters to the centers of their nearest CD53 cluster. The nearest neighbor 
distance distributions were compared to distributions generated from 10 mock images with similar cluster densities and 
sizes but with completely random and uncorrelated cluster distributions (red dashed curves). Clusters of at least 16 sheets 
were analyzed per condition. (F) Percentage of MHC clusters of which the distance from their center to the center of the 
nearest CD53 cluster was less than 100 nm. Clusters of at least 16 sheets were analyzed for both unstimulated and LPS 
stimulated DCs. Significance was tested with a Student T-test.
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Quantification of the number of tetraspanin molecules per cluster
By investigating the tetraspanin web with dual color STED microscopy, we observed that the 
studied tetraspanin proteins were almost exclusively clustered with themselves and these 
clusters were largely devoid of other members of the tetraspanin family. To investigate the 
biophysical nature of these tetraspanin clusters further, we estimated the number of CD53 
molecules per CD53 cluster (Table 1). We first calculated the total amount of endogenous CD53 
protein in a single B cell by quantitative immunoblotting using recombinant CD53 protein (Fig. 
8A). On average, a total of 53,000 molecules of CD53 were present per B cell (Table 1). By 
immunolabeling B cells with the CD53-antibody recognizing the extracellular domain with or 
without membrane permeabilization, we estimated that 30% of these CD53 molecules localized 
to the plasma membrane whereas the remainder was present in intracellular membranes (Fig. 
8B). After correcting for this intracellular pool of CD53 protein, we quantified that about 
16,000 molecules of CD53 were expressed at the cell surface of a single B cell. To obtain the 
total number of clusters on the plasma membrane, we first estimated the average total cell 
surface area. To eliminate membrane inconsistencies, plasma membranes were stretched by 
disrupting the cytoskeleton with Latrunculin A and placing cells in hypotonic medium (Fig. 
8C). The radius at the equatorial plane of these spherical cells was measured to determine an 
average cell surface area of 1,040 μm2. Since STED microscopy analysis revealed that the CD53 
cluster density was 4.4 clusters / μm2 in the plasma membrane (Fig. 2D), this indicates that a 
single B cell contains on average approximately 4,500 CD53 clusters per cell. Consequently, 
we estimated that each of these clusters contains on average 3.5 molecules of CD53 on the 
cell surface of B cells. Although this value should be taken with great caution due to cellular 
heterogeneities and an experimental error in any of these steps cannot be excluded, we believe 
that it is warranted to conclude that the number of CD53 molecules per domain is lower than 
10.
Table 1: Approximation of the number of CD53 molecules per cluster.
Amount of total 
CD53 in 0.8x106 
cells
Mass of CD53 
protein
CD53 proteins/ 
cell
Fraction of total CD53 
on plasma membrane
Surface area 
of the plasma 
membrane
Density of CD53(Mo) 
clusters 
1,638 pg 23.34 kDa 
4,042x10-8 pg
53,185 30.12% 1,040 μm2 4.4 clusters / μm2
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Figure 8: Quantification of the number of CD53 molecules per cluster.
(A) Quantitative Western blot to determine the number of CD53 molecules per cell. B cell lysate and titrated samples 
of recombinant CD53 protein were subjected to SDS-page and immunoblotted with CD53(Rab) antibody against the 
C-terminus of CD53. The difference in protein mass of cell-derived CD53 (curly bracket; multiple bands, 25-37 kDa) versus 
recombinant CD53 protein (22 kDa; arrowhead) is due to glycosylation. Graph: standard curve of CD53 recombinant 
protein determined by densitometric analysis. (B) Expression of CD53 on the plasma membrane and on intracellular 
membranes. B cells were stained with CD53(Mo) to measure plasma membrane (left) and total CD53 expression (right). 
CD53 expression was determined by flow cytometry (filled gray histograms) and corrected for a-specific antibody binding 
(isotype control antibodies, light grey curves). Graph: expression of CD53 on the plasma membrane and in the total B 
cell, corrected for a-specific staining and normalized to total CD53 expression. (C) Determination of the total surface area 
of B cells. Cell ruffles were eliminated by treating cells with Latrunculin A (5 μM) for 15 min and stretching the plasma 
membrane by decreasing the osmolarity of the imaging medium from 280 to 200 mOsm. Plasma membranes were stained 
with the lipophilic membrane dye DiI, and the diameter of spherical cells was measured at the equatorial plane by confocal 
microscopy. Scale bar represents 10 μm. Graph: frequency distribution of the radius of B cells, 63 cells were measured.
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Discussion
The superfamily of tetraspanin proteins is important in many fundamental cell biological 
processes, still the physical principles of the tetraspanin network in the plasma membrane 
are not adequately understood. The current hypothesis is that tetraspanins assemble multi-
molecular complexes (TEMs) composed of different tetraspanins and their interacting partner 
molecules that together build ‘the tetraspanin web’. Tetraspanins can interact with other 
tetraspanins in the plasma membrane as evidenced by biochemical and microscopy-based 
studies in many different cell types, including immune cells (reviewed in [6]). These tetraspanin-
tetraspanin interactions have been reported to be regulated by lipids, including gangliosides 
and cholesterol [39,40], and by palmitoylation of intracellular cysteine residues [35,41,42] that 
may also modulate tetraspanin dynamics [19] and their cluster size [23]. Recently, the δ-domain 
of the large extracellular loop of tetraspanin CD81 was shown to be important for CD81 cluster 
formation [43]. In several studies it was estimated that multiple (>3) different members of the 
tetraspanin family could exist in one single complex [3,7,8,44]. Still the organization of multiple 
members of the tetraspanin family in  native plasma membranes has not been studied at the 
nanoscale level. 
To resolve the architecture of the endogenous tetraspanin web at the cell surface, 
we employed dual color STED microscopy. Here, we elucidated the size, distribution and 
stoichiometry of tetraspanin clusters in human immune cells and propose a new view on the 
tetraspanin web (Fig. 9). Based on the densities, distribution and size of clusters containing four 
different members of the tetraspanin family and the interaction partners CD19 and MHC class 
II, we modeled the spatial organization of the tetraspanin domains on the plasma membrane 
of a human B cell (Fig. 9A). In our model, tetraspanin clusters are non-randomly distributed on 
the plasma membrane. In contrast to the current dogma of a TEM, we observed that individual 
members of the tetraspanin family (CD37, CD81 and CD82) are present in nanoscale clusters 
that are largely devoid of other members of the tetraspanin family (CD53). The clusters detected 
in this study had an average size of below 120 nm and contained less than 10 molecules of one 
member of the tetraspanin family (Fig. 9B). This size is comparable to the TEM size (CD63 in HeLa 
cells; 190 nm) reported in former electron microscopy studies [44] and recent STORM studies 
(CD82 in KG1a cells; 90 nm [23]). Our findings are in line with the tendency of tetraspanin 
proteins to undergo homotypic interactions. Covalently crosslinking tetraspanins CD9, CD81 
and CD151 showed that the level of homodimers exceeded the level of crosslinking between 
different tetraspanin members (heterodimers), and CD9 homodimers were found to assemble 
in the Golgi and subsequently expressed at the cell surface [45]. Studies using detergents of 
different strength showed that heterotypic tetraspanin-tetraspanin interactions are relatively 
weak [46,47]. Moreover, members of the tetraspanin family can have different localizations 
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within the cell membrane as shown by CD9 localization that has an opposite polarity to CD151 
in cells of the stratum basale in skin [48].
We now show for the first time in native plasma membranes that different members of the 
tetraspanin superfamily are indeed not intimately interacting with CD53 or CD37 in membrane 
clusters. Since it is estimated that leukocytes express 20 different tetraspanins [49], we do not 
exclude that the distribution of tetraspanin proteins not studied here may be different, as also 
indicated by our finding that CD37 domains show more (but still little) overlap with CD81 and 
CD82 compared to CD53. Based on the four different tetraspanins studied here, we propose 
that tetraspanin homo-oligomers together with their primary non-tetraspanin interaction 
partner (for example CD81-CD19) form the basic building blocks for a stable tetraspanin cluster 
(e.g. TEM). These clusters form a dynamic network across the plasma membrane involving weak 
CD53
CD37
CD81
CD82
tetraspanin MHC class II
MHC class II
CD19
A
B
Figure 9: The tetraspanin web revisited.
(A) Model of the spatial organization of tetraspanin clusters on the plasma membrane of a B cell. Based on the cluster 
sizes, densities and distributions derived from the STED images, CD53, CD37, CD81, CD82, CD19 and MHC class II 
clusters were modeled on the surface of a B cell. Scale bars represent 5 μm (left) and 1 μm (right). (B) Model of the 
nanoscale organization of TEMs on the plasma membrane. Separate clusters enriched in either CD53 (red), CD37 (green), 
CD81 (cyan) or CD82 (blue). Each cluster contains below 10 tetraspanin molecules of a single tetraspanin species. CD53 
clusters are excluded from clusters containing CD37, CD81 or CD82. In contrast, clusters of MHC class II molecules 
(yellow, transparent) are partly overlapping with tetraspanin clusters, facilitating regulation of the function of MHC class 
II by multiple members of the tetraspanin family. Similarly, CD19 (purple) clusters overlap with CD81 clusters. Clusters of 
different tetraspanin species are adjacently positioned and can dynamically interact with each other forming a functional 
tetraspanin web in the plasma membrane. Scale bar represents 20 nm.
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heterotypic interactions with other tetraspanin clusters or other non-tetraspanin interaction 
partners (the tetraspanin web), resulting in a non-random distribution of clusters of different 
tetraspanin members adjacent to each other. Such a model is supported by elegant single 
molecule tracking studies showing that tetraspanin interactions are highly dynamic and distinct 
diffusion modes of tetraspanins were observed which could correspond to different clustering 
states [19]. 
Tetraspanin proteins can control the function of their interacting partners by influencing the 
clustering of partner proteins [21,23]. In our study we found MHC class II molecules located in 
clusters on the plasma membrane of both B cells and primary DCs. These clusters likely enable 
the local high avidity of MHC class II that is crucial for efficiently activating T cells. Despite the 
finding that the interaction of MHC class II with CD53 on B cells is relatively weak (e.g. not 
preserved in harsh detergent conditions), MHC class II clusters were non-randomly distributed 
in close proximity to CD53 clusters. We observed MHC-II cluster size to increase upon DC and 
B cell activation, in contrast to the cluster size of CD53 which was unaltered. This suggests that 
CD53 plays no role in activation-induced MHC-II clustering, although we cannot exclude the 
role of other tetraspanin members in this process. We envision secondary tetraspanin partners 
to be localized between the stable primary tetraspanin clusters, where their function can be 
regulated by multiple members of the tetraspanin family in a dynamic manner (Fig. 9). 
Taken together, we visualized the tetraspanin network including interacting partner proteins 
on the cell surface of immune cells with super-resolution microscopy. Since the molecular 
basis of membrane segregation into microdomains in the plasma membrane is not well 
understood, dual color super-resolution microscopy techniques may also be applied to study 
other protein families that are postulated to cluster together into protein islands. A detailed 
molecular understanding of TEMs at the nanoscale level will significantly contribute to better 
comprehension of the molecular mechanisms underlying tetraspanin biology in immune cells 
and other cell types. 
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Supplementary figures
Supplementary figure 1: Whole cell STED imaging and antibody specificity.
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← Supplementary figure 1: Whole cell STED imaging and antibody specificity.
(A) CD53 visualized by STED microscopy on a whole B cell (left) and a B cell derived membrane sheet (right). Left: Raji 
B cells were permeabilized and stained with CD53(Mo) which was detected by anti-mouse KK114. Right: JY membrane 
sheet stained with CD53(Mo) which was detected by anti-mouse Atto594. Both images were acquired with 10 nm 
sized pixel steps. Scale bars represent 2 μm. (B) Membrane sheets were stained with phalloidin, fixed and imaged by 
epifluorescent microscopy. Scale bar represents 5 μm. (C) Images: B cells were treated with Latrunculin A (LatA) or 
vehicle (DMSO) for 5 min. Membrane sheets double stained for CD53 (red) and CD37 (green) were imaged by STED 
microscopy. Scale bars: 5 μm in whole sheets and 0.5 μm in zoomed images. Graphs: Nearest neighbor analysis. Distance 
distributions of CD37 clusters of DMSO (blue) or LatA (pink) treated cells to the nearest CD53(Rab) clusters from at least 
11 sheets. For every sheet the percentage of clusters within 100 nm from the nearest CD53(Rab) cluster was plotted. 
(D) B cell membrane sheets were stained for CD53(Rab) and mouse IgG1 control antibody (upper), or Rabbit IgG control 
antibody and CD53(Mo). Rabbit antibodies were detected with anti-rabbit KK114 secondary antibodies, mouse antibodies 
were detected with anti-mouse Atto594. Scale bars represent 5 μm (sheet overview, left) or 0.5 μm (zoomed images). 
(E) Membrane sheets of JY, HEK293 and LN229 cells were stained with CD53(Rab) or isotype control antibodies, and 
visualized by a lipid dye TMA-DPH. Sheets were imaged by epifluorescent microscopy. Scale bars represent 5 μm. (F) B cells 
were stained simultaneously with CD53(Mo) and CD53(Rab) antibodies and analyzed by FACS. The red dashed line depicts 
the expected trend when CD53(Mo) antibody would have had lower affinity for CD53 protein than CD53(Rab) antibody. 
Instead, a linear correlation in staining intensities was observed.
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Supplementary figure 2: Blob detection and secondary antibody dye swap.
(A) B cell membrane sheets were stained for CD53(Rab) (upper) and CD53(Mo) (lower). Left: CD53 clusters visualized by 
STED microscopy. Right: clusters annotated by blob detection. Graph: intensity profile of CD53 on the line indicated in 
the images. Positions of the detected clusters are indicated in shaded areas. Most left, merged picture in which yellow 
indicates overlap. Scale bar represents 0.5 μm. (B) B cell membrane sheets were stained for CD53(Rab) and CD53(Mo) 
(upper), or CD53 (Rab) and CD55 (lower) and imaged with conventional confocal microscopy or by STED microscopy. 
Rabbit primary antibodies were visualized with anti-rabbit Atto594 secondary antibodies. Mouse primary antibodies were 
detected with anti-mouse KK114 secondary antibodies. Merged image of CD53(Rab) (green) and CD53(Mo) or CD55 
(red) in which yellow indicates overlap. Right images show clusters that were annotated by blob detection. Graphs show 
distance distributions of CD53(Mo) (left) or CD55 (right) clusters to the nearest CD53(Rab) cluster. Green curves: sheets 
were stained with CD53(Mo) or CD55 which was detected by anti-mouse Atto594, and CD53(Rab) detected by anti-
rabbit-KK114. Red curves: secondary antibody dyes were swapped. At least 10 sheets were analyzed. At least 10 sheets 
were analyzed per condition.
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Supplementary figure 3: Secondary antibody controls.
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Supplementary figure 3: Secondary antibody controls. (continued)
(A-B) B cell membrane sheets stained with anti-CD53 primary antibodies  (a: CD53(Rab), b: CD53(Mo)) and Atto594-
labeled F(ab)-fragments (upper) or whole anti-rabbit antibody (lower). Two representative sheets are shown for each 
condition. Graph: intensity profiles of CD53 clusters detected with F(ab) (upper, red) or whole antibody (lower, black) 
on the line depicted in images, to visualize cluster size. Scale bars represent 5 μm in sheets overview images and 0.5 
μm in zoomed images. (C) Staining intensity of anti-mouse secondary antibody correlated with the staining intensity of 
CD53(Mo)-FITC. Left: FACS analysis of CD53 expression on whole B cells.  Middle: B cells were stained with CD53(Mo)-
FITC and anti-mouse-alexa647, followed by membrane sheets preparation. Right: intensity profile of FITC and alexa647 
staining on the line depicted in middle images. (D) B cells were labeled for CD37 or CD53 (single labeled cells), or for CD37 
and CD53 simultaneously (dual labeled cells) and analyzed for staining intensity of anti-CD53 (mIgG1) and anti-CD37 
(mIgG2a). B cells were stained with CD53(Mo) and/or CD37 antibodies, followed by staining with anti-mIgG1-alexa647 
and anti-mIgG2a-alexa488 (left) or anti-mIgG1-atto594 and anti-mIgG2a-KK114 (right).
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Supplementary figure 4: Expression of CD37, CD53, CD81 and CD82 on the plasma membrane of B cells. 
Unpermeabilized cells were stained for tetraspanin proteins and expression was determined by flow cytometry (filled gray 
histogram) and corrected for a-specific antibody binding (isotype control antibodies, light grey line). Graph: expression 
of CD53, CD37, CD81 and CD82 on the plasma membrane of B cells, corrected for a-specific staining, mean fluorescent 
intensity is depicted.
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Supplementary figure 5: CD53 does not overlap with CD82.
(A) B cell membrane sheets double stained for CD82(Rab) (red) and CD82(Mo) (green) were imaged by STED micros-
copy. Scale bars: 5 μm in whole sheets and 1μm in zoomed images. Graph: intensity profiles of CD82(Rab) (red curves) 
and CD82(Mo) (filled green) as depicted in the corresponding images. (B) B cells membrane sheets double stained for 
CD82(Rab) (red) and CD53(Mo) (green) were imaged by STED microscopy. Scale bars: 5 μm in whole sheets and 0.5 μm 
in zoomed images. Graphs: intensity profiles of CD82 (red line) and CD53 (filled green) as depicted in the corresponding 
images.
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Supplementary figure 6: Mock images of random and uncorrelated cluster distributions. 
(A) Mock images with completely random and uncorrelated cluster distributions that were simulated using the size and 
densities of tetraspanin clusters determined from the STED microscopy images of B cell membrane sheets. Distributions 
of CD73 clusters (red) with CD53(Mo), CD81 or CD82 clusters (green) were generated. Scale bars represent 5 μm in 
overview images and 0.5 μm in zoomed images. (B) Mock images with random cluster distributions that were generated 
using the size distributions and densities of CD53(Rab) and MHC class II clusters determined from the STED microscopy 
images of membrane sheets derived from untreated and BCR stimulated B cells. Distributions of CD53(Rab) clusters (red) 
and MHC class II clusters (green) were generated. Scale bars represent 5 μm in overview images and 0.5 μm in zoomed 
images. (C) Mock images with random cluster distributions that were generated using the size distributions and densities 
of CD53(Rab) and MHC class II clusters determined from the STED microscopy images of membrane sheets derived 
from untreated and LPS stimulated DCs. Distributions of CD53(Rab) clusters (red) and MHC class II clusters (green) were 
generated. Scale bars represent 5 μm in overview images and 0.5 μm in zoomed images.
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Supplementary figure 7: CD53 and CD9 are not overlapping on the plasma membrane of DCs.
(A) B cells were untreated or stimulated with LPS. Membrane sheets double stained for CD53(Rab) (red) and CD9 (green) 
were imaged by STED microscopy. Scale bars: 5 μm in whole sheets and 0.5 μm in zoomed and blob detection images. 
(B) Intensity profiles of CD19 (red line) and CD81 (filled green) as depicted in the corresponding images of panel A. (C) 
Percentage of CD9 clusters of which the distance from their center to the center of the nearest CD53 cluster was within 
100 nm. The percentage of clusters overlapping CD53 clusters was plotted per sheet. Clusters of >6 sheets were analyzed 
per condition.
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Abstract
The protein kinase C (PKC) family plays a key role in biological signaling networks 
regulating cell proliferation, differentiation and apoptosis. PKCs translocate to 
the plasma membrane for activation, but the mechanisms regulating their spatial 
membrane distribution are incompletely understood. Using live cell imaging, we 
show that B cell receptor (BCR) triggered production of diacylglycerol results in 
translocation of PKCβ to tetraspanin CD53 microdomains at the plasma membrane 
of B cells. CD53 is specifically enriched at sites of BCR signaling, demonstrating 
that BCR-dependent PKC signaling is initiated at tetraspanin microdomains. 
Fluorescence lifetime imaging microscopy studies confirmed the molecular 
recruitment of PKC to CD53 microdomains. We generated CD53-deficient 
mice and show that primary B cells lacking CD53 are defective in PKC substrate 
phosphorylation. Thus, CD53 is required for BCR-dependent PKC signaling by 
spatially coordinating PKC with its substrates. This study demonstrates that 
tetraspanin domains act as signaling hotspots in the plasma membrane.
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Introduction
PKCs are serine/threonine kinases that are highly conserved in evolution, ranging in complexity 
from a single isoform in yeast to 4 isoforms in C. elegans and >10 in mammals. PKCs play a major 
function in many signaling networks regulating cell proliferation, differentiation, apoptosis, and 
malignant transformation [1]. Activation of the conventional PKC isoforms PKCα, -βI, -βII and -γ 
is  controlled by Ca2+-dependent binding of their C2 domains to anionic phospholipids as well 
as by binding of their C1 domains to diacylglycerol (DAG). Binding of PKC to DAG and anionic 
lipids changes the conformation of the enzyme resulting in release of the pseudosubstrate-like 
inhibitory N-terminus from the catalytic site. This leads to local activation of PKC, which enables 
PKC to phosphorylate its substrates [2]. However, how PKC protein complexes are targeted to 
specific sites on the plasma membrane remains elusive. 
In immune cells, PKC isoforms are crucial components of antigen receptor signal transduction 
pathways [3]. In particular, conventional isoform PKCβ is indispensable for optimal B cell receptor 
(BCR) signaling [4]. Engagement of the BCR by antigen results in phospholipase C γ2-mediated 
hydrolysis of phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) to inositol-1,4,5-trisphosphate 
(IP3) and DAG. Cytosolic IP3 releases Ca2+ from intracellular stores which together with DAG 
regulate translocation of PKCβ to the plasma membrane where PKC is activated. PKCβ-deficient 
mice are impaired in humoral immune responses [5], and PKCβ inhibitors are under investigation 
in clinical trials for patients with B cell malignancies [6]. Although PKC-binding proteins have 
been hypothesized to recruit PKC isoforms to distinct subcellular regions [2,7], the mechanisms 
underlying the spatiotemporal regulation of PKC at the membrane have not been resolved.
Specialized membrane microdomains enriched in tetraspanin proteins have been proposed 
as a possible mechanism for the organization of signaling complexes at the plasma membrane 
[8,9]. Tetraspanins are small (~25 kDa) hydrophobic proteins that are composed of four 
transmembrane domains, a small and a large extracellular loop, and short intracellular C- and 
N- termini. They associate in cis with other membrane proteins, cytosolic proteins and other 
tetraspanins, whereby they form so-called tetraspanin microdomains also referred to as ‘the 
tetraspanin web’ [10]. By organizing membrane proteins like integrins and signaling receptors, 
tetraspanins are implicated in diverse cellular processes including cell adhesion and activation 
(reviewed in [8,11,12]). PKCs have been hypothesized to be regulated by tetraspanins, as 
biochemical data showed that tetraspanins can interact with PKC isoforms [13–15]. However, 
actual localized PKC signaling at tetraspanin microdomains has never been directly visualized in 
living cells. In this study, we show that upon stimulation of the BCR, PKCβ specifically translocates 
to tetraspanin microdomains. Notably, we find that PKC signaling is impaired in tetraspanin 
CD53-deficient B cells, demonstrating that PKC signaling is dependent on tetraspanin CD53 
microdomains.
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Materials and Methods
Antibodies, reagents and expression constructs
The following antibodies were used: F(ab’)2 Fragment goat anti-human IgA + IgG + IgM (H+L) 
(referred to as anti-BCR), ChromePure goat IgG, and F(ab’)2 Fragment goat anti-mouse IgG 
(referred to as anti-BCR) are from Jackson ImmunoResearch, anti-human CD55 (143-30, 
eBioscience), FITC anti-mouse CD53 (OX-79, Biolegend), Alexa647 rat anti-mouse CD45R 
(B220) (RA3-6B2, BD Pharmingen), Alexa488 goat anti-mouse IgG (Invitrogen), Allophycocyanin 
anti-mouse CD19 (eBio1D3, eBioscience), PKC (H-300, Santa Cruz), PKCβII (C-18, Santa Cruz), 
Phospho-(ser) PKC Substrate antibody (Cell Signalling), Syk (N-19, Santa Cruz), Phospho-Syk 
(C87C1, Cell Signalling), mouse anti-actin (AC-40, Sigma), donkey anti-rabbit IRDye680 and 
goat anti-mouse IRDye800 (LICOR). BAPTA-AM (Life Technologies) was dissolved in anhydrous 
DMSO and directly used. For the cell mask, we used a PEGylated cholesterol analogue labeled 
with a far-red fluorescent dye (kindly provided by Alf Honigmann). Phorbol-12-myristate-13-
acetate (PMA) (Calbiochem) was stored in DMSO. PKC inhibitor Gö6983 (Sigma) was diluted 
in DMSO and used at a final concentration of 1mM. The PKCβII construct was a kind gift 
from Dr. Hannun [16]. Fluorescent proteins were swapped using AgeI and BsrGI restriction 
sites. Super GFP2 (sGFP2)-CD53 and mCherry-CD53 were generated by cloning hCD53 cDNA 
(NM_000560, Thermo Scientific) into psGFP2-C1 [17] and pmCherry-C1 [18] respectively. GPI-
RFP has been described previously [19].
Cells and transfections
The EBV-negative human B cell line BJAB [20] has been widely studied as a model for 
signaling through the B cell receptor. BJAB B cells were maintained in RPMI 1640 (Gibco) 
supplemented with 10% Fetal Bovine Serum (Greiner Bio One), stable Glutamine (PAA) and 
Antibiotic-Antimycotic (Gibco). BJAB B cells were transiently transfected by electroporation 
using Nucleofector 2b system (Amaxa, Lonza) according to the manufacturers guidelines using 
program M013 and cells were imaged 24 hours after transfection. 
Micro contact printing experiments
Poly(dimethylsiloxane) stamps containing a regular pattern of 5 μm circular spots were prepared 
as described in [21,22]. Stamps were incubated for 1 hour with PBS containing 100 μg/ml 
anti-BCR or control antibodies mixed with 10 μg/ml fluorescent antibody, donkey anti-rabbit 
IgG (H&L)-Alexa647 (Invitrogen) to visualize the spots. Stamps were washed with demineralized 
water and dried under a nitrogen stream. The stamp was applied to a cleaned glass coverslip 
for 20 s and then removed. Transfected cells were seeded on the stamped area and incubated 
for 3 or 15 min at 37˚C. PFA was added to the cells to a final concentration of 2% PFA or the 
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coverslips were washed with PBS and fixed with 2% PFA in PBS for 20 min at room temperature. 
Samples were washed with PBS and demineralized water and embedded in Mowiol (Sigma). 
Live cell imaging and microscope setups
Wide field imaging was performed using an Olympus IX71 inverted microscope equipped with 
60x 1.45 NA oil objective and two lasers at 491 and 561 nm for excitation. Fluorescence 
emission was separated from the excitation light with a CMR-U-M4TIR-SBX quadruple 
(405/491/561/640) dichroic (Olympus). GFP and RFP fluorescence were projected separately on 
the CCD with a Dual-view image splitter (DV2; Photometrics), where emission was separated 
with a 565 LP dichroic mirror and a 612/69 band-pass filter in the red channel. Fluorescent 
signals were collected with a C9100-13 EM-CCD (Hamamatsu). Images were taken sequentially 
and appropriate filter sets were used to prevent bleed through. During image acquisition was 
performed at 37˚C with a cycle time of 269 ms. For the caged DAG experiments, uncaging was 
performed by manually opening a shutter for approximately 1 s resulting in illumination with a 
mercury lamp (X-Cite, series 120Q) coupled to a 365/50 band-pass filter. 
PKC and CD53 co-localization, calcium chelating and micro-contact printing experiments 
were imaged on an epi-fluorescence Leica DMI6000 microscope with a 63x oil 1.4 NA objective, 
a metal halide EL6000 lamp for excitation, a DFC365FX CCD camera (Leica) and GFP, DsRed and 
Y5 filter sets (for GFP, RFP and AF647, respectively; all from Leica). Focus was kept stable with 
the adaptive focus control from Leica. 
Live cell microscopy of PKC co-localization with CD53 and the fluorescently labelled 
cholesterol analogue, and fluorescent lifetime imaging microscopy (FLIM) were performed on a 
SP8 confocal microscope equipped with a 60× water 1.2 NA objective (Leica) using appropriate 
laser lines and settings. FLIM images were recorded using the same setup with excitation light 
at 495 provided by a pulsed white light laser (Leica). Fluorescence (from 500 to 535 nm) was 
collected with an internal photomultiplier tube and processed by a Picoharp 300 time-correlated 
single-photon counting system (Picoquant, Berlin, Germany). At least 50,000 photons were 
recorded for each individual cell. 
Caged-DAG experiments 
For the uncaging experiments, 1-stearoyl-2-arachidonoyl-sn-glycerol (SAG) and 1,3-di-O-
octanoyl-sn-glycerol (1,3-DOG) both protected with a coumarinylmethylene group were 
synthesized as described [19]. A final concentration of 30 μM from a 10 mM stock solution in 
DMSO was added immediately prior to the imaging experiment. Cells were imaged with an 
Olympus IX71 microscope as described above. Uncaging was performed by manually opening a 
shutter for approximately 1 s resulting in illumination with a mercury lamp (X-Cite, series 120Q) 
coupled to a 365/50 band-pass filter.
Chapter 5
140
Image analyses and data fits
All image analyses was performed using Fiji software [23]. To quantify PKC translocation to the 
plasma membrane, the expression of PKC on a line profile, before and at maximal translocation 
was plotted. The width of the broadest peak representing cytosolic PKC  was compared with 
that of the corresponding peak of membrane bound PKC at half maximal intensity. For PKC 
response curves, region of interests were selected that reflected the larger part of the cytoplasm, 
while excluding the nucleus and plasma membrane regions of the cell at any time point. Mean 
grey intensities of PKC fluorescence in the cytoplasm were measured over time and intensities 
were normalized to the first few data points before stimulation. The average fluorescence 
intensity of the whole cell over time was used to correct for photobleaching. Co-localization 
of PKCβ, CD53 and cholesterol at the plasma membrane was analyzed with polar plots of the 
plasma membrane using the JACoP plugin (ImageJ). CD53 enrichment at microcontact prints 
was quantified by a custom analysis algorithm. Prints were segmented based on an intensity 
threshold applied to the print image. Cells were segmented using an edge finding algorithm 
applied to the Differential Interference Contrast image and an intensity threshold applied to 
the GFP image, to select transfected cells only. Combining the segmentations resulted in masks 
for cellular parts covering the spots and cellular parts covering the surrounding area. These 
masks were used to measure the intensity of GFP-CD53 on the spots and the surrounding 
area that is covered by the cell, and as regions of interest for co-localization analysis. Pearson’s 
correlation coefficients were calculated per cell using the Coloc 2 plugin (Fiji). PKC enrichment 
on microcontact prints was quantified by selecting cellular parts covering the spots and cellular 
parts covering the surrounding area, and the mean fluorescent intensities of GFP-PKCβ in these 
areas were compared, after correcting for the background.
FLIM images were generated with SymPhoTime (Picoquant). For obtaining the fluorescence 
lifetimes,  photon histograms containing all photons pooled for each individual cell were 
reconstructed from the photon traces with a custom programmed algorithm (C#.NET) and 
these histograms were fitted with single exponential decay curves (OriginLab) to obtain donor 
fluorescent lifetimes. A bi-exponential fit was used to obtain the percentages of bound donor. 
The typical lifetime of the donor was a fixed fitting parameter in this analysis. Ratios of acceptor 
and donor expression level were determined at the single cell level using fluorescent intensities 
from confocal images acquired before FLIM imaging.
Generation of the CD53-/- mice 
LoxP sites were introduced downstream to exon 1 and upstream to exon 6 in the mouse CD53 
gene. Thereby, exons 2 through 5 were deleted upon crossing CD53 floxed/floxed mouse with a 
Cre deleter mouse. An inverted neomycin resistant gene was introduced downstream to exon 1 
and loxP site. Deletion of the CD53 gene was verified by PCR using the following WT and CD53-/- 
specific primers: WT forward: TGT GGT GTA AAT GGC TCA AGT G; CD53-/- forward: TGC CCA 
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TCC ATA CTT TCA CTC; reverse: CTC CAA CCC AGT GGA CCT AA. CD53 protein expression 
was analyzed on blood leucocytes by flow cytometry. CD53-/- mice were fully backcrossed to 
the C57Bl/6J background, and CD53-/- mice and sex and aged-matched C57Bl/6J wild-type 
mice were bred at the Central Animal Laboratory Nijmegen (The Netherlands). Mice were used 
at 8 to 12 weeks of age. All animal studies were approved by the Nijmegen Animal Experiments 
Committee. 
Murine B cell stimulation and detection of phosphorylated PKC substrates
Resting primary B cells were isolated from the spleens of wild-type and CD53-/- mice by depleting 
CD43+ cells with CD43-MACS beads (Miltenyi Biotec). B cell purity and CD53, BCR and CD19 
expression were detected by flow cytometry after incubating cells with anti-B220-Alexa647, 
anti-CD53-FITC, anti-mouse IgG-Alexa488 or anti-CD19-Allophycocyanin respectively. Pooled B 
cells from 3 mice (9x10^6) were stimulated with 10μg/ml F(ab’)2 goat anti-mouse IgG for 5 min. 
1 μM PKC inhibitor Gö6983 was added 30 min before stimulation. To detect phosphorylated 
Syk, cells were treated for 5 min with tyrosine phosphatase inhibitor pervanadate. Cells were 
lysed in Laemmli sample buffer supplemented with β-mercaptoethanol, proteins were separated 
by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore). Membranes 
were blocked with 5% BSA or 3% BSA and 1% skim milk powder in TBS and probed with 
specific antibodies, followed by IRDye-conjugated secondary antibodies and Odyssey infrared 
detection (LI-COR). Profiles of protein staining intensities were analyzed using Fiji software.
Results
PKCβ translocates to the plasma membrane upon BCR stimulation
We studied the spatiotemporal dynamics of PKCβ in human B cells transfected with fluorescently-
tagged PKCβ. PKCβ readily translocated to the plasma membrane upon stimulation with 
anti-Ig F(ab’)2 fragments that mimics BCR stimulation with antigen (Fig. 1A). This translocation 
was quantified from the distribution of PKCβ fluorescence over a line profile across the cell, 
which decreased significantly in width upon BCR stimulation. Maximal PKCβ translocation was 
reached within ῀20s after BCR activation and was transient (Fig. 1B). Cells stimulated with 
isotype controls or antibodies against an irrelevant membrane protein (CD55) did not induce 
PKC translocation (Fig. 1B). To investigate the requirement of Ca2+ and DAG for BCR dependent 
PKCβ translocation, we first studied the role of DAG by using photoactivatable DAG molecules 
attached to a fluorescent coumarinylmethylene caging group [19]. DAG (naturally occurring 
SAG (stearoyl-arachidonyl glycerol)) and as control a bio-inactive DOG (1,3-di-O-octanoyl 
glycerol) were introduced into living B cells expressing fluorescently-tagged PKCβ. The uptake 
and localization of caged DAG were visualized by measuring coumarin fluorescence at the time 
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Figure 1: PKCβ translocates to the plasma membrane after BCR stimulation.
(A) B cells expressing mStrawberry-tagged PKCβ were stimulated with F(ab’)2 anti-BCR antibodies. PKC distribution before 
stimulation (left) and at maximal PKCβ translocation (right). Left graph: PKCβ fluorescence intensity across the yellow 
line profile for unstimulated (shaded grey) and stimulated cells at maximal PKCβ translocation (black line). Right graph: 
width of PKCβ fluorescence, measured at 50% of the maximal fluorescent intensity (n=8 cells, representative cells of 
>8 independent experiments). (B) B cells expressing mStrawberry-PKCβ stimulated with isotype control, anti-CD55 or 
anti-BCR antibodies. Left graph: PKC intensity within the cytosol over time, normalized to the average cytosolic intensity 
before stimulation. Right graphs: width of PKC fluorescence, measured at 50% of the maximal fluorescent intensity 
(n≥6 cells). (C) sGFP2-PKCβ expressing B cells treated with coumarin-caged SAG or control DOG were subjected to UV 
light to photoactivate the DAG species. Left images: localization of caged DAG species during photoactivation. Right 
images: PKCβ localization before and after DAG photoactivation. Graphs: width of PKC fluorescence before and after 
photoactivation, measured at 50% of the maximal fluorescent intensity (n≥6 cells, from 2 independent experiments). 
(D) mStrawberry-CD53 expressing B cells pretreated with 10 μM BAPTA-AM or DMSO (30 min at 37°C) were imaged in 
medium containing 2 mM EGTA. PKCβ localization before and after stimulation with anti-BCR antibodies (representative 
cells from 3 experiments).
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of DAG photoactivation by UV light. Both caged DAG and the control DOG displayed similar 
subcellular localization, with the largest fraction present in intracellular membranes (Fig. 1C). 
Photoactivating DAG resulted in evident translocation of PKCβ. Notably, PKCβ translocated 
almost exclusively to the plasma membrane. PKCβ remained in the cytosol upon uncaging of 
the bio-inactive DAG analogue (Fig. 1C). Depletion of intracellular and/or extracellular Ca2+ did 
not affect PKCβ translocation upon BCR stimulation (Fig. 1D) indicating that DAG is sufficient to 
drive BCR-induced PKCβ translocation. However, since the largest active DAG pool was located 
at intracellular membranes (Fig. 1C), DAG cannot be the sole determinant for PKC recruitment 
specifically to the plasma membrane. Since PKC isoforms have been reported to interact with 
tetraspanin proteins and tetraspanins are implicated in sequestering signaling molecules in 
membrane domains, we hypothesized that PKC recruitment to the plasma membrane was 
dependent on tetraspanin microdomains.
PKC translocates to tetraspanin domains
The tetraspanin CD53 is of particular interest since it is specifically expressed in immune cells 
and has been suggested to play a role in PKC signaling [24,25]. Correlating the intensity of 
fluorescently-tagged CD53 with that of PKCβ at the plasma membrane revealed that PKCβ 
became highly co-localized with CD53 upon BCR stimulation (Fig. 2A). Since these patches also 
correlated with the presence of cholesterol, they likely represent regions of higher membrane 
density (e.g. membrane ‘ruffles’) [26] (Fig. 2B). To resolve whether PKC translocation was 
specifically directed to CD53 microdomains, we employed a cell imaging system in which the 
BCR was locally engaged by means of microcontact printing of anti-BCR antibodies. PKCβ was 
specifically recruited to the anti-BCR patterns supporting that these are sites of BCR signaling, 
in contrast to isotype control patterns (Fig. 3A and B and Fig. S1A). Moreover, evident and 
stable CD53 enrichment on anti-BCR prints was observed in the majority of B cells (Fig. S1B). 
This CD53 enrichment was specific for the sites of BCR signaling, as CD53 was not recruited to 
sites with control antibodies (Fig. 3C and D). We confirmed that PKCβ and CD53 specifically co-
localized at the anti-BCR print in contrast to cellular regions surrounding the print (Fig. 3E). The 
recruitment of a glycosylphosphatidylinositol (GPI)-linked fluorescent control protein to anti-
BCR prints was significantly less than CD53 recruitment (Fig. 3F). Together, our data indicate 
that BCR activation and subsequent PKC recruitment occur at tetraspanin CD53 microdomains 
in the plasma membrane of B cells.
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Figure 2: PKCβ co-localizes with tetraspanin CD53 after stimulation.
(A) From left to right: PKCβ distribution before translocation, PKCβ location at maximal translocation upon BCR 
stimulation, CD53 localization and a merged picture of PKCβ (green) and CD53 (red) during maximal PKC translocation 
(scale bar is 5 μm). Below: a polar plot of the plasma membrane showing PKC (upper) and CD53 (lower) distribution during 
maximal PKC translocation. Right: Pearson’s correlation coefficients between CD53 and PKCβ in polar plots (n=10 cells, 
p<0.0001, paired T-test, data from 3 independent experiments). (B) B cells expressing mCherry-CD53 and sGFP2-tagged 
PKCβ stained with labeled cholesterol analog (cell mask) were stimulated with anti-BCR antibodies. Merged picture: PKCβ 
(green), CD53 (red) and cell mask (blue). Scale bar is 5 μm. Below: polar plots of the plasma membrane showing PKCβ, 
CD53 and cholesterol distribution during maximal PKCβ translocation. Right: Pearson’s correlation coefficients between 
CD53 and PKCβ were plotted against the correlation coefficients of cholesterol and PKCβ (n=17 cells from 3 experiments).
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Figure 3: PKC translocates to tetraspanin domains at the site of BCR signaling.
(A) B cells expressing sGFP2-PKCβ were seeded on coverslips printed with isotype control or anti-BCR spots and analyzed 
after 3 min. Merged picture: antibody print (red) and PKCβ (green). Graphs: PKCβ fluorescence intensity across the 
yellow line profiles. Shaded areas: location of the antibody print. (B) Quantification of PKC enrichment at sites of BCR 
engagement. The ratio between the average PKCβ intensity on and outside antibody prints is depicted for isotype prints 
versus anti-BCR prints. Error bars represent SD, n = 10 cells, data from two independent experiments, * p < 0.0001, one 
sample T-test. (C) B cells expressing sGFP2-CD53 were seeded on a coverslip printed with isotype control or anti-BCR spots 
and analyzed after 15 min. Merged picture: antibody print (red) and CD53 (green). Graphs: CD53 fluorescence intensity 
across the yellow line profiles. Shaded areas: location of the antibody print.(D) Ratio between the average CD53 intensity 
on and outside antibody prints within CD53-expressing cells (n>22 overviews, * p < 0.0001, one sample T-test, data 
represents 2 independent experiments). (E) B cells expressing sGFP2-CD53 and mStrawberry-PKCβ were seeded on anti-
BCR spots and analyzed after 15 min. Below: zoomed merged picture of PKCβ (green) and CD53 (red). Site of the BCR 
print: yellow circle, scale bar: 2 μm. Graph: Pearson’s correlation coefficients of CD53 and PKCβ on the anti-BCR print and 
on cellular parts surrounding the print (n=9 cells). (F) B cells expressing GPI-RFP were seeded on coverslips printed with 
anti-BCR spots and analyzed after 15 min. Merged picture: anti-BCR print (red) and GPI expression (green). Graph: ratio 
between the average intensity on and outside anti-BCR prints within GPI or CD53 expressing cells (n=10 overviews, * p = 
0.0003, unpaired T-test). Error bars are SD, scale bars: 5 μm, unless stated otherwise.
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Nanoscale proximity of PKCβ to CD53 in living B cells
We employed fluorescence lifetime imaging microscopy (FLIM) based on Förster resonance 
energy transfer (FRET) to detect molecular interactions at the nanometer scale. We first studied 
the interaction between individual CD53 molecules in the plasma membrane. In B cells expressing 
green fluorescent protein (GFP)-CD53 (GFP-donor only) we determined an average fluorescent 
lifetime of the donor (GFP) of 2.58 ± 0.03 ns (fitting with mono-exponential decay functions). 
In B cells co-expressing GFP-tagged and red fluorescent protein (RFP)-tagged CD53 (both GFP-
donor and RFP-acceptor), the fluorescent lifetime of the donor decreased significantly to 2.33 
± 0.09 ns (mono-exponential decay functions) (Fig. 4A, B and C) indicating an interaction 
between CD53 proteins. This corroborates with multiple CD53 molecules clustering together 
within CD53 microdomains [27]. Fitting the curves to bi-exponential decay functions with the 
slowest decay lifetime fixed at the lifetime of donor only (i.e. 2.58 ns) revealed that ῀30% of 
the GFP-CD53 molecules were in close proximity (<5 nm Förster distance) to RFP-tagged CD53 
molecules. 
Next, the nanoscale proximity of PKCβ to CD53 in the plasma membrane was investigated 
upon B cell stimulation. In unstimulated B cells, PKCβ was predominantly localized in the cytosol 
and co-expression of RFP-PKCβ did not significantly alter the lifetime of GFP-CD53 (Fig. 4A, 
B and C). PKC translocation upon BCR stimulation was too transient to obtain a sufficient 
number of photon traces. Upon B cell stimulation with PMA, PKCβ translocated to the plasma 
membrane (Fig. 4A) accompanied by a significant drop in lifetime of donor-GFP to 2.48 ± 
0.06 ns (single exponential decay; Fig. 4C and Fig. S2A) indicating nanoscale proximity of PKC 
molecules to CD53. In these experiments, the donor-GFP was present on membrane-anchored 
CD53 and the acceptor-RFP on soluble PKC. This arrangement excludes potential artefacts 
arising from changes in the GFP lifetime caused by membrane binding (i.e. independent from 
CD53). Moreover, the decrease in lifetime of GFP was not caused by differential ratios of 
acceptor and donor expression levels (Fig. S2B). By fitting with bi-exponential decay curves, we 
estimated that the percentage of GFP-CD53 bound to RFP-PKCβ increased significantly from 
8% to 16% upon B cell stimulation showing that PKCβ and CD53 are in close proximity to each 
other (i.e. < 5 nm) when PKCβ is activated (Fig. 4A, B and C). We conclude that PKCβ is directly 
recruited to tetraspanin CD53 at the plasma membrane upon activation of B cells. 
Tetraspanin CD53 is essential for optimal PKC signaling activity
We investigated the functional consequences of the recruitment of PKC molecules to tetraspanin 
microdomains in B cell signaling by generating mice that were deficient for CD53 (CD53-/-) 
using homologous recombination in embryonic stem cells (Fig. 5A, B and C). Primary naive 
B cells (CD43- B220+) were isolated from spleens of CD53-/- and wild type (WT) mice with 
comparable purity. We first analyzed whether the different components of the BCR complex 
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were present in the plasma membrane in the absence of CD53. Notably, CD53-/- B cells had 
comparable protein expression of the BCR itself and the BCR co-receptor protein CD19 on the 
cell surface (Fig. 5D). In addition, we observed similar PKCβ and total PKC protein expression 
in lysates of purified WT and CD53-/- B cells (Fig. 5E). Moreover, total protein levels of Syk 
and the ability to phosphorylate Syk were comparable between WT and CD53-/- B cells (Fig. 
5E). These results suggest that the BCR complex and the BCR signaling cascade upstream of 
PKC are intact in CD53-/- B cells. Next, we evaluated the activity of PKC by directly examining 
phosphorylation of PKC substrates upon B cell stimulation (Fig. 5F). A clear increase in PKC 
substrate phosphorylation was observed upon BCR activation in WT B cells. The specific PKC 
inhibitor Gö6983 showed complete blockage of additional PKC substrate phosphorylation 
induced by BCR activation, verifying the specificity of the assay. In unstimulated cells, the 
phosphorylation of PKC substrates in CD53-/- and WT B cells was comparable. Strikingly, when 
CD53-/- B cells were activated by BCR stimulation no increase in PKC substrate phosphorylation 
was observed in contrast to WT B cells (Fig. 5F and G). Together, these studies demonstrate that 
tetraspanin CD53 is crucial for optimal PKC function after BCR stimulation.
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Figure 4: Recruitment of PKCb to CD53 proteins at the nanoscale level.
B cells expressing sGFP2-CD53 alone, co-expressing sGFP2-CD53 and RFP-CD53 or co-expressing sGFP2-CD53 and 
RFP-PKCβ were subjected to FLIM analysis. B cells co-expressing sGFP2-CD53 and RFP-PKCβ were imaged during PKC 
translocation upon stimulation with PMA. (A) Upper: FLIM images of sGFP2-CD53. Bar: color scale of GFP lifetime. Lower: 
confocal microscopy showing the distribution of CD53 and PKCβ. (B) Lifetime histograms of B cells depicted in A. The 
distribution of fluorescence lifetime values per pixel is plotted and fitted with a Gaussian function. (C) Left: lifetimes 
of sGFP2-CD53 obtained by fitting fluorescent decay curves with mono-exponential decay functions (n≥10 cells, *p < 
0.0001, unpaired T-test with Welch’s correction). Right: fluorescent decay curves were fitted with bi-exponential decay 
functions with the lifetime of the donor in absence of FRET fixed. The percentage of GFP-CD53 in close proximity to 
acceptor molecules (i.e. with shorter lifetime than donor only) is shown (* p = 0.0005, unpaired T test). Experiments were 
repeated 3 times. Error bars are SD, p-values ≤0.01 were considered statistically significant.
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Figure 5: Generation CD53-/- mice, and impaired PKC substrate phosphorylation in CD53-/- B cells.
(A) Gene map showing the deleted portion of the murine CD53 gene. (B) DNA from CD53-/-, CD53+/- and WT mice 
was used as a template for a PCR reaction using WT and CD53-/- specifi c primer sets. (C) Expression of CD53 (gray 
line) on blood leukocytes of WT, CD53+/- and CD53-/- mice was analyzed by fl ow cytometry. Isotype control: shaded 
gray. (D) Expression of CD53, B220, BCR and CD19 on purifi ed B cells from WT (shaded grey) and CD53-/- (black line) 
spleens analyzed by fl ow cytometry. Percentage B220-positive cells: WT 83.6 ± 1.3%, CD53-/- 89.1 ± 0.8%. (E) Equal 
amounts of B cells from 2 (left) or 3 (middle) mice were pooled and stimulated with F(ab’)2 anti-IgG antibodies. Western 
blot: expression of pan-PKC protein (80 kD), PKCβ (80 kD), Syk (72 kD) and actin (42 kD) as loading control. Right: Equal 
amounts of B cells from 3 mice were pooled and treated with pervanadate to block tyrosine phosphatases. Western blot: 
phosphorylation of Syk (75 kD) and expression of actin (42 kD) as loading control. (F) Equal amounts of B cells from 3 
mice were pooled and pre-treated with PKC inhibitor Gö6983 and/or stimulated with F(ab’)2 anti-IgG antibodies. Western 
blot shows presence of phosphorylated PKC substrates and actin as loading control. Data represents 3 in dependent 
experiments. (G) Graphs shows intensity profi les of the upper part (250-60 kD) of lanes of the Western blot in F, corrected 
for protein loading (left WT, right CD53-/- cells).
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Discussion
Understanding the spatiotemporal activation of PKCs at the level of the plasma membrane is 
central to unravelling the complex PKC signaling network. Here we demonstrate that recruitment 
of PKCβ toward tetraspanin microdomains is important for PKCβ activation upon B cell 
stimulation, which is the first study showing recruitment of signaling molecules to tetraspanins 
in living cells. CD53-deficient B cells are impaired in PKC substrate phosphorylation, indicating 
that CD53-microdomains provide a hotspot for localization of PKC in close proximity to its 
substrates at the site of BCR activation. 
Experiments with photoactivatable DAG revealed that, despite the large fraction of activated 
DAG at intracellular membranes, PKCβ translocated exclusively to the plasma membrane, which 
is likely due to the high concentration of phosphatidylserine and PI(4,5)P2 [28,29]. In addition, 
our data now show that PKCβ is specifically recruited to tetraspanin microdomains and CD53 
is a requisite for PKC function in B cells. Co-immunoprecipitation studies reported a molecular 
association between conventional PKCs and tetraspanins (PKCα and CD9, CD53, CD81 and 
CD82; PKCβ and CD9, CD81 and CD151), but the functional implications of these interactions 
were not studied [15]. The interaction between PKCβ and tetraspanins CD53 and CD9 at the 
nanoscale level indicates that tetraspanins function as docking site in the plasma membrane 
for PKC. We postulate that tetraspanin microdomains maintain a local lipid composition that 
favors PKC binding. Interestingly, the tetraspanin-binding protein EWI-2 specifically interacts 
with negatively charged PIPs [30]. These findings support a new mechanism of localized 
PKC signaling at the plasma membrane which may not be limited to BCR-induced signaling 
considering the important role of PKC in signaling by other (immune) receptors [31]. 
The local recruitment of PKC to tetraspanins is of functional significance, because phosphorylation 
of PKC substrates is impaired in CD53-/- B cells after B cell stimulation. The presence of other 
PKC-binding tetraspanins (CD9, CD151, CD81) on CD53-/- B cells did not compensate for this 
defect, showing that individual tetraspanins can have specific functions. Indeed, CD81 is crucial 
for the localization of co-receptor CD19 in close proximity to the BCR at the plasma membrane 
[32]. Our findings corroborate with the recent finding that tetraspanin CD151 may recruit PKCα 
to α6β4 integrin, which modulates PKCα-dependent phosphorylation of β4 integrin in tumour 
models [13,33]. Moreover, it is becoming increasingly clear that tetraspanins are key players 
in tumour initiation, promotion and metastasis (reviewed in [34]). Taken together, this study 
demonstrates that tetraspanin microdomains act as signaling hotspots for PKC activation in the 
plasma membrane of B cells. Our data support a general mechanism of localized PKC signaling 
at tetraspanin microdomains in which compartmentalization of PKC enzymes and their substrates 
controls the stability of PKC signaling. Tetraspanins have been implicated in the regulation of many 
signaling pathways [9,35,36], and our current findings will increase our understanding as to why 
tetraspanin-deficiency leads to defects in human biology [37–41]. 
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Supplementary figure 1: PKCβ and CD53 localize at the site of BCR signaling.
(A) B cells expressing sGFP2-PKCβ were seeded on coverslips printed with anti-BCR spots and analyzed after 3 min. 
Merged picture: antibody print (red) and PKCβ (green). Graphs: PKCβ fluorescence intensity across the yellow line profiles. 
Shaded areas: location of the anti-BCR print. (B) B cells expressing sGFP2-CD53 were seeded on coverslips printed with 
anti-BCR spots and analyzed after 15 min. Merged picture: anti-BCR print (red) and CD53 (green).
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Supplementary figure 2: PKC is recruited to CD53 microdomains in PMA stimulated B cells.
B cells co-expressing sGFP2-CD53 and RFP-PKCβ were subjected to FLIM during PKC translocation upon stimulation with 
PMA. (A) Left: Decay of fluorescent signal of sGFP2-CD53 during FLIM analysis, right: fluorescent decay curves were fitted 
with a mono-exponential decay function to obtain donor lifetimes. (B) Ratio between the expression of sGFP2-CD53 
(donor) and RFP-PKCβ (acceptor) measured by confocal microscopy is plotted against the lifetime of the donor.
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Abstract
Dendritic cells (DCs) have the ability to activate naïve antigen-specific CD4+ T cells 
by presenting exogenous antigens on major histocompatibility complex (MHC) 
class II. In addition, DCs possess the capacity to take up exogenous antigens and 
present them via the MHC class I pathway, a process termed cross-presentation. The 
molecular mechanisms underlying antigen cross-presentation remain ill defined. 
Tetraspanins function to organize DC membranes by forming multimolecular 
complexes, which can include MHC molecules. In this study we investigated the 
role of tetraspanin CD53 in antigen presentation by DCs. In maturing human 
monocyte-derived DCs, CD53 located to intracellular vesicles where it interacted 
with both MHC I and MHC II molecules. The functional consequence of this 
interaction was studied in DCs from CD53-deficient (Cd53-/-) mice. Spleen-
derived CD8+ DCs, CD11b+ DCs and plasmacytoid DCs from WT and Cd53-/- mice 
showed comparable plasma membrane expression levels of both MHC I and MHC 
II. Despite normal MHC I expression on Cd53-/- bone marrow-derived DCs, these 
cells were impaired in cross-presenting immune-complexed ovalbumin. This study 
indicates a role for CD53 in regulating Fc-receptor dependent cross-presentation 
by DCs.
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Introduction
When dendritic cells (DCs) take up pathogens, they undergo a complex maturation process and 
migrate towards lymph nodes. In the lymph nodes, DCs present pathogen-derived antigens to 
T cells, thereby initiating an adaptive immune response. Effective pathogen recognition and 
antigen presentation is dependent on a tight organization of membrane receptors at the cell 
surface of DCs [Chapter 1 [1]]. For example, the immunological synapse formed between DCs 
and T cells is composed of multiple immunoreceptors (MHC, integrins among others) that are 
located in a hierarchical fashion [2]. Tetraspanin four-transmembrane proteins organize the 
cell membrane by forming tetraspanin-enriched microdomains (TEMs). Tetraspanins interact 
in cis with a wide variety of proteins like integrins, metalloproteases, immunoreceptors and 
signalling molecules [3], and form clusters of approximately 120nm on the membrane [Chapter 
4 [4]]. Furthermore, they interact with other members of the tetraspanin family, thus forming 
a tetraspanin web with direct and indirect interaction partners. The diversity of proteins that 
are regulated by tetraspanins may underlie the multiple functions that have been documented 
for tetraspanins on immune cells [5]. The composition of TEMs is dependent on the specific 
cell type studied; for example, the expression of tetraspanin CD53 (and CD37) is restricted 
to cells of the immune system. We recently have shown that CD53 is highly expressed on 
professional antigen-presenting cells (APC) including human and murine DC subsets [Chapter 
2 [6]]. Plasmacytoid dendritic cells (pDCs) differ from conventional dendritic cells (cDCs) in their 
ability to produce large amounts of type 1 IFNs in response to viral infection. Murine cDCs 
can be further subdivided in CD8+ (CD11b-) and CD11b+ (CD4+, CD172+) cDCs [7]. These DC 
subsets differ in expression of pattern recognition receptors and cytokine secretion and have 
specialized functions, such as the ability to efficiently present antigens.  
All nucleated cells, including DCs, continually present peptides that are derived from 
endogenous/cytosolic proteins on MHC class I molecules (MHC I). This enables the immune 
system to eliminate transformed or infected cells, when modified self or foreign peptides 
presented by MHC I are recognized by CD8+ effector T cells. In addition, being professional APC, 
DCs have the capacity to take up external antigens and present these non-self antigens to CD4+ 
T cells via MHC class II molecules (MHC II). This involves degradation of exogenous proteins in 
endosomal/lysosomal compartments and access of MHC II molecules to these compartments 
for peptide binding. Newly synthesized MHC II molecules interact with invariant chain (Ii) which 
targets MHC II via the trans-Golgi network and the plasma membrane to multivesicular bodies 
(MVB). There, Ii is degraded and removed from MHC II, allowing antigenic peptides to bind 
to MHC II. Peptide-MHC II complexes are subsequently delivered to the plasma membrane for 
presentation to CD4+ T cells [8,9]. 
DCs stand out in the ability to present exogenous antigens to CD8+ T cells via the MHC 
class I pathway, a process called cross-presentation. Naïve antigen-specific CD8+ T cells need to 
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be activated by APC to become effector T cells with cytotoxic function. Cross-presentation is 
thus considered as a crucial step in the initiation of an immune response to viruses, intracellular 
bacteria and tumor cells. Still, the mechanisms involved in this pathway are still incompletely 
understood. Two main routes of cross-presentation have been proposed; the cytosolic and 
the vacuolar pathway. Cross-presentation through the cytosolic pathway is dependent on 
proteasome activity and involves transfer of internalized proteins to the cytosol. After antigen 
degradation by the proteasome, peptides are transported into the ER via TAP1 and TAP2, 
and loaded on MHC I molecules, thus following the classical MHC I antigen presentation 
pathway. Alternatively, loading of proteasome-generated peptides can take place in endocytic 
compartments, as ER resident proteins involved in MHC I peptide loading, including TAP, are 
found in DC phagosomes. Cross-presentation via the vacuolar pathway is independent of 
the proteasome and TAP, instead antigens are degraded directly in endocytic compartments 
by lysosomal proteases, where they are subsequently loaded on MHC I molecules [10]. 
Understanding why some dendritic cell (DC) subsets are better than others in cross-presenting 
antigens will shed light on the involved molecular mechanisms controlling cross-presentation 
[11].
Members of the tetraspanin family have been implicated in antigen presentation by DCs. 
DCs of mice  deficient in tetraspanin CD151, CD37 or tspan32 (Tssc6) are hyper-stimulatory to T 
cells, either via elevated co-stimulation or increased efficiency in peptide presentation via MHC 
II [12,13]. It has been hypothesized that tetraspanins regulate MHC II clustering on the plasma 
membrane of DCs [14,15]. CD53 interacts with MHC I and MHC II on B cells [16,17], however, the 
functional consequences of this interaction have not been studied to date. Here we investigated 
the subcellular location and function of CD53 in human and murine DCs and present data that 
support a role for CD53 in facilitating cross-presentation of immune complexed protein.
Materials and methods
Cells and mice
MoDCs were generated from peripheral blood mononuclear cells from healthy donors 
as described previously (romani) Plastic-adherent monocytes were cultured in RMPI1640 
medium with 10% Fetal Bovine Serum, stable Glutamine and Antibiotic-Antimycotic, IL-4 
(300 U/ml) and GM-CSF (450 U/ml) for 6-8 days. At 6 days of culture, immature DCs were 
stimulated with 10 ng/ml TNFα, 10 μg/ml PEG2, 5 ng/ml IL-1β and 15 ng/ml IL-6. B3Z is a T 
cell hybridoma that recognizes SIINFEKL in H-2Kb, which carries a β-galactosidase construct 
driven by NF-AT elements from the IL-2 promoter (Sanderson, Int Immunol, 1994). Single cell 
suspensions of murine spleens were made by DNAse and collagenase treatment, after which 
DCs were enriched by Nycodenz density centrifugation as described in [Vremec J. Immunol. 
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2000]. Bone marrow cells were isolated and cultured in the presence of 20 ng/ml GM-CSF 
(Peprotech) in RPMI supplemented with 10% FCS, 1% glutamine (Cambrex), 0.5% antibiotic/
antimycotic (Invitrogen) and 50mM beta-mercaptoethanol  at 37°C, 5% CO2 for 7 days. Cd53-
/-  mice (C57Bl/6J background) and C57Bl/6J wild-type mice were bred at the Central Animal 
Laboratory Nijmegen (The Netherlands). All animal studies were approved by the Nijmegen 
Animal Experiments Committee. 
Antibodies 
The following anti-human antibodies were used: CD53 (mem53, Serotec), MHC class II (Q5/13, 
in house produced), MHC class II (Tü39), MHC class I (W6/32), CD80-PE, CD83-PE and CD86-
PE. Anti-mouse antibodies: MHC class II-PE, MHC class II-PerCP, MHC class I-PE, B220-FITC, 
B220-alexa647, Siglec-H-alexa647, CD11c-PeCy7, CD11c-APC, CD8α-FITC, CD172-APC and 
H2kb SIINFEKL-PE. Isotype control antibodies: mouseIgG1 (MOPC-21, BioLegend), mouseIgG2a 
(MOPC-173, BioLegend), mouseIgG1-PE, mouseIgG2a-PE and ratIgG2b-PE and secondary 
antibodies goat anti-mouse IgG Alexa488, anti-mouse IgG1 Alexa647, anti-mouse IgG2a 
Alexa488 (all Invitrogen), and goat anti-mouse IRDye800 (LICOR).
Flow cytometry 
The plasma membrane of cells was stained with antibodies in PBS containing 1% BSA and 
0.01% NaN3 (PBA) with 2% human serum (moDCs) or 2% goat serum (murine cells). Geometric 
mean fluorescence intensity was measured using flow cytometry (FACS Calibur, BD Biosciences; 
Cyan ADP, Beckman Coulter) and analyzed using FlowJo software (TreeStar Inc.). 
Confocal imaging
MoDC were adhered to poly-L-lysine coated coverslips and fixed in 2% PFA in PBS. Cells were 
blocked in 3% BSA, 1% filtered human serum and 10 mM glycine in PBS. Membranes were 
permeabilized with 0.5% saponin, 3% BSA, 1% filtered human serum and 10 mM glycine 
in PBS. Cells were stained with antibodies in saponin containing block buffer and washed. 
Coverslips were washed with PBS and ultrapure water, and embedded in Mowiol. Cells were 
imaged with an Olympus FV1000 Confocal Laser Scanning Microscope and image analysis was 
performed using Fiji software [18].
Immunoprecipitation and Western blot
Immature and mature moDC were lysed in lysis buffer containing  1% detergent (Brij97), 10 
mM Tris (pH 7.5), 150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM NaF, 1 mM Na3VO4 with 
protease inhibitors (EDTA free, Roche). Cell lysates were precleared with bare protein G sepharose 
beads (GE Healthcare) and isotype control antibody-bound beads. Immunoprecipitation was 
performed with CD53(Mo)-bound beads and isotype control antibody-bound beads. Beads 
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were incubated with the lysate for 2 hrs at 4°C, washed in lysis buffer, and stored in sample 
buffer. Samples were boiled at 95°C, separated by SDS-PAGE under non-reducing conditions 
and blotted on polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were 
blocked with 3% BSA and 1% skim milk powder in TBS and probed with antibodies against 
overnight at 4°C. Detection was performed with IRDye-conjugated secondary antibodies and 
the Odyssey infrared detection system (LI-COR). 
Cross-presentation assay and antigen degradation assay
OVA-ICs were pre-formed by incubating different concentrations of soluble OVA (Endograde, 
Hyglos GmbH) with purified polyclonal rabbit IgG anti-OVA for 30 min at 37°C. 105 BMDCs per 
well were stimulated with OVA-ICs or soluble OVA protein for 5 hrs, or with positive control 
SIINFEKL peptide for 30 min at 37°C. After washing of the cells, 105 B3Z cells were added 
to each well and incubated o.n. at 37°C. Presentation of SIINFEKL in H-2Kb was measured 
by the activation of B3Z cells, measured by a colorimetric assay using chlorophenol red-β-D-
galactopyranoside as substrate to detect lacZ activity in B3Z lysates. DQ-BSA was added to 105 
BMDCs for 5 hrs at 4 or 37°C, after which antigen degradation was analyzed by flow cytometry.
Results
Previous studies show apparent expression of CD53 on the plasma membrane of resting DCs 
[Chapter 2 [6]], however possible changes in expression of CD53 upon DC maturation were not 
studied. Therefore we first investigated the expression and localization of CD53 on immature 
and mature human monocyte-derived dendritic cells (moDCs). CD53 was indeed expressed on 
the plasma membrane of immature moDCs. Upon stimulation of moDCs with a cytokine cocktail 
(TNFα, PEG2, IL-1β and IL-6), CD53 expression on the plasma membrane was downregulated. 
Maturation of moDCs was confirmed by the upregulation of maturation marker CD83 and 
costimulatory molecules CD80 and CD86. As expected MHC II and MHC I were expressed at 
higher levels on the cell surface of matured moDCs compared to immature DCs (Fig. 1A). 
Next, we analyzed the subcellular localization of CD53 relative to MHC molecules in DCs 
by confocal microscopy. In immature moDCs, CD53 was found on intracellular vesicles and 
in distinct patches on the plasma membrane. Here, CD53 did not co-localize with patches 
enriched in MHC II (Fig. 1B) or MHC I (Fig. 1C). In mature moDCs, CD53 was mainly localized in 
larger intracellular vesicles, with a very low residual expression on the plasma membrane. CD53 
co-localized with MHC II in these intracellular vesicles, which included vesicles reminiscent of 
MVB (Fig 1B). CD53 did not appear to co-localize with MHC II molecules that were present 
in smaller vesicles or on the plasma membrane. Similarly, CD53 only co-localized with MHC I 
molecules within intracellular vesicles in mature moDCs (Fig 1C). 
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To confirm that CD53 interacted with MHC II and MHC I inside mature moDCs we performed 
co-immunoprecipitation experiments (Fig. 2). Profoundly less CD53 protein could be precipitated 
from lysates of mature moDCs as compared to lysates of immature moDCs, still CD53 in 
mature DCs did interact with both MHC II as well as with MHC I (Fig. 2). In contrast, CD53 
complexes precipitated from immature moDCs were not enriched with MHC molecules. The 
increased interaction between CD53 and MHC molecules upon DC maturation stimulated us 
to investigate a possible role for CD53 in antigen presentation.
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Figure 1: CD53 localization upon moDC maturation. 
(A) Plasma membrane expression of CD53, MHC II (Q5/13), MHC I and maturation markers CD80, CD83, and CD86 
(black line) or isotype controls (grey line) on human immature and mature moDC determined by flow cytometry. MoDC 
were stimulated with a cytokine cocktail (TNFα, PEG2, IL-1β and IL-6) at day 6 of differentiation and analyzed after 48 
hours. Experiments were repeated five times yielding similar results. (B-C) Immature and mature moDC were analyzed for 
localization of CD53 (purple), and MHC II (Tü39, green; b) or MHC I (green; c) by confocal microscopy, with the Z-focus at 
the basal membrane. MoDC were stimulated at day 6 of differentiation and analyzed after 24 hours. Scale bars represent 
10μm.
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To test the role of CD53 in MHC function, we undertook studies with CD53-deficient (Cd53-/-) 
mice. We were able to isolate similar numbers of DCs from spleens of Cd53-/- mice and wild-
type (WT) controls indicating that CD53 was not required for DC development. The expression 
of both MHC I and MHC II was evaluated on splenic-derived DC subsets. pDCs from WT and 
Cd53-/- mice expressed comparable levels of MHC I and MHC II (Fig. 3). In addition, cDCs 
derived from WT and Cd53-/- mice showed similar expression levels of MHC I and MHC II. In 
line with this, MHC I and II expression on subpopulations of cDCs (CD8+ and CD11b+/CD172+ 
cDCs) was not altered by deficiency of CD53 (Fig. 3). Thus, expression of MHC on splenic 
dendritic cells seemed not affected by the absence of CD53. In addition, we studied the effect 
of loss of CD53 on MHC expression on bone marrow derived DCs (BMDCs). Differentiation of 
dendritic cells from bone marrow from Cd53-/- mice was comparable to WT mice. Moreover, 
Cd53-/- BMDCs had similar MHC I and MHC II expression levels at the cell surface, compared 
to expression of MHC molecules on WT BMDCs (Fig. 4A). 
To investigate the functional consequences of loss of CD53 on antigen presentation, we first 
analyzed antigen uptake and degradation by Cd53-/- BMDCs. We used double-quenched BSA 
(DQ-BSA) as antigen, of which fluorescence is relieved upon degradation by cells. We observed 
no significant difference in bulk degradation between WT and Cd53-/- BMDCs after testing 
different concentrations of antigen (Fig. 4B). Next we investigated the ability of Cd53-/- BMDCs 
to cross-present peptides derived from the model antigen ovalbumin (OVA) via MHC I. Externally 
loaded OVA peptide (SIINFEKL) was captured by MHC I molecules at the plasma membrane of 
Cd53-/- BMDCs to a similar extent as WT BMDCs (Fig. 4C). This indicates that in steady-state 
conditions, Cd53-/- BMDCs have a normal expression of cell surface MHC I molecules capable 
IP: mIgG1
moDC: I+M I M
CD53 CD53
WB:
CD53
MHC II
MHC I -  41 kDa
-  25 kDa
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}
Figure 2: CD53 interacts with MHC II and MHC I in mature moDC. 
CD53 was immunoprecipitated from immature (I) and mature (M) moDC cell lysates as described in the Methods. moDC 
were stimulated with TNFα, PEG2, IL-1β and IL-6 at day 6 of differentiation and analyzed after 48 hours. Lysates of 
immature and mature moDC were pooled for the isotype control precipitation with mIgG1 antibody. The precipitates 
were investigated for the presence of CD53 (multiple bands as CD53 is glycosylated), MHC I and MHC II (Q5/13) by 
immunoblotting.
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of binding the SIINFEKL peptide. The ability of WT and Cd53-/- BMDCs to process and cross-
present whole OVA protein to T cells was investigated using B3Z cells, a CD8+ T-cell hybridoma 
which produces β-galactosidase upon specific recognition of SIINFEKL presented by MHC I (Fig. 
4D). Both WT and Cd53-/- BMDCs were not efficient in cross-presenting whole OVA protein in 
this system. Therefore, we generated OVA immune-complexes (OVA-IC), which are taken up by 
cells via Fc-receptor-mediated endocytosis. WT BMDCs were able to present SIINFEKL peptide 
derived from degraded OVA-IC in MHC I, which was shown by proper activation of B3Z cells 
in a concentration dependent manner. Notably, Cd53-/- BMDCs were significantly impaired 
in cross-presenting OVA-IC compared to WT BMDCs (Fig. 4D). Both WT and Cd53-/- BMDCs 
externally loaded with SIINFEKL were able to activate B3Z cells, indicating that Cd53-/- and WT 
BMDCs were equally viable. Taken together, these results indicate that CD53 is involved in the 
cross-presentation pathway, but not in regulating expression levels of MHC I. 
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Figure 3: CD53-deficient (Cd53-/-) spleen-derived DC express normal levels of MHC I and MHC II. 
(A) Plasma membrane expression of MHC I and MHC II on pDC (Siglec H+, B220 int.) and cDC (CD11c+, B220-) which 
were subdivided in CD8+ cDC and CD172+/CD4+ cDC. Dendritic cells from spleen of WT (black line) and Cd53-/- (filled grey 
histogram) mice, analyzed by flow cytometry. Left: dot plots shows cell populations gated for analyses. (B) Expression of 
MHC I and MHC II on splenic DC subsets derived from WT and Cd53-/- mice. Floating bars with mean, upper and lower 
values indicated. Data from 3 mice.
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Discussion
Participation of MHC molecules in the tetraspanin web is well documented. Tetraspanins may 
regulate different aspects of the MHC life cycle, like intracellular trafficking of peptide loaded-
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Figure 4: CD53-deficient BMDCs are impaired in cross-presentation. 
BMDCs were differentiated from bone marrow of WT (black line) and Cd53-/- (filled gray histogram) mice. (A) BMDCs were 
gated on CD11c (dotplots). MHC I and MHC II expression was analyzed by flow cytometry. Data from one representative 
mouse out of three is shown. Experiments were repeated two times yielding similar results. (B) BMDCs were incubated 
with DQ-BSA (10 μg/ml or 50 μg/ml) for 5 hours at 37°C or 4°C as control. Percentage of BMDCs which degraded DQ-BSA, 
measured by an increase in FITC expression. Error bars indicate SEM, data from 3 mice shown. (C) BMDCs were incubated 
with SIINFEKL peptide and analyzed for the extent of SIINFEKL loading on MHC I with antibodies specifically recognizing 
SIINFEKL in MHC I (grey line represents isotype control staining). (D) Cross-presentation assay. BMDCs were incubated with 
whole OVA protein or OVA immune complexes (OVA-IC) for 5 hours, or with SIINFEKL peptide for 30 min, and analyzed 
for the ability to cross-present OVA peptide to B3Z cells, measured by β-galactosidase production (OD595nm). Error bars 
indicate SEM. Data from 3 mice shown. Experiments were repeated two times yielding similar results.
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MHC, and/or MHC clustering at the plasma membrane [Chapter 1 [1]]. In this study we focused 
on the role of tetraspanin CD53 and show that CD53 interaction with MHC molecules mainly 
takes place in intracellular vesicles of activated DCs. Moreover, we show involvement of CD53 
in the antigen cross-presentation pathway. 
Tetraspanins are proposed to organize and pre-cluster MHC-peptide molecules on the DC 
surface, to allow for efficient antigen-specific T cell activation [15]. Studies addressing this 
hypothesis are controversial due to the use of the antibody CDw78 that is supposed to identify 
tetraspanin-associated MHC II but was proven to be a-specific [14,19]. In addition, a report 
on the requirement of CD9 for MHC II multimerization in murine DC was contradicted in a 
subsequent study showing that the absence of CD9 (or CD81) had no effect on the interaction 
between MHC II molecules [20,21]. In the current study, the decreased expression of CD53 on 
the plasma membrane of matured human moDC raised the question whether CD53 is involved 
in the organization of MHC I and MHC II molecules on the plasma membrane of activated DCs. 
In resting murine DCs, MHC I and MHC II expression levels on the plasma membrane were not 
affected by loss of CD53. When Cd53-/- BMDCs were externally loaded with SIINFEKL peptide, 
MHC I molecules were able to capture this peptide and to present it to B3Z cells normally. Thus, 
although CD53 interacts with MHC I, CD53-deficiency does not lead to disorganization of 
MHC I molecules on the plasma membrane in such a way that would impede recognition by 
CD8+ T cells. Recently we visualized the (co)localization of CD53 and MHC II molecules on the 
plasma membrane of immature and mature moDC using super-resolution microscopy [Chapter 
4 [4]]. MHC II clusters were in closer proximity to CD53 clusters compared to the distance 
between CD53 and other members of the tetraspanin family. However, the proximity of MHC 
class II clusters to CD53 clusters on the plasma membrane did not significantly increase upon 
cell activation. These results suggests that CD53 is not involved in the organization of MHC 
molecules on the plasma membrane of activated DCs.
Upon activation of human moDCs, CD53 does interact more with MHC II and MHC I molecules. 
We found that this interaction mainly took place in intracellular vesicles. Therefore, CD53 could 
potentially be involved in intracellular MHC trafficking or peptide loading in activated DCs. Based 
on the localization studies of CD53 and MHC molecules during DC activation we hypothesize 
that CD53 traffics from the plasma membrane to the antigen processing compartments 
where it interacts with MHC molecules. We observed that CD53 became enriched in vesicles 
reminiscent of MVBs, where CD53 could regulate loading of antigen on MHC II. MVBs are 
composed of limiting membranes (LMs) that surround small intraluminal vesicles (ILVs) and 
contain the MHC II loading machinery and proteases. Tetraspanins, including CD53, have been 
reported to be enriched in MVBs [22,23] although they do not seem to play a role in peptide 
loading, as was shown by silencing of CD9, CD63, CD81 and CD82 [24]. Using FRET technology 
it was shown that MHC II is in close proximity/interacts with CD63 on both ILVs and the LMs 
(of expanding MVBs), whereas CD82-MHC II interactions were only observed on the LMs. The 
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stable interaction of CD63 and MHC II is hypothesized to regulate MHC II exit from the MVB, 
as silencing of CD63, but not CD82, increased MHC II expression [24]. We show that upon DC 
activation, CD53 plasma membrane expression is decreased. This implies that the interaction 
of MHC II with CD53 is lost before trafficking of peptide loaded MHC II towards the plasma 
membrane. This is in contrast to tetraspanins CD63 and CD82, which both are clearly present 
in endolysosomal tubules, long tubular structures that deliver peptide-MHC II complexes from 
the MVBs to the plasma membrane [25]. This indicates complex and specific roles for different 
members of the tetraspanin family in the MHC II antigen presentation pathway.
We here show that Cd53-/- BMDCs are hampered in cross-presenting immune-complexed 
antigen, despite having normal expression of MHC I on the plasma membrane. It has been 
shown that antigens are cross-presented more efficiently when the degradation of antigen 
is limited, compared to antigens that are targeted to highly degradative late endocytic 
compartments. In our experiments, whole OVA protein was not efficiently taken up, processed 
or cross-presented by BMDCs. We therefore investigated cross-presentation of OVA upon Fcγ-
receptor (FcγR)mediated endocytosis using OVA-IC [26]. We show that the bulk degradation of 
BSA in Cd53-/-  BMDCs is normal, however it remains to be determined if the process of uptake 
and degradation of OVA-IC is not affected by loss of CD53. Tetraspanins have been reported to 
interact with Fc-receptors [27,28] and regulation of FcγR by CD53 could directly influence the 
uptake of antigen-immune complexes like OVA-IC. 
Taken into account the subcellular distribution of CD53 upon DC activation, we hypothesize 
that during FcγR-mediated endocytosis, CD53 co-internalizes and remains present on the 
membranes of these intracellular vesicles, meanwhile the antigen is degraded. CD53 could 
be facilitating the transfer of antigenic peptides to MHC I loading compartments, and thereby 
influencing cross-presentation. Alternatively, CD53 could play a role in the transport to and 
organization of the MHC I peptide loading complex within DC phagosomes. Tetraspanins have 
been reported to regulate membrane fusion and trafficking of associated partner proteins 
between cellular organelles and the plasma membrane [29]. In our studies we have not yet 
identified a specific role for CD53 in either the cytosolic or the vacuolar pathway of antigen 
cross-presentation. Further research is required to decipher the molecular mechanisms of cross-
presentation of immune-complexed antigen and the role of CD53 in this process. Understanding 
how cross-presentation is regulated will help to develop new vaccination strategies for the 
induction of immunity against viruses and tumors.
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The humoral immune response comprises of a complex interplay between immune cells. 
Biological processes like antigen recognition and uptake, intercellular communication and cell 
migration require tight regulation of constituents within the plasma membrane. Although 
novel high-resolution and other sensitive microscopy methods have generated new insights 
into plasma membrane biology, the nanoscale organization of the plasma membrane remains 
enigmatic. In this thesis I investigated the expression and nanoscale organization of tetraspanin 
proteins at the cell surface of immune cells. In addition, I focused on studying the role of 
tetraspanin CD53 in BCR signaling and antigen presentation. The results presented in this thesis 
provide novel insight into the organization of the plasma membrane by tetraspanin proteins 
and into the function of tetraspanin CD53 in the immune response.
The nanoscale organization of the plasma membrane
It is well established that membrane components are laterally segregated within the plasma 
membrane. The dynamic organization of proteins and lipids in a mosaic of nano- and 
microdomains of various size and composition allows for compartmentalization of events in 
space and time. One of the first concepts of membrane segregation is the lipid raft hypothesis, 
in which favored interactions between cholesterol and sphingolipids lead to their co-segregation 
in tightly packed “rafts” at the cell membrane. Specific signaling molecules have been proposed 
to sequester to lipid rafts, and certain protein modifications, like glycophosphatidylinositol 
(GPI)-anchors or palmitoylation have been reported to mediate protein partitioning in raft 
domains [1]. Although lipid phase separation has been observed in artificial membranes, the 
organization of the membrane in living cells is more complex involving multiple lipid-lipid, lipid-
protein and protein-protein interactions within a crowded membrane. It is therefore questioned 
whether lipid rafts truly exist in membranes of living cells. Due to recent developments in 
super-resolution microscopy techniques, it is now possible to detect single diffusing molecules 
in the plasma membrane of living cells. For example, it has been shown that sphingolipids and 
GPI-anchored proteins are transiently trapped in areas smaller than 20 nm in diameter, which 
was only observed in the presence of cholesterol [2]. This trapping was more pronounced for 
sphingolipids than for phosphoglycerolipids [3]. These nanoscale lipid rafts may be important 
for regulating the location and function of membrane components due to their differential 
affinity for lipid environments [4]. A different concept of membrane segregation is based on 
restriction by the cytoskeleton (confinement zones), in which membrane proximal actin (as a 
fence) and anchored transmembrane proteins (pickets) restrict lateral diffusion of membrane 
proteins [5]. This model is based on studies in which the diffusion of single membrane proteins 
was tracked in time and explains the observed confined diffusion in zones (between 30 and 
700 nm in diameter) and jumping between these compartments, termed hop diffusion [6]. 
Simultaneous imaging of single FcεRI molecules and membrane proximal actin in living cells 
directly showed that actin acts as a physical barrier for transmembrane protein diffusion [7]. In 
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addition, it has recently been shown that also lipid diffusion can be confined by cortical actin 
networks [8]. 
In my view, the organization of the plasma membrane in living cells is primarily protein 
driven and is in first instance based on protein oligomerization. Protein oligomers interact 
with matching lipids, which is based on the lipid polar-head group, the length of the proteins 
transmembrane domain [4,9] or certain co- or posttranslational modifications. I thus envision 
that protein nano-clusters surrounded by “lipid shells” [10] move dynamically across the plasma 
membrane. Proteins that bind or enrich certain lipids may have a tendency to associate better 
with membrane components that interact with a similar lipid shell. Protein clusters “lubricated” 
by lipids will be physically restricted in diffusion due to collision with the cytoskeleton and 
transmembrane proteins linked to cytoskeleton, similar to the picket-fence model of Kusimi 
[6]. In addition, proteins are organized via interactions with scaffolding proteins like caveolins, 
galectins and tetraspanins.
Tetraspanins interact with themselves, and other membrane associated partner proteins 
including adhesion molecules, proteins with Ig domains, ecto-enzymes and signaling molecules. 
The importance of tetraspanins has been shown by their high evolutionary conservation across 
species, their function in various biological processes (cell adhesion, migration, cell-cell fusion), 
and, when deregulated, in malignant and infectious disease [11–13]. Tetraspanins contribute 
to the lateral segregation of the proteins with which they associate and are thought to 
organize the plasma membrane via a network of molecular interactions (‘tetraspanin web’). 
The observation that specific crosslinking of different tetraspanin protein family members 
led to similar phenotypes (for example homotypic aggregation), suggested that tetraspanin 
proteins are interconnected. This principle of the ‘tetraspanin web’ was further based on the 
observations that members of the tetraspanin protein superfamily co-immunoprecipitate the 
same proteins and that different tetraspanins tend to associate with one another [14–16]. Pre-
clearing experiments revealed that at least three different tetraspanins could exist in one single 
complex [14], which was confirmed by visualization of tetraspanin-enriched microdomains by 
confocal microscopy [17]. Furthermore, tetraspanins were found to be the link that connects 
their partner proteins to other tetraspanin family members. For example, a complex containing 
tetraspanin CD82 and the CD9 partner protein CD9P-1 can only be observed when CD9 is 
co-transfected in CHO cells [18]. Similar observations were made for interactions between 
tetraspanin CD151, partner integrin α3β1, and other tetraspanins [19]. These studies led to 
the model in which tetraspanins form functional complexes within membranes (tetraspanin-
enriched microdomains) that contain multiple members of the tetraspanin family and their 
interaction partners. Based on super-resolution imaging experiments presented in Chapter 4, 
we now challenge this model and provide evidence that tetraspanin-enriched microdomains 
contain predominantly one specific member of the tetraspanin family (discussed below). 
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Although these studies brought us insight in tetraspanin-partner interactions, the use of 
detergents can make results unreliable as they may not represent physiological interactions in 
living cells. Different detergents have a different ability to solubilize tetraspanins and whether 
tetraspanin-tetraspanin interactions are preserved depends on the strength of the detergent 
and type of the buffer used (for example bivalent cations are required to preserve tetraspanin-
tetraspanin interactions). It is therefore questioned whether interactions preserved in strong 
detergents are functionally superior over those interactions only observed in mild detergents. 
This is illustrated by the distinct contributions of different tetraspanins to α3β1 integrin function. 
Immunoprecipitation experiments show that CD151 and α3β1 are directly linked, and loss of 
CD151 disrupts association of α3β1 with other tetraspanins like CD9 and CD81. It is therefore 
predicted that loss of CD151 would have a greater impact on α3β1 function than loss of 
other tetraspanins. However, CD9/CD81-silenced cells, but not CD151-silenced cells, displayed 
impaired α3β1-dependent directed motility [20] indicating that tetraspanin interactions found 
to be indirect by biochemical methods can have a similar functional impact as direct interactions. 
I believe that the hierarchical network of interactions within the tetraspanin web (primary 
interactions with a direct interaction partner, secondary interactions through tetraspanin-
tetraspanin interactions and tertiary interactions only found in weak detergents), needs to be 
investigated in more depth using methods that are not solely based on the identification of 
tetraspanin complexes in cell lysates.
Imaging tetraspanin proteins on membranes of living cells provides a means to study 
tetraspanin interactions without the need of detergents and concerns about potential post-
lysis artefacts. This is only successful when the biology of tetraspanins and the used imaging 
methodology is taken into account. Tetraspanins are small proteins that protrude only a few 
nm from the membrane. Therefore, addition of a relatively big fluorescent tag, or ligation 
by antibodies could potentially disturb the organization of tetraspanin proteins within the 
membrane. Antibodies against tetraspanins should be chosen with care, as different antibodies 
raised against the same tetraspanin may differentially label tetraspanin localization. We noticed 
that antibodies directed against the large extracellular loop recognized less tetraspanin clusters, 
compared to antibodies directed against an intracellular epitope (observed for CD53 and 
CD82, Chapter 4). Similarly, certain CD81 antibodies recognized only a subpopulation of CD81 
molecules organized in patchy structures, and not total GFP-tagged CD81 [21]. This can be 
explained by epitope masking, or by the specific recognition of tetraspanin-partner epitopes 
(for example integrin-free CD151 [22]). In addition, steric hindrance between antibodies against 
tetraspanins has been observed in fluorescence resonance energy transfer (FRET) microscopy 
studies [23]. Although FRET can demonstrate interactions between tetraspanin pairs and partner 
proteins [24,25] in living cells, it provides no information on stoichiometry or heterogeneity of 
these complexes. In this thesis, we employed super-resolution microscopy aiming to provide an 
unbiased view of the tetraspanin web.
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A new view of the tetraspanin web 
In Chapter 4, we studied the organization of the tetraspanins on the plasma membrane of 
B cells using dual color stimulated emission depletion (STED) microscopy. One of the most 
striking findings was the observation that different tetraspanin species did not localize to the 
same cluster. Tetraspanin proteins were present on the plasma membrane in distinct clusters of 
100-150 nm in diameter containing 2-10 (homotypic) tetraspanin proteins. We observed larger 
clusters for CD37 relative to the other tested tetraspanins. This could be due to a higher amount 
of CD37 protein present at the cell surface of B cells. However, increased concentrations of 
CD81 in Jurkat T cells were rather associated with more clusters on the plasma membrane than 
with increased cluster size [21]. The stability of (homotypic) tetraspanin protein clusters is in first 
instance regulated by the highly conserved dimerization interface in transmembrane domain 
1 and 2 [26]. Next to this, palmitoylation could be important for the stability of tetraspanin 
protein clusters, as is shown for CD82. Super-resolution imaging of CD82 clusters in AML 
cells revealed that unpalmitoylated CD82 was more randomly distributed on the cell surface 
and was present in bigger deregulated clusters compared to WT CD82 [27]. In addition, it has 
been shown that the delta domain of the large extracellular loop is required for the stability of 
CD81 clusters [21]. Thus, differences between individual tetraspanins exist, and it needs to be 
determined whether these mechanisms of tetraspanin cluster stabilization are applicable to all 
members of the tetraspanin family.
For the first time, two different members of the tetraspanin family were imaged 
simultaneously at super-resolution. Strikingly, tetraspanin CD53 protein clusters never 
contained other (tested) members of the tetraspanin family. We did however observe that 
CD53 clusters were in close proximity to clusters containing other tetraspanins (CD37, CD81, 
CD82). By classical epifluorescence or confocal microscopy, this proximity of distinct subclusters 
would be interpreted as one domain containing multiple tetraspanin family members [17]. Still, 
it remains unclear whether the distinct but adjacent tetraspanin clusters are interconnected 
via their edges. FRET has been observed between CD9 and CD151 and between CD63 and 
CD82, indicating close proximity between different tetraspanin proteins [24,25]. Our data 
are supported by biochemical studies that indicate that heterotypic tetraspanin-tetraspanin 
interactions are scarce and that tetraspanin homodimers represent the basic building blocks of 
the tetraspanin web [28].
Analyzing nano-scale distances between tetraspanin clusters and (clusters of) direct and 
indirect interaction partners using super-resolution imaging, enabled us to further reconstruct the 
tetraspanin web. CD81 was found in closer proximity to (although not completely overlapping 
with) its direct interaction partner CD19, than to CD53. CD53 clusters were found to be slightly 
closer to clusters of the indirect interaction partner MHC class II, as compared to clusters of 
CD37, CD81 or CD82. Recently, the localization of CD37 and its potential (indirect) interaction 
partner CD18 were simultaneously imaged using STORM microscopy [29]. No significant co-
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clustering of these molecules was observed on neutrophils. This suggests that, in line with 
biochemical studies, tetraspanin proteins are only intimately interacting with their ‘bona fide’ 
direct interaction partners. To fully grasp the organization of tetraspanin web, super-resolution 
studies should be combined with studies on tetraspanin(-partner) dynamics in living cells.
To date, not much is known about tetraspanin dynamics in living membranes. One elegant 
study provides insight into the dynamics of CD9 on the plasma membrane of PC3 (prostate 
carcinoma) cells using single molecule tracking [30]. Within these cells, large “tetraspanin 
enriched areas” were observed that contained CD9, CD9P1 and CD81, but not GPI-anchored 
protein CD55. Diffusing CD9 molecules were transiently confined in these areas. At the rest of 
the plasma membrane, CD9 exhibited mostly free (Brownian) diffusion and was predicted to 
diffuse in the plasma membrane embedded in small clusters. In contrast to the GPI-anchored 
protein CD55, directed trajectories were never detected for CD9 molecules. Single molecule 
tracking has also been used to study the influence of tetraspanins on the dynamics of specific 
partner proteins. In the presence of CD151, α6 integrin displayed mainly random or confined 
diffusion, whereas in the absence of CD151, mostly directed diffusion was observed [31]. 
Similarly, CD19 molecules diffuse faster in CD81-/- B cells [32]. Tetraspanin partner proteins can 
thus be restrained in mobility through their interaction with tetraspanins. In contrast, epidermal 
growth factor receptor (EGFR) diffusion was found to be restricted in CD82 depleted cells, which 
is similar to changes in EGFR diffusion mode observed upon cholesterol depletion [33,34]. This 
suggests that tetraspanins can bring partner protein in specific lipid nano-environments enriched 
in cholesterol, that may facilitate faster/free diffusion modes. This hypothesis is strengthened 
by the observations that cholesterol depletion and mutation of CD9 palmitolyation sites lead 
to altered CD9 dynamics [30]. Tetraspanin proteins differ in the amount of juxtamembrane 
cysteine residues, i.e. the sites where palmitoylation can occur (for example CD9 and CD81 have 
six, CD82 and CD37 have four, whereas CD53 has three cysteine residues) [35,36]. It would 
be interesting to compare the diffusion modes of different tetraspanin proteins at endogenous 
expression levels and to correlate diffusion mode to the length of their transmembrane domains, 
the extent of palmitoylation and other posttranslational modifications. Having a preference for 
similar lipid nano-environments could explain why we found CD82 clusters to be in closer 
proximity to CD37 clusters than CD53 protein clusters (Chapter 4). Moreover, CD53 did not 
enrich at sites where CD81 was stabilized by anti-CD81 antibodies, suggesting that CD53 
clusters move independently of CD81 clusters (data not shown).
In contrast to PC3 prostate carcinoma cells [30], we did not observe the so called “tetraspanin 
enriched areas” in B cells (Chapter 4). Still, we did observe a non-random organization of 
the different tetraspanin clusters relative to each other, indicating a preference of tetraspanin 
clusters for certain membrane areas. The plasma membrane is likely differently organized in 
different cell types, especially when comparing immune cells with adhering cells. When taking 
into account the picket fence model of Kusumi, tetraspanin clusters could collide against 
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proteins immobilized by the cytoskeleton or ligand engagement. This results in lower diffusion 
rates of tetraspanin proteins in for example endothelial adhesive platforms that are formed 
upon the interaction of leukocytes with endothelial cells [25]. However, the recruitment of 
tetraspanin clusters to sites of ligand engagement could be a passive event and may not be an 
indication of the existence of pre-formed tetraspanin-organized platforms, in which partner 
proteins are actively recruited by tetraspanins. 
Taken together, I envision clusters of homotypic tetraspanin proteins to be intimately 
interacting with direct interaction partners and dynamically moving across the plasma membrane 
favoring (transient) associations with other tetraspanin clusters and specific partner proteins. 
As such, tetraspanins modulate the nano-environment of interacting partner proteins, thereby 
influencing their mobility, aggregation state and proximity to other proteins like co-receptors or 
signaling molecules. Immobilization of tetraspanin partner proteins could induce stabilization 
of tetraspanin clusters. Advanced imaging experiments investigating tetraspanin and partner 
stoichiometry and dynamics should be combined with biochemical studies to fully explain the 
dynamic architecture of the tetraspanin web. Unraveling the organization of the tetraspanin 
web will aid in the understanding how tetraspanins functionally regulate their interacting 
molecules.
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Figure 1: a new view of the tetraspanin web and its dynamics. 
(A) Schematic representation of the tetraspanin web. Tetraspanins are present on the plasma membrane in homotypic 
protein clusters. These clusters are non-randomly organized in the plasma membrane and are in close proximity to 
clusters containing other tetraspanin family members and their interaction partners. (B) Dynamics of a tetraspanin cluster 
within the plasma membrane. (1) Tetraspanin clusters likely favor certain membrane nano-environments (for example 
cholerestol-rich), and can be restricted in diffusion due to collision with transmembrane proteins linked to cytoskeleton. 
(2) Tetraspanin clusters interact (transiently) with other tetraspanin clusters and interacting partner proteins. (3) Through 
protein-protein  interactions, tetraspanins can modulate the nano-environment of partner proteins. (4) Tetraspanin clusters 
can be immobilized through ligation of partner proteins.
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Tetraspanins and the humoral immune response
In Chapter 2 we studied the expression of tetraspanins CD37 and CD53 on B and T cells 
present within human secondary lymphoid organs and blood. These tetraspanins are both 
exclusively expressed on cells of the immune system. We show that CD37 was especially highly 
expressed on circulating B cells in blood. CD53 was higher expressed on antigen presenting 
cells (B cells, monocytes and dendritic cells) than on T cells and NK cells. In addition, we made 
use of multispectral imaging to identify B cell follicles and T cell zones within human spleen and 
appendix tissue, which enabled us to study CD53 and CD37 expression on B cell and T cells 
within and outside these structures. Compared to flow cytometry of single cell suspensions of 
lymphoid tissue, this technique provides additional information on cell location, which could 
be relevant in deciphering tetraspanin function. Compared to B cells that reside within B cell 
follicles, CD53 was lower expressed by B cells residing in the red pulp or marginal zones of 
the spleen. It remains to be determined whether B cells outside the B cell follicle represent a 
different B cell subset or migrating follicular B cells. The difference in CD53 expression could 
indicate a specific role for this tetraspanin in a specialized function of a certain B cell subset 
or during a certain B cell activation/migratory status [37]. By including additional markers, 
the various B cell differentiation stages could be identified. Given the role of tetraspanins in 
immune cell migration (by modulating the function of integrins and selectins [38,39]) it would 
be interesting to correlate tetraspanin expression to tissue localization of B cells during the 
humoral immune response.
Tetraspanins play a crucial role in B cell responses as shown by impaired antibody production 
in CD37- and CD81-deficient mice. CD37-/- B cells produce elevated levels of IgA, which was 
dependent on the high levels of IL-6 present in these mice [40]. In addition, CD37-/- mice 
show reduced levels of IgG, due to increased apoptosis of IgG+ B cells in germinal centers. 
CD37 is required for clustering of α4β1 integrin molecules on the plasma membrane of B 
cells. The interaction between α4β1 integrin on B cells and VCAM-1 on follicular dendritic 
cells is important for the α4β1 integrin-Akt signaling pathway leading to cell survival [41]. 
CD81-/- B cells are impaired in B cell activation and the production of antibodies in response 
to T cell-dependent antigens. CD81 is necessary for ER exit and surface expression of mature 
CD19, and loss of CD81 disrupts the BCR signaling complex [42–44]. Consequently, impaired 
humoral immunity has been observed in a patient expressing a truncated from of CD81, which 
is similar to the phenotype of patients with CD19 deficiency [45,46]. Thus, CD81 and CD37 
control antibody responses via  a different mechanism, which is most likely due to their specific 
interaction partners. In Chapter 6 we present data that support an important role for CD53 in 
BCR activation, which may be linked to the observed impaired antibody production in CD53 
deficient mice (unpublished data Mark Wright). The expression of CD53 is increased in certain 
types of B cell malignancies [37] and high levels of CD53 could be associated with aberrant BCR 
signaling leading to increased survival of malignant B cells. In addition, it has been shown that B 
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cells are activated and protected from apoptosis when CD53 is ligated/crosslinked [47,48]. This 
is in contrast to CD37, which acts as a tumor suppressor in B cell malignancies and ligation of 
this tetraspanin induces apoptosis [49,50]. 
The role of tetraspanins in BCR signaling
The BCR is comprised of the antigen binding membrane bound immunoglobulin molecule 
and a signaling subunit, the Igα/Igβ heterodimer. Upon B cell activation, the immunoreceptor 
tyrosine-based activation motif (ITAM) of Igα becomes phosphorylated and bound by tyrosine 
kinase Syk, which initiates the BCR signaling cascade. How the high number of BCR molecules 
present on the cell surface are organized and kept silent on resting cells is still not fully resolved 
[51]. On the surface of resting B cells, BCR molecules are present in oligomers [32,52]. Advanced 
imaging techniques revealed recently that upon antigen binding, the BCR oligomers dissociate 
and form clusters of active monomers [53]. This ‘dissociation activation’ model refutes the 
long held paradigm in which crosslinking of BCR monomers leads to B cell activation. Antigen-
induced BCR signaling leads to a wave of actin depolymerization and increased BCR diffusion. 
The crucial role of the actin cytoskeleton in BCR organization is illustrated by the onset of BCR 
signaling upon exposure to actin depolymerizing agents such as Latrunculin A, in the absence 
of antigen [54]. CD81 is also critically involved in BCR signaling through its interaction with 
co-receptor CD19. Next to a decreased CD19 plasma membrane expression, CD81-/- B cells 
display faster diffusion of CD19 clusters [32]. The impaired BCR signaling in CD81-/- B cells is 
therefore likely due to misplacement of CD19 in the membrane resulting in failure to interact 
with mobile BCR clusters upon actin disruption. Upon BCR stimulation with soluble anti-BCR 
antibodies, we did not observe coalescence of CD81 or CD19 clusters into bigger platforms 
(Chapter 4). In addition, the proximity of CD81 clusters relative to CD19 clusters did not change 
upon BCR ligation, in line with the hypothesis that upon cell activation BCR are released from 
the cytoskeleton to interact with CD19 that is held in place by CD81 [32]. We did however 
observe a bigger diversity in the percentage of CD19-proximal CD81 clusters in activated B cells. 
This indicates that CD81-CD19 proximity is a dynamic process, which is not captured by single 
snapshots of membrane sheets. In would be interesting to study the interaction between CD81 
and CD19 clusters on living B cells settling on a lipid bilayer containing antigen.
Our data support an additional means of regulation of the BCR signaling complex by 
tetraspanin proteins. On CD53-/- B cells, CD19 plasma membrane expression is normal and 
CD53 therefore most likely plays a different role in the organization of components of the BCR 
signaling complex than CD81. In Chapter 5 we show that CD53 is enriched at sites of BCR 
immobilization and signaling. Moreover, CD53 was found in close proximity to translocated 
PKCβ upon B cell activation. Recently, we observed that CD53-/- B cells were less efficient 
in PKC translocation upon BCR crosslinking compared to WT B cells (data not shown). CD53 
is thus involved in the recruitment and spatial organization of PKC at the plasma membrane 
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upon BCR signaling. In consequence, PKC activation is impaired in BCR stimulated CD53-/- B 
cells demonstrating that CD53 is essential for optimal BCR signaling (Chapter 5). Future studies 
should address whether CD53 plays a similar role in the regulation PKC signaling downstream 
of activating immunoreceptors on dendritic cells (DCs) [55]. 
CD53 and DCs
DC subsets are increasingly studied as separate cell populations and differences in their response 
to pathogens are appreciated [56]. Therefore, the role of tetraspanins on DC function should 
be studied on each individual subset. In Chapter 3 we analyzed tetraspanin expression on 
human and murine DC subsets and indeed found differential protein expression patterns. Tight 
regulation of the expression levels of members of the tetraspanin protein family could fine-tune 
the different and complex functions of DC subsets. This mechanism is illustrated by a recent 
study on DC function in CD37 and CD82 deficient mice [57]. CD37 was found to promote 
DC migration but to negatively regulate antigen presentation. In contrast, CD82 promoted 
antigen presentation and negatively regulated DC migration. By coordinating the expression of 
these tetraspanins with opposing function (CD82 is upregulated in maturing DC, while CD37 
is downregulated), DCs can adapt to accommodate their different specialized functions. One 
striking observation was the high protein expression of CD53 on human pDCs, while other 
tested tetraspanins were nearly absent or at least lower expressed on pDC compared to other 
DC subsets. This phenotype was similar in mice and may be partially explained by the expression 
of the transcription factor early B cell factor (EBF) in a category of pDCs [58]. EBF is crucial for 
the commitment to the B cell lineage. pDC are, in contrast to mDC, derived from lymphoid 
progenitors and are therefore closely related to B cells [59]. 
CD53 expression is, in contrast to CD9, CD37 and CD81 under the direct control of EBF. 
However, ectopic expression of EBF in fibroblast cell line NIH3T3 did not induce CD53 gene 
expression [60], indicating that the ability of transcription factors to activate endogenous CD53 
depends on the cellular context [61] and is likely restricted to the hematopoietic lineage. Next 
to transcriptional regulation, CD53 is also controlled by its subcellular location. In Chapter 6 we 
demonstrate that upon activation of monocyte derived dendritic cells (moDCs) these cells lost 
plasma membrane expression of CD53. We observed that CD53 was still present on intracellular 
vesicles. This phenomenon of tetraspanin subcellular relocation was also observed in a study 
on blood cells of patients harboring an acute infection, which showed lower expression levels 
of tetraspanin protein (CD53, CD81 and CD82) on the plasma membrane of blood leukocytes 
compared to healthy individuals [62]. The reduction of CD53 expression specifically on the 
plasma membrane upon DC activation may be related to its function. We speculate that CD53 
acts as a negative regulator of plasma membrane proteins that are important for maturing 
DCs, for example proteins involved in cell migration. Alternatively, it is possible that all CD53 
protein is sequestered intracellularly to prevent CD53 partner proteins to access the cell surface. 
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Tetraspanins are known to regulate the trafficking of their partner proteins (CD81-CD19 [63], 
TspanC8-ADAM10 [64]). Pulse chase experiments should clarify whether plasma membrane 
CD53 is actively internalized or not replenished. 
DCs initiate the adaptive immune response by presenting antigen to helper T cells. For 
various tetraspanins, a role in antigen presentation has been described, although the underlying 
mechanisms remain unclear. Many tetraspanin family members are able to interact with MHC 
molecules and a role for tetraspanins in MHC clustering at the plasma membrane has been 
proposed [65–67]. In Chapters 4 and 6, we show an (indirect) interaction between MHC 
molecules (class I and II) and CD53 in human B cells and moDCs respectively. Importantly, in 
moDC, this interaction was observed exclusively within intracellular vesicles. CD53 did not 
influence the expression of MHC I and MHC II on the plasma membrane of murine bone 
marrow derived DCs (BMDCs) (Chapter 6) and did not interact intimately with MHC II on 
the plasma membrane of human B cells (Chapter 4). Therefore an active, positive role for 
CD53 in MHC II clustering upon immunological synapse formation is unlikely. We observed 
impaired antigen cross-presentation via MHC I in CD53-/- BMDCs. The precise role of CD53 
in this complex process needs further investigation to determine whether CD53 is involved in 
immune-complexed antigen uptake, antigen loading or delivery of functional MHC I-peptide 
complexes to the plasma membrane.
Cytokines secreted by DCs at the time of antigen presentation play an important role in the 
subsequent differentiation of effector T cells. In Chapter 3, we show that cytokine expression 
by DCs is regulated by CD53. Upon TLR stimulation, CD53-/- BMDCs secreted more IL-6 than 
WT cells, whereas the secretion of IL-10 was unaffected. Next to the primary function of B cells 
(production of antibodies), recent studies have demonstrated that B cells can also have  immune 
modulating functions. Regulatory B (Breg) cells suppress excessive inflammation through the 
secretion of IL-10 and other immune-regulatory cytokines [68,69]. The specific dampening of 
IL-6 secretion by CD53 suggests that regulation of CD53 expression or function could tip the 
balance between a pro-inflammatory or immunosuppressive B cell phenotype.
New potential CD53 interaction partners
In our search to uncover additional roles of CD53 in B cell function, we performed a pilot 
experiment to characterize CD53 protein complexes by mass spectrometry to identify new 
potential CD53 interaction partners. B cells (human B cell line JY) were lysed in mild detergent 
(Brij97) followed by immunoprecipitation of CD53-containing protein complexes that were 
analyzed by mass spectrometry. Contaminating proteins were identified by inclusion of an 
identical immunoprecipitation experiment using a control IgG1 antibody and were excluded 
from the analysis. Due to a low protein abundance, most proteins were identified by only one 
unique peptide, which makes the obtained results preliminary. In addition, the interaction of 
CD53 with new partners is not validated and the results should therefore be interpreted with 
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caution. Still, known interaction partners of CD53 were identified by this method, suggesting 
that this experiment can serve as a starting point to identify potential novel CD53 interaction 
partners. Table 1 displays known interaction partners and a selection of new potential interaction 
partners of CD53. Full lists can be found in the appendix.
Conclusions and outlook
In this thesis we demonstrate that tetraspanin CD53 is involved in multiple functions of antigen 
presenting cells. We show that 1) antigen cross-presentation is impaired in CD53-/- DCs and 
that 2) CD53 is important for BCR-dependent PKC signaling in B cells. The underlying molecular 
mechanism involves the association of CD53 with its partner proteins (MHC, PKC, integrins, 
novel partners) that each have a specific role in the immune response including immune cell 
activation, migration and intercellular communication. An impaired immune response upon 
challenging CD53-/- mice is to be expected, which will be the outcome of multiple immunological 
events in which CD53 is involved.
We studied the nanoscale organization of tetraspanin proteins on the plasma membrane 
of immune cells and propose a new model of the tetraspanin web. Tetraspanins are present 
in nanoscale homotypic protein clusters devoid of other members of the tetraspanin family. 
Clusters of different tetraspanin members are adjacently positioned (in a non-random fashion) 
Tabel 1. CD53 interaction partners identified by mass spectrometry.
Known CD53 interaction partners Ref Novel potential CD53 interaction partners Gene
MHC class II [16] Sec24c SEC24C
MHC class I [23] Sec1 STXBP3
Ig heavy and light chain [70] Annexin II ANX2
Gamma-glutamyltransferase [71] Janus kinase 1 JAK1
ADAM-10 [72] Phosphatidylinositol-4,5-bisphosphate 3-kinase PIK3CA
CD20 [23] Rho-associated protein kinase 1 ROCK1
Tetraspanin G protein subunit β2 GNB2
CD37 Protein phosphatase 4 regulatory subunit 1 PP4R1
CD151 ALK tyrosine kinase receptor ALK
In CD53 immune complexes we were able to identify tetraspanins CD37 and CD151. Although CD37 and CD53 protein 
clusters were not overlapping in our super resolution studies, these tetraspanins do associate with each other most likely 
via cluster edges (Chapter 4). The possible association of CD53 with proteins involved in protein sorting, vesicle trafficking 
and fusion (Sec proteins, annexin II), may be linked to the role of CD53 in antigen presentation, as these processes involve 
numerous events of vesicle formation and fusion. Furthermore, we identified various receptors or other components of 
signaling cascades in CD53 immune complexes. Thus, the influence of CD53 in B cell signaling may not be restricted to 
BCR-dependent PKC activation. Of special interest is the potential interaction of CD53 with Janus kinase 1 (JAK1) and 
phosphoinositide-3-kinase. JAK1 is a crucial link in cytokine receptor signaling cascades [49,73]. Phosphoinositide-3-
kinase converts PtdIns(4,5)P2 to PtdIns(3,4,5)P3, which plays a key role in activating signaling cascades involved in cell 
survival, proliferation and motility, by recruiting PH domain-containing proteins like AKT to the membrane [74]. 
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and associate dynamically with each other forming a functional tetraspanin web in the plasma 
membrane. To fully understand the function of tetraspanin proteins, we need to investigate 
tetraspanin organization in living cells at a high spatial and temporal resolution. Exciting 
developments in advanced microscopy based techniques facilitating high spatial resolution 
during live cell imaging (for example lattice light sheet fluorescent microscopy) will ultimately 
enable us to map the dynamic membrane landscape of immune cells. Moreover, understanding 
nanoscale events during BCR signaling and antigen presentation can help the generation of 
improved vaccination strategies or smarter targets for cancer and auto-immune disease.
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Appendix 
Table 1: Parameters of mass spectrometry data analyses. 
Analysis FDR 0.01/12 peak FDR 0.05/NQ FDR 0.05/GlyGly
Top MS/MS peaks per 
100Da. (FTMS)
12 10 10
Top MS/MS peaks per 
100Da. (ITMS)
18 6 6
Peptide FDR 0.01 0.05 0.05
Protein FDR 0.01 0.05 0.05
Site FDR 0.01 0.05 0.05
Site tables Deamidation (NQ)Sites Deamidation (NQ)Sites GlyGly (K)Sites
Oxidation (M)Sites Oxidation (M)Sites Oxidation (M)Sites
MS/MS: tandem mass spectrometry; FTMS: Fourier transform mass spectrometry; ITMS: Ion trap mass spectrometry; FDR: 
false discovery rate.
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De organisatie van het celmembraan
Het celmembraan omsluit de inhoud van een cel en speelt een unieke rol in de communicatie 
met de omgeving waarin de cel zich bevindt. Een specifieke plaatsing van eiwitten in het 
membraan is cruciaal om signalen van buiten de cel goed door te geven. De opbouw van het 
celmembraan is dan ook niet homogeen. De vetten (lipiden) en eiwitten waaruit het membraan 
bestaat, zijn georganiseerd in een mozaïek van kleine domeinen. Deze segregatie is dynamisch 
en zorgt ervoor dat signalen in ruimte en tijd gescheiden worden. Hoe de organisatie van het 
celmembraan precies wordt gereguleerd, is nog niet volledig begrepen. Membraaneiwitten 
hebben een voorkeur voor de lipide omgeving, en worden verondersteld te segregeren in de 
zogenaamde “lipid raft” of “non-raft” fracties. Daarnaast vormen structurele eiwitten die de 
cel vorm geven, barrières vlak onder het celmembraan, waardoor membraaneiwitten beperkt 
worden in hun beweging over het celoppervlak. Ook zijn er mechanismen om membraaneiwitten 
actief te groeperen. Gespecialiseerde eiwitten, zoals tetraspanins, binden een specifieke set 
eiwitten en beïnvloeden zo hun plaatsing in het membraan. 
Tetraspanins
Op menselijke cellen komen in totaal 33 verschillende tetraspanins voor in verschillende 
samenstellingen. Tetraspanins CD53 en CD37 komen bijvoorbeeld alleen voor op cellen die 
betrokken zijn bij het afweersysteem. De eiwitstructuur van tetraspanins is opgebouwd uit 
vier domeinen die het celmembraan doorkruisen, een kleine en een grote lus die zich aan de 
buitenkant van de cel bevinden en twee korte uiteinden aan de binnenkant van de cel. De 
kenmerkende eigenschap van tetraspanins is hun vermogen tot het vormen van eiwitclusters 
op het membraan. Tetraspanins gaan specifieke interacties aan met diverse membraaneiwitten. 
Hierdoor beïnvloeden tetraspanins de stabiliteit en de rangschikking van deze partnereiwitten 
op het celmembraan. Gedocumenteerde interactie partners zijn onder andere receptoren, 
adhesie en signalering eiwitten. Door deze verschillende membraaneiwitten te organiseren in 
functionele netwerken op de buitenkant van de cel, controleren tetraspanins diverse essentiële 
cel functies, zoals activatie en migratie. Defecten in de functie van individuele tetraspanins 
leiden tot zeer verschillende ziektebeelden, van mentale retardatie tot infectieziekten.
Een nieuwe kijk op het tetraspanin web
Door een fluorescent label aan tetraspanins vast te maken kunnen we de locatie van tetraspanins 
visualiseren door middel van lichtmicroscopie. We zien dat het celmembraan bezaaid is met 
kleine domeinen (clusters) die verrijkt zijn met tetraspanins. Dit komt overeen met de membraan-
organiserende functie van deze eiwitten. Om de precieze werking van tetraspanins te bestuderen 
is echter een beter begrip nodig van hoe deze domeinen zijn opgebouwd. Eerdere studies 
hebben, door middel van biochemische experimenten, aangetoond dat tetraspanins betrokken 
zijn in een hiërarchisch netwerk van eiwit-eiwit interacties. Elk type tetraspanin gaat allereerst 
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een interactie aan met een specifieke set membraaneiwitten. Daarnaast kunnen tetraspanins 
binden aan andere typen tetraspanins. Tetraspanins zijn dus op een secundair niveau gelinkt 
aan de partner eiwitten van andere typen tetraspanins. Dit netwerk wordt ‘’het tetraspanin 
web’’ genoemd. Eerdere studies naar de werking van tetraspanins zijn gebaseerd op een model 
waarin één tetraspanin-verrijkt domein is opgebouwd uit meerdere typen tetraspanins en de 
specifieke partner eiwitten. Het suggereert dat de verschillende typen tetraspanins en hun 
partnereiwitten functioneel met elkaar verbonden zijn. We testen dit model in hoofdstuk 4, 
door het tetraspanin web direct te visualiseren op cellen van het afweersysteem. 
Er zit een grens aan de scherpte die je met conventionele lichtmicroscopie kunt behalen, 
veroorzaakt door de diffractie van licht. Dit betekent dat fluorescente moleculen die minder 
dan 200nm uit elkaar liggen niet onderscheiden kunnen worden en geobserveerd worden als 
één vlek. STED (STimulated Emission Depletion) microscopie omzeilt dit door de fluorescente 
emissie te manipuleren. Hierdoor kunnen we de locatie van tetraspanins met hoge precisie 
(superresolutie) bestuderen. We tonen aan dat tetraspanins inderdaad zijn gelokaliseerd in 
afgebakende domeinen op het membraan. De clusters zijn 100-150nm breed en bevatten elk 
2-10 tetraspanin moleculen. In tegenstelling tot het biochemische model van het tetraspanin 
web, hebben we ontdekt dat deze tetraspanin clusters maar één type tetraspanin bevatten. Deze 
tetraspanin clusters zijn niet random gedistribueerd, maar zijn gepositioneerd in de nabijheid 
van clusters die een ander type tetraspanin bevatten. Deze groepering van verschillende clusters 
wordt door conventionele microscopie geobserveerd als één groot domein dat meerdere typen 
tetraspanins bevat. Door gebruik te maken van super-resolutie microscopie, kunnen we het 
oude model van het tetraspanin web, waarin meerdere typen tetraspanins georganiseerd zijn in 
één domein, weerleggen. Dit heeft implicaties voor studies naar de manier waarop tetraspanins 
membraaneiwitten organiseren in functionele netwerken op het celmembraan. Gebaseerd op 
onze bevindingen presenteren we een nieuw model, waarin tetraspanin clusters bestaan uit 
één type tetraspanin en grenzen aan clusters die verrijkt zijn met een andere tetraspanin. 
Het immuunsysteem
Het afweersysteem, ofwel het immuunsysteem, verdedigt ons lichaam tegen indringers van 
buitenaf, zoals bacteriën en virussen (pathogenen). Ook wordt het gevaar van binnenuit 
bestreden, wanneer lichaamseigen cellen veranderen in kankercellen. Het immuunsysteem wordt 
onderverdeeld in het aspecifieke immuunsysteem, wat direct reageert op ziekteverwekkers, en 
het adaptieve immuunsysteem. Dendritische cellen (DC) spelen een cruciale rol in de opbouw 
van een adaptieve immuunreactie tegen specifieke ziekteverwekkers. DC kunnen pathogenen 
opnemen en afbreken, en vervolgens kleine stukjes van deze pathogenen, de zogenoemde 
antigenen, plaatsen op hun celoppervlak. Cellen met deze eigenschap worden ‘’antigeen-
presenterende cellen’’ genoemd. DC kunnen op deze manier kleine stukjes van een pathogeen 
presenteren aan andere afweercellen van het adaptieve immuunsysteem; de B en T cellen. Deze 
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specifieke B en T cellen vermenigvuldigen zich en zijn in staat het pathogeen op een selectieve 
en efficiënte manier op te ruimen. T cellen doden virus-geïnfecteerde cellen of kankercellen, of 
helpen bij de activatie van andere immuun cellen. Geactiveerde B cellen produceren antistoffen 
die pathogenen neutraliseren. In hoofdstuk 1 wordt het belang van membraan organisatie in 
de werking van antigeen-presenterende cellen bediscussieerd.
Tetraspanins in het immuunsysteem
In hoofdstuk 2 beschrijven we hoeveel CD37 en CD53 moleculen voorkomen op cellen van 
het immuunsysteem. We laten zien dat, in vergelijking met andere immuun cellen, CD37 vooral 
hoog tot expressie komt op B cellen en CD53 veel aanwezig is op antigeen-presenterende 
cellen. Met de techniek “multispectral imaging” hebben we de expressie van CD37 en CD53 
bestudeerd in relatie tot de locatie van immuun cellen in verschillende weefsels van de mens. 
In de milt kunnen we B cel en T cel gebieden onderscheiden. We tonen aan dat B cellen 
in B cel follikels een hogere CD53 expressie hebben dan B cellen in andere regio’s van de 
milt. T cellen gelokaliseerd in T cel zones hebben een lagere CD37 en CD53 expressie dan T 
cellen buiten deze zones. Ook in de appendix zijn er verschillen in tetraspanin expressie op 
immuun cellen afhankelijk van hun locatie. T cellen aanwezig in B cel follikels hebben een 
lagere CD37 expressie en een hogere CD53 expressie in vergelijking tot T cellen buiten deze 
weefsel structuren. Verschillen in tetraspanin expressie zouden een verandering in immuun cel 
functie binnen en buiten deze zones kunnen reflecteren.
In hoofdstuk 3 brengen we de expressie van de hele tetraspanin eiwit familie op DC 
subtypes in kaart. DC worden onderverdeeld in subtypes die gespecialiseerde functies hebben 
in het immuunsysteem. Ze verschillen bijvoorbeeld in de efficiëntie van antigeen presentatie of 
spelen een belangrijke rol in antivirale immuunreacties. Voor elk DC subtype vinden we een 
specifiek expressie profiel van tetraspanin eiwitten. CD53 komt bijvoorbeeld relatief in grote 
hoeveelheden voor op plasmacytoïde DC, terwijl andere tetraspanins laag tot expressie komen 
op dit DC subtype. De relatieve expressie niveaus van tetraspanin RNA en eiwit komen niet altijd 
overeen, wat suggereert dat de expressie van tetraspanins strak wordt gereguleerd. Dit kan 
betekenen dat in elk DC subtype verschillende sets tetraspanins van belang zijn in de regulatie 
van de gespecialiseerde DC functies. 
De rol van CD53 in antigeen presentatie en B cel activatie
CD53 komt alleen voor op immuun cellen en we vermoeden dat CD53 een belangrijke rol 
speelt in afweerreacties. Deze hypothese wordt versterkt door de observatie dat individuen 
die geen CD53 eiwitten tot expressie brengen, aan meerdere infectieziekten leiden. Echter, 
hoe CD53 de functie van immuun cellen reguleert, is nog steeds onduidelijk. In hoofdstuk 
6 bestuderen we de rol van CD53 in antigeen presentatie. DC presenteren antigeen via een 
eiwit complex genaamd MHC (major histocompatibility complex). CD53 gaat een interactie aan 
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met MHC moleculen in het celmembraan. De relevantie van deze interactie is nog onduidelijk, 
aangezien CD53 de expressie en clustering van MHC moleculen op het celmembraan niet lijkt 
te beïnvloeden. B cellen herkennen gepresenteerde antigenen via de B cel receptor (BCR). 
Binding van de BCR aan het antigeen leidt tot een cascade van signalen in de B cel die leiden 
tot cel activatie. Een van de betrokken signalering moleculen is protein kinase C (PKC). In 
hoofdstuk 5 laten we zien dat tetraspanin CD53 een belangrijke rol speelt in de activatie van 
B cellen. We tonen aan dat CD53 moleculen zich in de buurt van de BCR bevinden en een 
interactie kunnen aangaan met PKC. CD53 reguleert op deze manier de plaatsing van PKC in 
de cel tijdens het proces van cel activatie. Daarnaast laten we zien dat in B cellen die geen CD53 
hebben, PKC niet goed functioneert. 
In hoofdstuk 7 worden de resultaten van het onderzoek, zoals beschreven in dit proefschrift, 
samengevat en bediscussieerd. De bevindingen hebben geleid tot een verbeterd begrip van de 
organisatie van het tetraspanin web en vormen een basis voor nieuwe inzichten in de manier 
waarop tetraspanins het celmembraan van immuun cellen reguleren. Het belang hiervan wordt 
onderstreept door de verschillende (klinische) studies die gericht zijn op tetraspanins, naar de 
ontwikkeling van nieuwe therapieën tegen kanker en infectieziekten. 
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Allereerst wil ik Annemiek bedanken voor de uitstekende begeleiding, je deur stond altijd open. 
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aan de andere kant de mogelijkheid gaf om ontzettend veel technieken kunnen leren. In deze 
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jouw carrière als een voorbeeld. Bedankt voor al je adviezen, ik heb veel van je geleerd. 
Carl, door jouw ervaring en brede kennis van de nieuwste ontwikkelingen leidde onze 
besprekingen vaak tot nieuwe inspiratie. Bedankt voor je waardevolle inzichten. Geert, het 
was super om met je samen te werken! Door jouw input heeft het project een goede richting 
gekregen en heb ik het microscopie-virus te pakken gekregen.
De tetraspanin-girls zijn de reden dat ik altijd met plezier naar het werk ging. Alie, je hebt 
me wegwijs gemaakt in het lab en ik heb veel tips en tricks van je geleerd die mij nog lang van 
pas zullen komen. Super bedankt voor je hulp tijdens de enorme experimenten. Lotte, als Utje 
genootje heb je mijn PhD rollercoaster het beste meebeleeft. Je was een luisterend oor tijdens 
stress periodes maar ik wil je vooral bedanken voor het mee vieren van alle hoogtepunten! Het 
verschil tussen onze manier van werken was goed te zien aan de staat van onze bureaus ;). 
Het was tof om je ook even hier in Birmingham als collega te hebben! Heel veel succes met de 
laatste loodjes! Vera, je bent begonnen als mijn student, toch heeft het je niet afgeschrikt ;). 
Het was super om met je samen te werken, je bracht het geek-gehalte in utje 1 en 2 weer op 
peil. Ik kan me geen beter persoon wensen om het CD53 project (toch mijn science-baby) te 
adopteren. Anoek, thanks dat ik terecht kon in utje 1 om (misschien iets te vaak) mijn computer 
scherm te ontvluchten. Alhoewel, gingerbeards zijn natuurlijk een belangrijk discussiepunt voor 
de vooruitgang van de wetenschap.
Tessa, Chewie, het duurde niet lang voordat we onze mooie bijnamen hadden bedacht in 
de confocal ruimte. Je stageperiode in de tspan groep was een feestje en het begin van onze 
vriendschap. Ik denk graag dat ik positieve invloed heb gehad op je keuze om voor een PhD 
te gaan, en ik ben trots op je! Fijn dat ik tijdens onze lunches mijn ei even kwijt kon en dat ik 
gedurende mijn hele PhD kon rekenen op je enorme voorraad block buffer ;). Ik vind het super 
epic dat je naast me staat (of een stiekem gaylion dansje doet) tijdens mijn promotie! 
Dear Tspanners, thank you all for the enlightening and enjoyable conferences and 
collaborations. For me the tetraspanin web not only represents the organization of tetraspanin 
clusters on cellular membranes, but also the friendly network between the tetraspanin groups 
across the world. I would also like to thank Fabian for hosting me in Göttingen, I really enjoyed 
working on the STED microscope that you build. It resulted in a brilliant paper. Ook wil ik Sonja 
bedanken voor de waardevolle input en enthousiasme voor het werk. Merel, bedankt voor de 
fijne samenwerking aan het PKC stuk, ik heb veel van je geleerd.
Beste TILlers, ik heb een geweldige tijd gehad tijdens mijn PhD en ik wil jullie allemaal 
enorm bedanken voor al jullie advies, hulp bij experimenten, de vele koekjes en de gezelligheid! 
Ik denk graag terug naar de vele biertjes in de Aesculaaf, dagjes uit, de bokbiertochten, 
carnavalsdinsdagen en vierdaagse woensdagen (Eric, het varken aan het spit was toch echt 
briljant!). Het heuse TIL kampeerweekend, de filmavonden en de kerstfeesten (met op de 
valreep toch nog Star Wars als thema). De TILband wil ik ook bedanken! Ik weet namelijk geen 
originele tekst van Bon Jovi nummers meer. In short, the atmosphere in and outside the lab was 
fantastic! Gelukkig heb ik er lang genoeg over gedaan om echt weg te gaan ;).
Lieve vrienden; rondje van Malou!! Bedankt voor de nodige ontspanning. Mijn hoofd kon 
ik goed leegmaken en weer opladen tijdens de carnaval. Gelukkig zijn er genoeg hersencellen 
overgebleven om mijn PhD te volbrengen. Laura, bedankt voor je vriendschap en steun. Bij 
jou kon ik terecht om alles te relativeren en misschien ben jij de enige waarvan ik advies echt 
opvolg. Je was bij mijn eerste echte experiment, namelijk ons fantastische profielwerkstuk, en 
ik ben blij dat je straks naast me staat tijdens de afronding van mijn promotie. 
Peter en Jacky, Mandy en Patty, bedankt voor jullie gastvrijheid, gezelligheid en belangstelling! 
Ik beloof Kevin over een paar jaar weer mee terug te nemen naar de mooiste stad, Nijmegen. 
Wouter, mijn thesis gaat totaal niet over plaveiselcelcarcinomen, daar hebben we het nog wel 
over tijdens de vele gezellige gin en tonic en sushi avonden samen met Marloes. 
Lieve pap en mam, bedankt dat jullie er altijd voor mij zijn. Zonder jullie stond ik hier niet! 
Jullie hebben reislustige kinderen gekregen, maar voor mij voelt het bij jullie nog altijd als thuis. 
Bedankt voor alle liefde en steun.
Kevin, het is af!! Bedankt voor je enorme geduld, steun en de liefdevolle schop onder mijn 
kont.  If I didn’t have you … ;). Je hebt een gave om mij na stressvolle dagen op het lab tot rust 
te brengen of juist een dosis positieve energie te geven. Ik vind het awesome dat we samen het 
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Curriculum Vitae (Nederlands)
Malou Zuidscherwoude werd geboren op 18 september 1987 te Nijmegen. Na haar Gymnasium 
diploma te hebben behaald aan de Nijmeegse Scholengemeenschap Groenewoud, begon 
ze in 2005 met de bachelor Biomedische Wetenschappen aan de Radboud Universiteit te 
Nijmegen. Tijdens deze studie liep ze stage op de afdeling Pathologie van het Radboudumc 
onder begeleiding van dr. Ilse Roodink en dr. William Leenders, waarin ze onderzocht of single 
domain antilichamen gericht tegen tumor bloedvaten ingezet kunnen worden als therapie 
tegen hersentumoren. Na het cum laude behalen van haar bachelor diploma, begon ze in 2008 
met de onderzoeksmaster Molecular Mechanisms of Disease aan de Radboud Universiteit. Op 
de afdeling Tumor Immunologie van het Radboud Institute for Molecular Life Sciences (RIMLS), 
onder begeleiding van dr. Marleen Ansems en prof. Gosse Adema, deed ze onderzoek naar de 
rol van DC-SCRIPT in dendritische cellen en borstkanker. Haar laatste stage van acht maanden 
vond plaats in het Walter and Eliza Hall Institute in Melbourne, Australië. In de groep van dr. 
Fred Masson en prof. Gabrielle Belz onderzocht ze de functie van transcriptie factor Id3 tijdens 
activatie van B en T cellen. Ze behaalde in 2010 haar master diploma cum laude en ontving 
een persoonlijke PhD grant van het Radboudumc. Op de afdeling Tumor immunologie van het 
RIMLS, onder begeleiding van dr. Annemiek van Spriel, dr. Geert van den Bogaart en prof. Carl 
Figdor werd het promotieonderzoek uitgevoerd zoals beschreven in dit proefschrift. Tijdens haar 
promotietraject heeft ze werkbezoeken gebracht aan het Max Planck Institute for Biophysical 
Chemistry te Göttingen, Duitsland. In het lab van Nobelprijswinnaar Stefan Hell onderzocht 
ze tetraspanin clusters met behulp van superresolutie microscopie. Vanaf januari 2016 is ze 
werkzaam als postdoc in de groep van prof. Steve Watson bij het Institute of Cardiovascular 
Sciences, University of Birmingham, UK waar ze de activatie van bloedplaatjes onderzoekt met 
behulp van light sheet microscopie.
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Curriculum Vitae (English)
Malou Zuidscherwoude was born on the 18th of September 1987 in Nijmegen, the Netherlands. 
After completing her secondary education in 2005, she started her bachelor studies on 
Biomedical Sciences at the Radboud University in Nijmegen. She performed an internship 
at the department of Pathology of the Radboudumc, supervised by dr. Ilse Roodink en dr. 
William Leenders, during which she investigated the targeting of tumor vasculature by single 
domain antibodies for the treatment of brain cancer. After obtaining her bachelor degree with 
honours in 2008, she continued with the research master Molecular Mechanisms of Disease 
at the Radboud University. At the department of Tumor Immunology of the Radboud Institute 
for Molecular Life Sciences (RIMLS), under the supervision of dr. Marleen Ansems and prof. 
Gosse Adema, she studied the role of DC-SCRIPT in dendritic cells and breast cancer. Her final 
internship of eight months took place at the Walter and Eliza Hall Institute in Melbourne, 
Australia. In the group of dr. Fred Masson and prof. Gabrielle Belz, she studied the function of 
transcription factor Id3 during B and T cell activation. In 2010 she obtained her master degree 
with honours and received a personal PhD grant from the Radboudumc. At the department of 
Tumor Immunology of the RIMLS, under the supervision of dr. Annemiek van Spriel, dr. Geert 
van den Bogaart and prof. Carl Figdor she performed the research described in this thesis. 
During her PhD she paid work visits to the Max Planck Institute for Biophysical Chemistry 
in Göttingen, Germany. In the lab of Nobel prize winner Stefan Hell she studied tetraspanin 
clusters using super-resolution microscopy. As of January 2016 she works as a postdoctoral 
researcher in the group of prof. Steve Watson at the Institute of Cardiovascular Sciences at 
the University of Birmingham, UK and studies platelet activation using light sheet microscopy. 
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